Document:

EX-4.3

 Exhibit 4.3 

EXECUTION VERSION 
 May 21, 2021

 ASTRAZENECA AB 
 and 

MEREO BIOPHARMA GROUP PLC 
 DEED
OF AMENDMENT AND RESTATEMENT 
 relating to a Subscription Deed 

 
  

 
 

 
 99 Bishopsgate 

London 
 EC2M 3XF 

www.lw.com 
 Contact: James
Inness / Anna Ngo 

 This Deed (the “Deed”) is made on May 21, 2021 between: 

 

	(1)	 ASTRAZENECA AB, a company incorporated in Sweden under no. 566011-7482 with its registered office at SE-151 85 Sodertalje, Sweden (“AstraZeneca”); and 

  

	(2)	 MEREO BIOPHARMA GROUP PLC, a company incorporated in England and Wales with the registered number
09481161 and registered address at 4th Floor, One Cavendish Place, London, England, W1G 0QF (the “Company”). 

Whereas: 
  

	(A)	 AstraZeneca and the Company entered into the Original Subscription Deed on October 28, 2017.

  

	(B)	 AstraZeneca and the Company now wish to amend and restate the Original Subscription Deed in the form of the
Amended and Restated Subscription Deed. 

 It is agreed as follows: 

 

	1	 DEFINITIONS AND INTERPRETATION 

In this Deed, unless the context otherwise requires, the provisions in this Clause 1 apply: 

 

	1.1	 Incorporation of defined terms 

Unless otherwise stated, terms defined in the Original Subscription Deed shall have the same meaning in this Deed. 

 

	1.2	 Definitions 

“Amended and Restated Subscription Deed” means the Original Subscription Deed, as amended and restated in the form set out in
the Schedule to this Deed; 
 “Effective Date” means May 21, 2021. 

“Original Subscription Deed” means the Subscription Deed entered into between AstraZeneca and the Company on October 28,
2017; and 
 “Party” means a party to this Deed. 
  

	1.3	 Interpretation clauses 

 

	 	1.3.1	 The principles of interpretation set out in Clause 1 of the Original Subscription Deed shall have effect
as if set out in this Deed, save that references to “this Agreement” shall be construed as references to “this Deed”. 

  

	 	1.3.2	 References to this Deed include its Schedule. 

 

	2	 AMENDMENT 

  

	2.1	 The Parties agree that the Original Subscription Deed shall be amended and restated in the form set out
in the Schedule to this Deed. 

	2.2	 The amendment and restatement of the Original Subscription Deed pursuant to Clause 2.1 shall take effect
from the Effective Date. 

  

	2.3	 Upon this Deed being entered into, the Amended and Restated Subscription Deed shall supersede the
Original Subscription Deed in its entirety. 

  

	3	 INCORPORATION OF TERMS 

The provisions of clauses 9, 10, 12, and 13 of the Amended and Restated Subscription Deed shall apply to this Deed as if set out in full in
this Deed and as if references in those clauses to “this Agreement” are references to this Deed and references to “party” or “parties” are references to parties to this Deed. 

 In witness whereof this Deed has been delivered on the date first stated above. 

 

			
		
	 EXECUTED and delivered as a DEED by
	  	
	 MEREO BIOPHARMA GROUP PLC
	  	
	 acting by Denise Scots-Knight, a director,
	  	  

	 and Charles Sermon, its secretary
	  	Director
		
		  	  

		  	 Secretary

		
	 EXECUTED and delivered as a DEED by
	  	
	 ASTRAZENECA AB (publ)
	  	
	acting by two authorised signatories	  	
		
		  	  

		  	Name:
		  	Title:
		
		  	  

		  	Name:
		  	Title:

 ASTRAZENECA AB 

and 
 MEREO BIOPHARMA GROUP PLC

  
  

 
 SUBSCRIPTION
DEED 
  
  

 
 

 
 99 Bishopsgate 

London 
 EC2M 3XF 

www.lw.com 
 Contact: James
Inness / Anna Ngo 

 TABLE OF CONTENTS 

 

							
	Clause	  	Page	 
	1	  	DEFINITIONS AND INTERPRETATION	  	 	2	 
			
	2	  	SUBSCRIPTION	  	 	6	 
			
	3	  	CERTIFICATES, ADSS AND U.S. SECURITIES AND EXCHANGE COMMISSION REGISTRATION	  	 	7	 
			
	4	  	ADJUSTMENTS AND ACCELERATION EVENTS	  	 	9	 
			
	5	  	WARRANTIES	  	 	9	 
			
	6	  	ACKNOWLEDGEMENTS	  	 	12	 
			
	7	  	[NOT USED]	  	 	13	 
			
	8	  	REORGANISATION OF THE MEREO GROUP	  	 	13	 
			
	9	  	THIRD PARTY RIGHTS	  	 	13	 
			
	10	  	NOTICES	  	 	13	 
			
	11	  	FURTHER ASSURANCE	  	 	15	 
			
	12	  	ENTIRE AGREEMENT	  	 	15	 
			
	13	  	APPLICABLE LAW	  	 	15	 
		
	 SCHEDULE 1 ADJUSTMENTS
	  	 	16	 
		
	 SCHEDULE 2 SHARE CAPITAL
	  	 	17	 
		
	 SCHEDULE 3 [NOT USED]
	  	 	18	 
		
	 SCHEDULE 4 ADS ISSUANCE AND DELIVERY INSTRUCTION
	  	 	19	 

  
 i 

 THIS DEED was made on 28 October 2017 and is amended and restated by an amendment deed dated May
21, 2021 (as amended and restated, this “Agreement”) 
 BETWEEN 

 

	(1)	 ASTRAZENECA AB, a company incorporated in Sweden under no. 566011-7482 with its registered office at SE-151 85 Sodertalje, Sweden (“AstraZeneca”); and 

  

	(2)	 MEREO BIOPHARMA GROUP PLC, a company incorporated in England and Wales with the registered number
09481161 and registered address at 4th Floor, One Cavendish Place, London, England, W1G 0QF (the “Company”). 

WHEREAS 
  

	A.	 AstraZeneca owns and controls certain intellectual property rights and assets relating to a compound
designated AZD9668, which is an orally delivered form of a neutrophil elastase inhibitor that has been the subject of Phase II clinical trials in respiratory diseases, and to a compound designated as AZD9819, which is a neutrophil elastase inhibitor
delivered by inhalation that has been the subject of Phase I clinical trials. 

  

	B.	 AstraZeneca wishes to grant, and Mereo wishes to obtain, the License pursuant to the terms set forth in
the License Agreement. 

  

	C.	 The Company has agreed to allot and issue the Subscription Shares, credited as fully paid, to
AstraZeneca in consideration for Mereo issuing the Loan Notes to the Company subject to the terms and conditions set out in the Transaction Documents. 

IT IS AGREED THAT: 
  

	1	 DEFINITIONS AND INTERPRETATION 

 

	1.1	 Words and expressions not otherwise defined in this Agreement shall have the meanings given to them in the
License Agreement. 

  

	1.2	 In this Agreement, the following words and expressions shall have the meanings set out below.

 “Acceleration Event” means any of the following: 

 

	 	(a)	 a Change of Control; or 

 

	 	(b)	 a Mereo Sale Event; 

“Adjustment Event” has the meaning given in paragraph 2.1 of Schedule 1; 

“ADSs” means American Depositary Shares, each representing Ordinary Shares, of the Company; 

“Business Day” means any day other than a Saturday or Sunday or a day on which banking institutions in London or
Stockholm, Sweden are permitted or required to be closed; 
 “Calculation Agent” means the auditors (from time to time) of
the Company or, if they are unwilling or unable to act, an independent firm of chartered accountants (of international repute) as the parties shall agree (or, if they are unable to reach agreement within ten (10) Business Days of a notice to
agree being served by either party on the other, as nominated by the President of the Institute of Chartered Accountants in England and Wales on the application of either party); 

  
 2 

 “Change of Control” means the occurrence of: 

 

	 	(a)	 an offer (as such term is defined the Takeover Code) being made by a person or group of persons acting in
concert (as such term is defined in the Takeover Code), other than AstraZeneca or any person acting in concert with AstraZeneca, to all holders of Ordinary Shares (other than the offeror and/or any associate (as defined in section 988 of the
Companies Act) of the offeror, and any person to whom the offer is not made (i) pursuant to a dispensation granted by the Panel on Takeovers and Mergers; and/or (ii) in reliance on any exception to Rule 30.4 provided in the Takeover Code
(including the note on Rule 30.4)) to acquire the whole of the issued ordinary share capital of the Company (other than that held by the offeror and/or any associate (as defined in section 988 of the Companies Act) of the offeror) and such offer
being declared unconditional in all respects; or 

  

	 	(b)	 a proposal being made by a person or group of persons acting in concert, other than AstraZeneca or any person
acting in concert with AstraZeneca, to undertake a scheme of arrangement pursuant to Part 26 of the Companies Act as a means of effecting an acquisition of the whole of the issued ordinary share capital of the Company (other than that held by the
offeror and/or any associate (as defined in section 988 of the Companies Act) of the offeror) and such scheme becoming effective; 

“Closing Date” means the First Closing Date, the Second Closing Date, and Third Closing Date, as relevant; 

“Companies Act” means the Companies Act 2006; 

“Deposit Agreement” means the deposit agreement dated 23 April 2019 among the Company, Citibank, N.A. (as depositary) and
all Holders (as defined therein) and Beneficial Owners (as defined therein) of ADSs issued thereunder; 
 “Depositary” has
the meaning given in the Deposit Agreement; 
 “Disposal” means directly or indirectly, offer, issue, lend, mortgage,
assign, charge, pledge, sell or contract to sell, issue options in respect of, or otherwise dispose of, directly or indirectly, or announce an offering or issue of, any Subscription Shares (or any interest therein or in respect thereof) or any other
securities exchangeable for or convertible into the Subscription Shares or agree to do any of the foregoing; 
 “Effective
Date” means 28 October 2017; 
 “Encumbrance” means any mortgage, charge (fixed or floating), pledge, lien,
hypothecation trust, right of set-off or other third party right or interest (legal or equitable) including any right of pre-emption, assignment by way of security,
reservation of title or any other security interest of any kind however created or arising or any other agreement or arrangement (including a sale and repurchase arrangement); 

“Exchange Act” means the U.S. Securities Exchange Act of 1934, as amended; 

“FCA” means the UK Financial Conduct Authority and any successor to its functions from time to time; 

  
 3 

 “First Closing Date” means the date on which the Subscription Shares
comprised in the First Equity Tranche were allotted and issued to AstraZeneca pursuant to clause 2.1; 
 “First Equity
Tranche” means 490,798 Ordinary Shares; 
 “Guarantee” means the parent company guarantee entered into between
AstraZeneca and the Company on or around the Effective Date; 
 “License” means the license granted by AstraZeneca to Mereo
pursuant to the License Agreement; 
 “License Agreement” means the exclusive license and option agreement entered into
between AstraZeneca and Mereo on or around the Effective Date; 
 “Loan Note 1” means the loan note issued by Mereo to the
Company for the principal amount of $2.0 million pursuant to clause 8.2.1(a) of the License Agreement; 
 “Loan Note 2”
means the loan note to be issued by Mereo to the Company for the principal amount of $1.75 million pursuant to clause 8.2.1(b) of the License Agreement; 

“Loan Note 3” means the loan note to be issued by Mereo to the Company for the principal amount of $3.75 million pursuant
to clause 8.2.1.(c) of the License Agreement; 
 “Loan Notes” means Loan Note 1, Loan Note 2, and Loan Note 3; 

“MAR” means the Market Abuse Regulation (Regulation 596/2014); 

“Mereo” means Mereo BioPharma 4 Limited, a company incorporated in England and Wales with the registered number 11029583 and
registered address at 4th Floor, One Cavendish Place, London, England, W1G 0QF; 

“Mereo Group” means the Company and its Affiliates from time to time; 

“Mereo Sale Event” means, directly or indirectly: 
  

	 	(a)	 the effecting of any transaction as a result of which the Company is no longer the ultimate holding company of
Mereo (except for a transaction to which clause 8.1 applies); or 

  

	 	(b)	 the completion of a sale of all, or substantially all, of Mereo’s business, assets or undertakings to
which the License Agreement relates at the time of such a sale (including, for clarity, any sale, transfer or assignment of all, or substantially all, of the intellectual property rights owned by Mereo at the relevant time if that constitutes all,
or substantially all, of Mereo’s business, assets or undertakings to which the License Agreement relates at such time); 

“Ordinary Shares” means the ordinary shares each with a nominal value of £0.003 in the capital of the Company (and, if
there is a sub-division, consolidation or reclassification of those shares, the shares resulting from the sub-division, consolidation or reclassification); 

“Prospectus Regulation” means Regulation (EU) 2017/1129 of 14 June 2017 on the prospectus to be published when securities
are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71/EC, as amended; 

  
 4 

 “Registrars” means Link Group, 10th Floor, Central Square, 29 Wellington
Street, Leeds, LS1 4DL; 
 “Registration Statement” means a registration statement on Form
F-3 (or Form S-3, as applicable) or, if the Company is not eligible to use such form, on Form F-1 (or Form S-1, as applicable), or any successor forms thereto; 
 “Regulation S” means Regulation S
under the Securities Act; 
 “SEC” means the U.S. Securities and Exchange Commission; 

“Second Closing Date” means the date on which the ADSs representing the Subscription Shares comprised in the Second Equity
Tranche are issued to AstraZeneca pursuant to clause 2.2; 
 “Second Equity Tranche” means such number of ADSs that
represent a number of Ordinary Shares (rounded down to the nearest whole Ordinary Share) as results from the following calculation: 
  

					
	No. of Ordinary Shares =	  	$1.75 million	  	
		  	Subscription Price	  	

 “Securities Act” means the U.S. Securities Act of 1933, as amended; 

“Subscription Price” means $4.075, subject to adjustment from time to time pursuant to clause 4; 

“Subscription Shares” means the Ordinary Shares subscribed for by AstraZeneca, and allotted and issued by the Company,
pursuant to this Agreement, comprised of the First Equity Tranche, together with, to the extent applicable, the Ordinary Shares to be allotted to AstraZeneca by the Company as part of the Second Equity Tranche and the Third Equity Tranche; 

“Takeover Code” means The City Code on Takeovers and Mergers; 

“Third Closing Date” means the date on which the ADSs representing the Subscription Shares comprised in the Third Equity
Tranche are issued to AstraZeneca pursuant to clause 2.3; 
 “Third Equity Tranche” means such number of ADSs that represent
a number of Ordinary Shares (rounded down to the nearest whole Ordinary Share) as results from the following calculation: 
  

					
	No. of Ordinary Shares =	  	$3.75 million	  	
		  	Subscription Price	  	

 “Tranche” refers to the First Equity Tranche, and to the extent applicable, each of the Second
Equity Tranche and Third Equity Tranche, as relevant; 
 “Transaction Documents” means this Agreement, the License Agreement
and the Guarantee; 
 “UK MAR” means MAR as it forms part of domestic law by virtue of the European Union
(Withdrawal) Act 2018; 

  
 5 

 “UK Prospectus Regulation” means the Prospectus Regulation as it forms part
of domestic law by virtue of the European Union (Withdrawal) Act 2018; and 
 “U.S. Stock Exchange” means the Nasdaq Global
Market or such other U.S. market on which the ADSs are listed. 
  

	1.3	 References in this Agreement to any act, statute or statutory provision include references to any such
provision as amended, re-enacted or replaced from time to time and any former statutory provision replaced (with or without modification) by the provision referred to. 

 

	1.4	 References in this Agreement to the singular include references to the plural and vice versa and references to
the masculine gender shall include references to the feminine and neuter gender and vice versa. 

  

	1.5	 Headings in this Agreement are inserted for convenience only and shall not affect the interpretation of this
Agreement or any part thereof. 

  

	1.6	 The ejusdem generis rule shall not apply, and the expression “including” shall be deemed to be
followed by “without limitation”. 

  

	1.7	 The expressions “subsidiary” and “holding company” shall have the meanings
given by the Companies Act and the expression “subsidiary” shall be deemed to include “subsidiary undertakings” as defined by the Companies Act. 

 

	1.8	 References to USD or “$” are to the lawful currency of the United States.

  

	1.9	 References to GBP or “£” are to the lawful currency of the United Kingdom.

  

	1.10	 References to a party or parties mean a party or parties to this Agreement. 

 

	1.11	 Reference to agreements are to those agreements as amended, varied, novated, restated or supplemented from time
to time. 

  

	2	 SUBSCRIPTION 

  

	2.1	 The Company has allotted and issued to AstraZeneca the Subscription Shares comprised in the First Equity
Tranche. The Subscription Shares comprised in the First Equity Tranche were issued credited as fully paid up in consideration for the issue by Mereo of Loan Note 1 to the Company. 

 

	2.2	 The Company agrees to allot the Subscription Shares and issue ADSs representing such Subscription Shares to
AstraZeneca comprised in the Second Equity Tranche no later than the earlier of: (i) the POC Full Enrollment Fee becoming due and payable pursuant to clause 8.3.1 of the License Agreement; and (ii) any Acceleration Event occurring. The
Subscription Shares comprised in the Second Equity Tranche shall be allotted and the ADSs representing such Subscription Shares shall be issued credited as fully paid up in consideration for the issue by Mereo of Loan Note 2 to the Company. The
Company’s obligations under this clause 2.2 and clause 4.3 shall terminate automatically on any termination of the License Agreement by Mereo becoming effective pursuant to clause 14.2 of the License Agreement. 

 

	2.3	 The Company agrees to allot the Subscription Shares and issue ADSs representing such Subscription Shares to
AstraZeneca comprised in the Third Equity Tranche no later than the earlier of: (i) the Pivotal Success Fee becoming due and payable pursuant to clause 8.3.3 of the 

  
 6 

	 	
License Agreement; and (ii) any Acceleration Event occurring. The Subscription Shares comprised in the Third Equity Tranche shall be allotted and the ADSs representing such Subscription
Shares shall be issued credited as fully paid up in consideration for the issue by Mereo of Loan Note 3 to the Company. The Company’s obligations under this clause 2.3 and clause 4.3 shall terminate automatically on any termination of the
License Agreement by Mereo becoming effective pursuant to clause 14.2 of the License Agreement. 

  

	2.4	 Any Subscription Shares that have been issued or will be allotted and any ADSs to be issued to AstraZeneca
pursuant to this clause 2 were or shall be, as applicable, allotted or issued free from all Encumbrances and in accordance with (and subject to) the Company’s articles of association then in force and, in the case of ADSs, the Deposit
Agreement. Any Subscription Shares that have been issued or will be allotted to AstraZeneca pursuant to this clause 2 rank or shall rank, as applicable, pari passu with all other Ordinary Shares then in issue provided that the right to
receive dividends and other distributions shall only apply to the extent that the record date therefor falls on or after the relevant Closing Date. AstraZeneca hereby applies for and consents to the entry of its name in the Company’s register
of members as the holder of all Subscription Shares issued to it credited as fully paid pursuant to this clause 2. 

  

	2.5	 For clarity, references in the License Agreement to Subscription Shares issued to AstraZeneca pursuant to
clause 2.2 or clause 2.3 above shall be deemed references to the ADSs issued to AstraZeneca pursuant to such clause. 

  

	3	 CERTIFICATES, ADSs AND U.S. SECURITIES AND EXCHANGE COMMISSION REGISTRATION 

 

	3.1	 [NOT USED] 

  

	3.2	 Subject to clause 3.3, the Company undertakes to AstraZeneca that it shall: 

 

	 	(a)	 procure that the Registrars register AstraZeneca, or such entity as AstraZeneca has confirmed in writing, as
the holder of each Tranche of the Subscription Shares; and 

  

	 	(b)	 issue the Subscription Shares in certificated form and deliver to AstraZeneca a duly executed share certificate
in respect of each Tranche of Subscription Shares in accordance with the Company’s articles of association, 

 in each
case, as soon as reasonably practicable following their issuance. 
  

	3.3	 The Company shall deliver ADSs representing the Subscription Shares in lieu of delivering Subscription Shares
at the Second Closing and the Third Closing, and such Subscription Shares shall be issued to, and deposited with (and otherwise registered in the name of) the custodian (or its nominee) of the Depositary. Following such issuance and deposit, the
Company undertakes to AstraZeneca that it shall direct the Depositary to issue an amount of ADSs to AstraZeneca comprising the Second Equity Tranche (in respect of the Second Closing) or the Third Equity Tranche (in respect of the Third Closing), in
each case, in book-entry form. The Company and AstraZeneca shall complete (as applicable), execute and deliver to the Depositary an instruction in the Form of Schedule 4 in connection with the Second Closing and the Third Closing.

  

	3.4	 AstraZeneca’s entitlement to ADSs shall be calculated using the ratio applicable to the exchange of
Ordinary Shares for ADSs at the time of such delivery of ADSs, being at the date of this Agreement a ratio of five Ordinary Shares to each ADS. No fractional ADSs or scrip representing fractional ADSs will be issued and any number of balancing
Ordinary Shares will be issued to AstraZeneca in certificated form. 

  
 7 

	3.5	 The Company undertakes to AstraZeneca that, prior to the Second Closing, at its own expense it will prepare and
file a Registration Statement with the SEC covering the resale of each Tranche of the Subscription Shares allotted and issued by the Company pursuant to the Transaction Documents in the form of ADSs (or any subsequent security of the Company listed
on a U.S. Stock Exchange), and use reasonable endeavours to have such Registration Statement declared effective by the SEC as promptly as reasonably practicable thereafter. 

 

	3.6	 The Company shall maintain the continuous effectiveness of the Registration Statement until the earlier of
(i) the date on which the ADSs issued to AstraZeneca hereunder may be resold without volume or manner of sale limitations pursuant to Rule 144 promulgated under the Securities Act and without the requirement for the Company to be in compliance
with the current public information required under Rule 144, and (ii) the date on which all such ADSs have actually been sold by AstraZeneca. 

  

	3.7	 The Company shall indemnify and hold harmless AstraZeneca, its officers, directors and agents, and each person
who controls AstraZeneca (within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act) to the fullest extent permitted by applicable law, from and against any and all losses, claims, damages, liabilities, costs
(including, without limitation, reasonable attorneys’ fees) and expenses (collectively, “Losses”), as incurred, that arise out of or are based upon any untrue or alleged untrue statement of a material fact contained in the
Registration Statement, any prospectus included in the Registration Statement or any form of prospectus or in any amendment or supplement thereto or in any preliminary prospectus, or arising out of or relating to any omission or alleged omission to
state a material fact required to be stated therein or necessary to make the statements therein (in the case of any prospectus or form of prospectus or supplement thereto, in light of the circumstances under which they were made) not misleading,
except to the extent that such untrue statements or alleged untrue statements, omissions or alleged omissions are based upon information regarding AstraZeneca furnished in writing to the Company by AstraZeneca expressly for use therein.

  

	3.8	 AstraZeneca shall indemnify and hold harmless the Company, its officers, directors and agents, and each person
who controls the Company (within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act) to the fullest extent permitted by applicable law, from and against any and all Losses, as incurred, that arise out of or
are based upon any untrue or alleged untrue statement of a material fact contained in the Registration Statement, any prospectus included in the Registration Statement or any form of prospectus or in any amendment or supplement thereto or in any
preliminary prospectus, or arising out of or relating to any omission or alleged omission to state a material fact required to be stated therein or necessary to make the statements therein (in the case of any prospectus or form of prospectus or
supplement thereto, in light of the circumstances under which they were made) not misleading, but only to the extent that such untrue statements or alleged untrue statements, omissions or alleged omissions are based upon information regarding
AstraZeneca furnished in writing to the Company by AstraZeneca expressly for use therein. 

  

	3.9	 To the extent the indemnification provided for in clause 3.7 or clause 3.8 is unavailable to an indemnified
party or insufficient in respect of any Losses referred to therein, then each indemnifying party under such paragraph, in lieu of indemnifying such indemnified party thereunder, shall contribute to the amount paid or payable by such indemnified
party as a result of such Losses in such proportion as is appropriate to reflect the relative fault of the indemnifying party or parties on the one hand and of the indemnified party or parties on the other hand in connection with the statements or
omissions that resulted in such Losses, as well 

  
 8 

	 	
as any other relevant equitable considerations. The relative fault of the indemnifying party or parties on the one hand and the indemnified party or parties on the other hand shall be determined
by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material fact relates to information supplied by the indemnifying party or parties on the one hand or
the indemnified party or parties on the other hand, and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. The amount paid or payable by an indemnified party as a
result of the losses, claims, damages and liabilities referred to above in this clause 3.9 shall be deemed to include, subject to the limitations set forth above, any legal or other expenses reasonably incurred by such indemnified party in
connection with investigating or defending any such action or claim. Notwithstanding the foregoing provisions of this clause 3.9, AstraZeneca shall not be required to contribute any amount in excess of the aggregate public offering price of the ADSs
offered and sold pursuant to the Registration Statement, and no person found guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) will be entitled to contribution from any person who was not guilty
of such fraudulent misrepresentation. 

  

	4	 ADJUSTMENTS AND ACCELERATION EVENTS 

 

	4.1	 If an Adjustment Event occurs, the Subscription Price shall be subject to adjustment in accordance with the
provisions of Schedule 1. 

  

	4.2	 Whenever an adjustment is to be made under this clause 4, the Company shall, subject to compliance with
applicable law (including the Takeover Code, MAR, UK MAR, U.S. securities laws and U.S. Stock Exchange rules, as applicable) and the requirements of the FCA and the Panel on Takeovers and Mergers, as soon as reasonably practicable, give notice to
AstraZeneca setting forth in reasonable detail the nature of the adjustment, the event giving rise to the adjustment and the effective date of the adjustment. 

 

	4.3	 Subject to compliance with applicable law (including the Takeover Code, MAR, UK MAR, U.S. securities laws and
U.S. Stock Exchange rules, as applicable) and the requirements of the FCA and the Panel on Takeovers and Mergers, the Company will give AstraZeneca not fewer than 10 Business Days written notice prior to the date on which any Acceleration Event
takes effect, and the Company will procure that no Acceleration Event takes effect until: (i) Mereo has issued all Loan Notes required to be issued to the Company pursuant to clause 8.2 of the License Agreement; and (ii) all Subscription
Shares (or ADSs representing such Subscription Shares) have been issued (credited as fully paid up in consideration for the issue of the Loan Notes to the Company) and the Company’s register of members has been updated, in each case in
accordance with clause 3, such that AstraZeneca is entitled to participate in any payment, dividend, distribution or other transfer of value made to the holders of Ordinary Shares (whether by the Company or another person) in connection with the
Acceleration Event. 

  

	5	 WARRANTIES 

  

	5.1	 AstraZeneca hereby warrants to the Company on the Effective Date, and on each Closing Date (provided that the
warranty in clause 5.3(e) below shall not be given on the Second Closing Date and the Third Closing Date), that: 

  

	 	(a)	 this Agreement has been duly authorised, executed and delivered by AstraZeneca and constitutes a valid and
legally binding agreement of AstraZeneca enforceable against AstraZeneca in accordance with its terms, subject to mandatory rules of law relating to insolvency, and general equitable principles; 

  
 9 

	 	(b)	 by reason of its, or of its management’s, business and financial experience, AstraZeneca has the capacity
to evaluate the merits and risks of its investment in the Subscription Shares (and any ADSs representing the Subscription Shares) and to protect its own interests in connection with the transaction contemplated in this Agreement;

  

	 	(c)	 it is a qualified investor within the meaning of the Prospectus Regulation and the UK Prospectus Regulation and
any relevant implementing measures and falls within Article 49(2) (“High Net Worth Companies, Unincorporated Association, etc.”) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005; 

 

	 	(d)	 it is authorised and entitled to subscribe for the Subscription Shares (and any ADSs representing the
Subscription Shares) under the laws of all relevant jurisdictions that apply to it, has complied with all such laws relating to the subscription of the Subscription Shares (and any ADSs representing the Subscription Shares) (including, where
applicable, the Criminal Justice Act 1993, MAR, UK MAR, the Proceeds of Crime Act 2002, U.S. securities laws and U.S. Stock Exchange rules, as applicable) and has obtained all applicable consents required to be obtained by it in relation to the
subscription of the Subscription Shares (and any ADSs representing the Subscription Shares); 

  

	 	(e)	 it is incorporated and located outside the United States; and 

 

	 	(f)	 it has not subscribed for the Subscription Shares (or any ADSs representing the Subscription Shares) for the
account or benefit of any person in the United States or entered into any arrangement for the transfer of the Subscription Shares (or any ADSs representing the Subscription Shares) or any economic interest therein to any person in the United States.

  

	5.2	 The Company hereby warrants to AstraZeneca on the Effective Date, that: 

 

	 	(a)	 the information given in Part 1 of Schedule 2 in relation to the issued share capital of the Company is true
and accurate in all respects and is not misleading in any respect because of any omission; 

  

	 	(b)	 all sums due in respect of the issued share capital of the Company have been paid up in full and received by
the Company and, save as disclosed in Part 2 of Schedule 2, there are no outstanding options or other rights to subscribe for or call for the allotment of any share or loan capital of the Company; and 

 

	 	(c)	 none of the owners or holders of shares in the Company will, following issue of such shares, have any rights,
in their capacity as such, in relation to the Company granted by the Company other than as set out in the articles of association of the Company or as has been publicly disclosed by the Company including in an admission document, in the
Company’s statutory annual report or via an RNS announcement. 

  

	5.3	 The Company hereby warrants to AstraZeneca on the Effective Date, and on each Closing Date (provided that
(i) the warranty in clause 5.3(e) below shall not be given on any Closing Date; and (ii) the warranty in clause 5.3(h) below shall be given on each Closing Date subject to the proviso referenced therein), that: 

 

	 	(a)	 the Company is duly incorporated and validly existing under the laws of England and Wales;

  
 10 

	 	(b)	 the Company has power under its articles of association and has obtained all necessary corporate authorities
(including without limitation relevant members’ resolutions) to create, allot and issue the Subscription Shares (or ADSs representing the Subscription Shares), to effect the subscription in the manner proposed and to enter into and perform this
Agreement without any further sanction or consent by members of the Company or any class of them and there are no consents or third party approvals, authorisations or orders of a government or regulatory nature or otherwise required under the laws
of England and Wales for the creation, allotment and issue of the Subscription Shares (or ADSs representing the Subscription Shares), to effect the subscription or to enter into and perform this Agreement, in each case which have not been obtained;

  

	 	(c)	 neither the entering into and performance of this Agreement nor the issue of the Subscription Shares (or any
ADSs representing the Subscription Shares) will: (i) result in a breach of any material agreements to which any member of the Mereo Group is a party or by which any such member or any of their respective properties or assets is bound; or
(ii) violate any requirement of any applicable laws, regulations or rules; 

  

	 	(d)	 this Agreement has been duly authorised, executed and delivered by the Company and constitutes a valid and
legally binding agreement of the Company enforceable against the Company in accordance with its terms, subject to mandatory rules of law relating to insolvency, and to general equitable principles; 

 

	 	(e)	 the Company is a “foreign private issuer” as defined in Regulation S and the Company reasonably
believes that there is no “substantial U.S. market interest” (as defined in Regulation S) in the Subscription Shares or any other securities of the Company of the same class as the Subscription Shares; 

 

	 	(f)	 neither the Company nor any of its Affiliates, nor any person acting on its or their behalf, has, directly or
indirectly, made or will make offers or sales of any security, or has solicited offers to buy, or has otherwise negotiated in respect of any security, under circumstances that would require registration of the Subscription Shares (or any ADSs
representing the Subscription Shares) under the Securities Act except as set forth in clause 3 of this Agreement; 

  

	 	(g)	 neither the Company nor any of its Affiliates, nor any person acting on its or their behalf, has engaged or
will engage in any directed selling efforts (as defined in Regulation S) with respect to the Subscription Shares (or any ADSs representing the Subscription Shares); 

 

	 	(h)	 so far as the Company is aware, the Company is not, other than in connection with the transactions contemplated
by the Transaction Documents, in possession of any unpublished price sensitive information which the Company is required to make public in accordance with Article 17 of MAR or Article 17 of UK MAR (provided that when this warranty is given on a
Closing Date, this is subject to any information that the Company is permitted to delay disclosure of pursuant to MAR or UK MAR, respectively); and the Company is not, as of each Closing Date, in possession of any material nonpublic information
(within the meaning of the U.S. securities laws) regarding the Company; 

  

	 	(i)	 no order has been made, no petition has been presented (so far as the Company is aware) and no meeting has been
convened to consider a resolution and no resolution has been passed for the winding up of any member of the Mereo Group; 

  
 11 

	 	(j)	 no administration order has been made, no petition has been presented or application made (in each case, so far
as the Company is aware) for such an order, and no administrator has been appointed in respect of any member of the Mereo Group; 

  

	 	(k)	 no receiver (which expression shall include an administrative receiver) or liquidator has been appointed in
respect of any member of the Mereo Group or all or any of its assets; 

  

	 	(l)	 no composition or similar arrangement with creditors (including a voluntary arrangement under Part 1 Insolvency
Act 1986) has been proposed by or in respect of any member of the Mereo Group; and 

  

	 	(m)	 the Deposit Agreement is a legal, valid and binding obligation of the Company, enforceable against it in
accordance with its terms, except as rights to indemnification thereunder may be limited by applicable law and public policy considerations, and subject, as to enforceability, to bankruptcy, insolvency, reorganization, moratorium and similar laws of
general applicability relating to or affecting creditors’ rights and to general equity principles. Neither the Company nor, to the Company’s knowledge, the Depositary is in default under the Deposit Agreement and the Company has not given
or received any written notice purporting to terminate the Deposit Agreement. 

  

	6	 ACKNOWLEDGEMENTS 

 

	6.1	 AstraZeneca hereby acknowledges that: 

 

	 	(a)	 in connection with the execution of this Agreement, it is not relying on any information or representation or
warranty in relation to the Company, its subsidiaries or the Subscription Shares (or any ADSs representing the Subscription Shares) other than: (i) currently publicly available information in relation to the Company; and (ii) warranties of
the Company set forth in clauses 5.2 and 5.3 above and the representations of Mereo set forth in the License Agreement; 

  

	 	(b)	 none of the Company or its Affiliates has made any representation or warranty to it, express or implied, with
respect to the completeness, accuracy or adequacy of any publicly available information in respect of the Mereo Group; 

  

	 	(c)	 its subscription of the Subscription Shares (and any ADSs representing the Subscription Shares) shall be on the
terms and subject to the conditions of this Agreement, the License Agreement and the articles of association of the Company in force at each Closing Date and that it shall be bound by such articles of association; and 

 

	 	(d)	 in respect of the First Closing Date only, (i) the Subscription Shares (and any ADSs representing the
Subscription Shares) have not been and will not be registered under the Securities Act, or with any securities regulatory authority of any state of the United States, and will be issued, offered, sold and allotted only outside the United States in
offshore transactions in compliance with Regulation S; (ii) it is not an affiliate of the Company or a person acting on behalf of such affiliate; and (iii) the Subscription Shares (and any ADSs representing the Subscription Shares) have
not been offered to it by means of any directed selling efforts (as defined in Regulation S). 

  
 12 

	7	 [NOT USED] 

  

	8	 REORGANISATION OF THE MEREO GROUP 

 

	8.1	 If there is any transaction (not being a Change of Control) as a result of which holders of Ordinary Shares (as
a class) receive shares or securities in another entity (“New Shares”) in exchange for (or in consideration for the cancellation or transfer of) their Ordinary Shares, whereby the New Shares are to be held in the same proportion as
the existing Ordinary Shares, then the Company will procure that such entity executes an agreement supplemental to this Agreement, providing AstraZeneca with subscription rights over New Shares (that when issued, will be credited as fully paid) in
exchange for (or in consideration for the cancellation or transfer of) its outstanding subscription rights over Subscription Shares (and any ADSs representing the Subscription Shares) under this Agreement at the time of such transaction. The number
of New Shares over which AstraZeneca shall have subscription rights shall represent the same proportion of the total number of issued New Shares (calculated inclusive of any New Shares to be issued on the exercise of any outstanding options,
warrants or other rights to subscribe for or call for the allotment of New Shares) as the Subscription Shares that are yet to be allotted under this Agreement at the time of such transaction represent of the total number of Ordinary Shares
(calculated on the same basis), as determined immediately prior to the completion of the transaction. 

  

	8.2	 Subject to clause 8.1, the subscription rights for the allotment and issue of any New Shares to AstraZeneca
will be subject to the terms and conditions of this Agreement and the License Agreement, mutatis mutandis, as if Ordinary Shares, when used in this Agreement and the License Agreement, were references to New Shares (in particular and without
limitation, in clause 2 of this Agreement). 

  

	8.3	 It is agreed that where the Company’s shares (or instruments or securities representing such shares,
including ADSs) are listed or admitted to trading on any stock exchange (including a U.S. Stock Exchange), the Subscription Shares (as and when issued) shall receive no less favourable treatment than the Ordinary Shares held by any other shareholder
in connection with such listing or admission to trading on a stock exchange, including as regards registration rights and any associated expenses. 

  

	9	 THIRD PARTY RIGHTS 

No person who is not a party to this Agreement may enforce any term of this Agreement. The parties agree that the Contracts (Rights of Third
Parties) Act 1999 shall not apply to this agreement or to any agreement or document entered into pursuant to this Agreement. 
  

	10	 NOTICES 

  

	10.1	 Any notice, request, demand, waiver, consent, approval or other communication permitted or required under this
Agreement shall be in writing, shall refer specifically to this Agreement and shall be deemed given only if delivered by hand or sent by email transmission (with transmission confirmed) or by internationally recognised overnight delivery service
that maintains records of delivery, addressed to the parties at their respective addresses specified in clause 10.2 or to such other address as the party to whom notice is to be given may have provided to the other party in accordance with this
clause 10.1. Such notice shall be deemed to have been given as of the date delivered by hand or transmitted by email (with transmission confirmed) or on the second Business Day (at the place of delivery) after deposit with an internationally
recognized overnight delivery service. Any notice delivered by email shall be confirmed by a hard copy delivered as soon as practicable thereafter. 

  
 13 

	10.2	 The addresses referred to in clause 10.1 are: 

in respect of the Company: 
 Mereo
BioPharma Group plc 
 4th Floor, 1 Cavendish Place 

London W1G 0QF 
 United Kingdom

 Attention: General Counsel 

Email: legal@mereobiopharma.com 

with copies (which shall not constitute notice) to: 

Latham & Watkins LLP 

140 Scott Drive 
 Menlo Park, CA
94025 
 United States of America 

Attention: Judith Hasko 
 Email:
Judith.Hasko@lw.com 
 and 

Latham & Watkins LLP 
 99
Bishopsgate 
 London, EC2M 3XF 

United Kingdom 
 Attention: James
Inness 
 Email: James.Inness@lw.com 

in respect of AstraZeneca: 

AstraZeneca AB 
 SE-151 85 Sodertalje, Sweden 
 Attention: Deputy General Counsel 

Email: legalnotices@astrazeneca.com 

with a copy (which shall not constitute notice) to: 

Covington & Burling LLP 

One City Center, 850 Tenth Street NW 

Washington, DC 20001-4956 
 United
States 
 Attention: Michael J. Riella 

Email: mriella@cov.com 
  

	10.3	 AstraZeneca shall at all times maintain an agent for the service of process and any other documents and
proceedings in England or any other proceedings in connection with this Agreement. Such agent shall be AstraZeneca UK Limited, and any writ, judgment or other notice of legal process shall be sufficiently served on AstraZeneca if delivered to such
agent at its registered address for the time being marked for the attention of the Deputy General Counsel. 

  
 14 

	10.4	 If for any reason, AstraZeneca UK Limited ceases to act as agent for service, AstraZeneca shall immediately
appoint a new agent for service of process in England and shall immediately notify the Company in writing of such appointment and the name and address of the new agent. 

 

	11	 FURTHER ASSURANCE 

Each party shall promptly execute and deliver such documents and perform such acts as may be reasonably required for the purpose of giving full
effect to this Agreement. 
  

	12	 ENTIRE AGREEMENT 

 

	12.1	 This Agreement, the License Agreement, the Guarantee and any other agreement entered into in connection with
this Agreement constitute the entire and only agreements between the parties relating to the subject matter of this Agreement. 

  

	12.2	 If any provision of this Agreement shall be held to be illegal, invalid or unenforceable, in whole or in part,
such provision or relevant part shall be deemed not to form part of this Agreement but the legality, validity and enforceability of the remainder of this Agreement shall not be affected. 

 

	13	 APPLICABLE LAW 

 

	13.1	 This Agreement (and any dispute or claim relating to it or its subject matter, including contractual and non-contractual claims) shall be governed by and construed in accordance with the laws of England. 

  

	13.2	 Each of the parties hereby submits to the non-exclusive jurisdiction of
the courts of England in relation to any matters (including non-contractual claims) arising out of this Agreement. This clause shall be without prejudice to the right of any party to bring proceedings in any
other jurisdiction for the purpose of enforcement or execution of any judgment or other settlement in any other court. 

  
 15 

 SCHEDULE 1 

ADJUSTMENTS 
  

	1	 Adjustments to be Made 

If there is an Adjustment Event, the Subscription Price (and, consequently, the number and/or nominal value of any Subscription Shares that
AstraZeneca subsequently becomes entitled to be allotted in accordance with the terms of the Transaction Documents) will be adjusted in the manner set out in this Schedule 1. 
  

	2	 Adjustment of Subscription Price 

 

	2.1	 If and whenever the nominal value of the Ordinary Shares is altered as a result of consolidation or subdivision
of the share capital of the Company (an “Adjustment Event”), the Subscription Price shall be adjusted by multiplying the Subscription Price in force immediately prior to such alteration by the following fraction:

 A 

B 
 where: 

A     is the nominal amount of one Ordinary Share immediately after such alteration; and 

B     is the nominal amount of one Ordinary Share immediately before such alteration. 

Such adjustment shall become effective on the date the alteration takes effect. 

 

	2.2	 In the case of any dispute as to the manner of any adjustment pursuant to this Schedule 1, the auditors (from
time to time) of the Company or, if they are unwilling or unable to act, the Calculation Agent shall determine the same. The costs of the auditors or the Calculation Agent (as the case may be) shall be borne jointly by the Company and AstraZeneca.

  

	2.3	 The auditors or the Calculation Agent shall act as expert and not as arbitrator and their/its good faith
determinations and calculations shall be binding on the Company and AstraZeneca in the absence of manifest error. If any doubt arises as to the appropriate adjustment to the Subscription Price a certificate of the auditors or the Calculation Agent
(as the case may be) shall be conclusive and binding on all concerned. 

  

	2.4	 The Subscription Price may not be reduced so that, on the subscription of any Subscription Shares, Ordinary
Shares would be issued at a discount to their nominal value. 

  

	2.5	 On any adjustment, the resultant Subscription Price shall be rounded down to the nearest $0.001 so that any
amount under $0.0005 shall be rounded down and any amount of $0.0005 or more shall be rounded up). Any amount by which the Subscription Price is rounded down shall be carried forward and taken into account in any subsequent adjustment.

  
 16 

 SCHEDULE 2 

SHARE CAPITAL 
 PART 1
– ISSUED SHARE CAPITAL AT THE EFFECTIVE DATE 
 Ordinary Shares: 70,604,176 

PART 2 – OUTSTANDING WARRANTS, OPTIONS, BONUS SHARES AND 

CONVERTIBLE DEBT AT THE EFFECTIVE DATE 

Warrants: 363,156 Ordinary Shares 

Share options: 11,705,469 Ordinary Shares 

Convertible debt: 1,031,408 Ordinary Shares 

Bonus shares: 864,988 Ordinary Shares 

  
 17 

 SCHEDULE 3 

[NOT USED] 

  
 18 

 EXECUTION PAGE TO SUBSCRIPTION DEED 

SCHEDULE 4 
 ADS ISSUANCE
AND DELIVERY INSTRUCTION 
 Date:
                     20[●] 
  

	To:	 Citibank, N.A., as Depositary 

	 	 388 Greenwich Street 

	 	 New York, New York 10013 

	 	Attn.:	 Mr. Brian M. Teitelbaum (brian.m.teitelbaum@citi.com) 

	 	 	 Mr. Keith Galfo (keith.galfo@citi.com) 

	 	 	 Mr. Leslie Deluca (leslie.deluca@citi.com) 

	 	 	 DR Broker Services (drbrokerservices@citi.com) 

With a copy simultaneously delivered to: 
  

	 	 Citibank, N.A., London Branch 

	 	 25 Canada Square 

	 	 Canary Wharf 

	 	 London E14 5LB, England 

	 	Attn.:	 UK Custody Settlements 

	 	 	 Custody Team (uksettlements@citi.com) 

Re: Issuance and Delivery Instruction – Mereo BioPharma Group plc (CUSIP No.: 589492107) – Deposit & Hold 

Dear Sirs: 
 Reference is made to the Deposit Agreement, dated
as of April 23, 2019, as amended and supplemented from time to time (the “Deposit Agreement”), by and among Mereo BioPharma Group plc, a public limited company incorporated under the laws of England and Wales and its successors
(the “Company”), Citibank, N.A., a national banking association organized and existing under the laws of the United States of America, as Depositary (the “Depositary”), and all Holders and Beneficial Owners of
American Depositary Shares (the “ADSs”) issued thereunder. All capitalized terms used, but not otherwise defined herein, shall have the meaning assigned thereto in the Deposit Agreement. 

In accordance with the terms and subject to the limitations set forth in the Deposit Agreement, promptly following the Depositary’s receipt of
confirmation from the Custodian that the Custodian has received a deposit of the number of Shares specified below made by the Company for the benefit of the undersigned holder (the “Holder” and together with the Company, the
“Undersigned”), the Undersigned hereby jointly instruct the Depositary, and the Depositary hereby agrees to promptly accept for deposit the number of Shares and issue the number of ADSs as specified below to the Holder. 

 

			
	 Number of Shares deposited:
	  	[●] Shares
	 Number of ADSs (CUSIP No.: 589492107; each ADS representing five (5) Shares) to be
issued:
	  	[●] ADSs

 Further, the Undersigned hereby jointly instruct the Depositary, and the Depositary hereby agrees to promptly deliver such
ADSs, as follows: 

			
	 Name of DTC Participant to which the ADSs are to be delivered:
	  	
	 DTC Participant Account No.:
	  	  

	 Account No. for recipient of ADSs at DTC Participant (f/b/o information):
	  	  

	 Name on whose behalf the above number of ADSs are to be issued and delivered:
	  	  

	 Contact person at DTC Participant:
	  	  

	 Daytime telephone number of contact person at DTC Participant:
	  	  

 The Company hereby confirms and certifies that (i) the registration statement on Form [S/F]-[1/3] (File No.
[●]-[●]) (the “Registration Statement”), filed with the U.S. Securities and Exchange Commission (the “Commission”) on [●], [●], registers the resale of the above ADSs, such ADSs will be freely transferable
following the issuance thereof by the Depositary, and there are no legal restrictions on subsequent transfers of the ADSs to be issued hereunder under the laws of England and Wales or the United States, (ii) the Registration Statement is
effective under the Securities Act of 1933, as amended (the “Securities Act”), and (iii) no stop order suspending the effectiveness of the Registration Statement has been issued and no proceedings for such purpose have been instituted
or are pending or, to the best knowledge of the Company, are contemplated or threatened by the Commission. 
 The Holder hereby represents and covenants to,
and for the benefit of, the Depositary and Citibank, N.A. – London Branch (the “Custodian”), that (i) the Holder is not an “affiliate” of the Company as that term is defined in Rule 405 promulgated by the
U.S. Securities and Exchange Commission under the Securities Act and has not been an affiliate for at least three months prior to the date hereof, and (ii) all stamp duty taxes, including, without limitation, the U.K. Stamp Duty Reserve Tax
(“SDRT”), will be paid in full and on a timely basis to the extent such taxes are payable in respect of the deposit of the Shares and the issuance and delivery of the ADSs as contemplated herein. 

Each of the Holder and, to the extent it is not unlawful for the Company to do so under the applicable laws of England and Wales, the Company agrees to
indemnify the Depositary and the Custodian for, and to hold the Depositary and the Custodian harmless against, all losses, liabilities, taxes, charges, penalties or expenses (including reasonable legal fees and disbursements), incurred by the
Depositary and/or by the Custodian or to which the Depositary and/or the Custodian may become subject to and arising directly or indirectly from the failure by any person to pay (or discharge) any applicable stamp duty taxes, including, without
limitation, SDRT, or any other similar duty or tax in connection with the deposit of the Shares and the issuance and delivery of the ADSs as contemplated herein, save to the extent that such losses, liabilities, taxes, charges, penalties or expenses
are due to the negligence or bad faith of the Custodian or the Depositary. 
  

									
	ASTRAZENECA AB	 		 	MEREO BIOPHARMA GROUP PLC

									
					
	By:	 	  
	  		  	By:	 	  

	Name:	 		  		  	Name:	 	
	Title:	 		  		  	Title:	 	

  
 20 

 This Subscription Deed has been executed as a deed and is delivered and takes effect on the date stated at
the beginning of it. 
  

											
	EXECUTED and delivered as a DEED by	  	 	)	 	 		  	
	ASTRAZENECA AB (publ)	  	 	)	 	 		  	
	 acting by an authorised signatory
	  	 	)	 	 		  	
		 		  	 	)	 	 	  
	  	
		 		  	 	)	 	 	Authorised signatory	  	
				
	EXECUTED and delivered as a DEED by	  	 	)	 	 		  	
	MEREO BIOPHARMA GROUP PLC	  	 	)	 	 		  	
	 acting by
	  	 	)	 	 		  	
		 		  				 	  
	  	
	 a director, in the presence of:
	  	 	)	 	 	Director	  	
				
	  
	 		  	 	Signature of Witness	  	
				
	  
	 		  	 	Name of Witness	  	
				
	  
	 		  	 	Address of Witness	  	
					
	  
	 		  				 		  	
					
	  
	 		  				 		  	
				
	  
	 		  	 	Occupation of Witness	  	

  
 21EX-4.4

 Exhibit 4.4 

EXECUTION VERSION 
 DEED
OF CONSENT AND AMENDMENT TO WARRANT INSTRUMENTS 
 THIS DEED is dated         December 2020 (such date
being the “Effective Date”) 
 BETWEEN: 
  

	(1)	 MEREO BIOPHARMA GROUP PLC, a public limited company incorporated in England and Wales with company
number 04206001 whose registered office is at 4th Floor, One Cavendish Place, London, England W1G 0QF (the “Company”); 

  

	(2)	 KREOS CAPITAL V (UK) LIMITED, a private limited company incorporated in England and Wales with company
number 09728300, whose registered office is at 25 Old Burlington Street, London W1S 3AN (“Kreos”); and 

  

	(2)	 SILICON VALLEY BANK, a California corporation with its principal place of business at 3003 Tasman Drive,
Santa Clara, California 95054, United States of America, and registered in England and Wales under numbers BR014561 and FC029579 with its UK branch at Alphabeta, 14-18 Finsbury Square, London, EC2A 1BR (“SVB”).

 WHEREAS 
  

	(A)	 The Company adopted a warrant instrument on 21 August 2017, a copy of which is appended hereto as Appendix
1 (the “2017 Warrant Instrument”) and another warrant instrument on substantively similar terms on 1 October 2018 (the “2018 Warrant Instrument”), a copy of which is appended hereto as Appendix 2, each of the
2017 Warrant Instrument and the 2018 Warrant Instrument constituting certain warrants to subscribe for Ordinary Shares in the capital of the Company. The 2017 Warrant Instrument and the 2018 Warrant Instrument are collectively referred to herein as
the “Warrant Instruments”. 

  

	(B)	 Pursuant to the Warrant Instruments, initial allocations of Warrants were issued to SVB and Kreos, with further
issues following adjustment of the Warrants from time to time, resulting in SVB and Kreos each holding 621,954 Warrants as of 11 December 2020 (as set out below, each such Warrant being exercisable at a Subscription Price of GBP 2.95, such
price representing the weighted average of the Warrants issued by the Company in favour of SVB and Kreos on 21 August 2017, 29 December 2017 and 1 October 2018). 

 

	(C)	 In 2020, the Company completed certain equity and debt financing transactions, including:

  

	 	(i).	 a commercial transaction with Aspire Capital Fund, LLC on 10 February 2020 that resulted in the issuance
of Equity Securities to Aspire (the “Aspire Transaction”); 

  

	 	(ii).	 a convertible loan note to Novartis Pharma AG (“Novartis”) on 10 February 2020 in the
amount of £3,841,479 (the “Novartis Convertible Note”) and also issued a warrant to Novartis on 10 February 2020 to subscribe for ordinary shares in the Company (the “Novartis Warrant”);

  

	 	(iii).	 a securities purchase agreement with Boxer Capital, LLC (“Boxer”) on 19 February 2020
pursuant to which Boxer agreed to make an investment of $3 million to purchase 12,252,715 of the Company’s ordinary shares (the “Boxer Transaction”); and 

 

	 	(iv).	 certain financing transactions on 3 June 2020, pursuant to which OrbiMed Partners Master Fund Limited,
OrbiMed Genesis Master Fund L.P. and OrbiMed Private Investments VII, LP and certain other investors subscribed for certain Equity Securities, including (i) Ordinary Shares, (ii) warrants to subscribe for Ordinary Shares, and
(iii) loan notes convertible into Ordinary Shares ((i), (ii) and (iii) together, the “PIPE Transaction”) 

 (the Aspire Transaction, Novartis Convertible Note, Novartis Warrant, Boxer Transaction and
PIPE Transaction together, the “2020 Adjustment Events”). 
  

	(D)	 Prior to the Effective Date, the Company, SVB and Kreos had not been able to reach agreement as to the
appropriate manner in which the Warrants should be adjusted to reflect the 2020 Adjustment Events. 

  

	(E)	 The Company is intending to cancel the admission to trading of its Ordinary Shares from the Alternative
Investment Market (“AIM”) operated by the London Stock Exchange, with effect from 18 December 2020 (the “Delisting”). Following the Delisting, the only listing maintained by the Company will be that of American
depositary receipts on NASDAQ, the tradeable entitlement representing American Depositary Shares (“ADSs”), each of which such ADSs represents five Ordinary Shares. 

 

	(F)	 The parties are entering into this Deed to (i) confirm how the Warrants will be adjusted in respect of the
2020 Adjustment Events; (ii) amend certain terms of the Warrant Instruments so as to limit the instances of future Adjustments; (iii) make appropriate changes to the Warrant Instruments to accommodate the Delisting; and (iv) amend
certain additional terms of the Warrant Instruments to add a mechanism for delivery of ADSs to a Warrantholder following a valid exercise of subscription rights and remove provisions relating to AIM-listed status which will cease to be relevant
after the Delisting. 

 IT IS AGREED AS FOLLOWS: 
  

	1.	 INTERPRETATION 

Terms defined in each of the Warrant Instruments shall have the same meanings as given therein when used in this Deed unless otherwise defined
herein. 
  

	2.	 TREATMENT OF TRANSACTIONS 

Each of the parties hereto: 
  

	 	(a)	 agrees and confirms that as at the Effective Date, no adjustment of the Warrants has been made in respect of
the 2020 Adjustment Events; 

  

	 	(b)	 agrees that, in full and final settlement of any adjustments that might have been required pursuant to the 2020
Adjustment Events under the terms of the Warrant Instruments prior to their amendment by the terms of this Deed and in consideration for the further changes to the Warrant Instruments as set out herein, the Company shall issue to each of SVB and
Kreos 621,954 further Warrants (such Warrants constituting an adjustment for the purposes of the Warrant Instruments, and to be apportioned between the 2017 Warrant Instrument and 2018 Warrant Instrument in the amounts of 469,575 and 152,379
Warrants respectively), which shall have a subscription price attached thereto of USD 0.4144 per Warrant Share (such price being the volume weighted average price of one (1) Ordinary Share during the ten (10) consecutive trading day
period immediately preceding the Effective Date converted into USD at an exchange rate of 1 GBP = 1.3226 USD (being the GBP-USD opening exchange rate published in the Wall Street Journal on the business day (being a day on which banks are open for
commercial business in New York) immediately preceding the Effective Date); and 

	 	(c)	 agrees that from the Effective Date, each of the Warrant Instruments shall be amended in the manner provided in
clause 3 of this Deed, including, for the avoidance of doubt: 

  

	 	(i)	 so as to restrict the Company’s obligation to adjust the Warrants issued thereunder to such events as set
out in the revised definition of “Adjustment” in the forms of amended 2017 Warrant Instrument and 2018 Warrant instrument appended to this Deed; and 

 

	 	(ii)	 so as to amend the Subscription Price for all Warrants issued pursuant to the 2017 Warrant Instrument or 2018
Warrant Instrument prior to the Effective Date to GBP 2.95 (such amount representing the weighted average exercise price of the warrants issued thereunder on 21 August 2017, 29 December 2017 and 1 October 2018) as set out in the
revised definition of “Subscription Price” in the forms of amended 2017 Warrant Instrument and 2018 Warrant instrument appended to this Deed. 

 

	3.	 AMENDMENTS AND CONSENT 

With effect from the Effective Date: 
  

	 	(a)	 the 2017 Warrant Instrument shall be amended so as to include all the changes marked within the version of the
2017 Warrant Instrument as set out at Schedule 1 (Amended 2017 Warrant Instrument). For the avoidance of doubt and for the future reference of the Warrantholders, the Company, their successors in title and any other persons with an interest
in the Warrants or the terms of the 2017 Warrant Instrument (if any), Schedule 2 attaches a complete and clean copy of the amended Note Instrument which incorporates the changes implemented pursuant to this Deed; and 

 

	 	(b)	 the 2018 Warrant Instrument shall be amended so as to include all the changes marked within the version of the
2018 Warrant Instrument as set out at Schedule 3 (Amended 2018 Warrant Instrument). For the avoidance of doubt and for the future reference of the Warrantholders, the Company, their successors in title and any other persons with an interest
in the Warrants or the terms of the 2017 Warrant Instrument (if any), Schedule 4 attaches a complete and clean copy of the Amended Note Instrument which incorporates the changes implemented pursuant to this Deed. 

 

	3.2	 For the purposes of clause 10.1 of each of the Warrant Instruments, by their execution of this Deed, SVB and
Kreos hereby grant Consent to the amendments herein and the provisions of this Deed (including the transactions contemplated herein). 

  

	4.	 MISCELLANEOUS 

 

	4.1	 This Deed shall be governed by and construed in accordance with English law and the parties submit to the
exclusive jurisdiction of the English courts. 

  

	4.2	 This Deed may be executed in counterparts which together shall constitute one document. 

 Schedule 1 

2017 Warrant Instrument (marked changes) 

 

 

EXECUTION
VERSION 
 EXECUTION VERSION 

DATED
DECEMBER 2020 2017 

MEREO BIOPHARMA GROUP PLC 
  

 
 AMENDED WARRANT INSTRUMENT DATED 21 

AUGUS
T
2017 

relating to the issue of warrants entitling the holders to 

subscribe for Warrant Shares in the capital of 

MEREO BIOPHARMA GROUP PLC 
  

 
 5 Fleet Place
London EC4M 7RD 
 Tel: +44 (0)20 7203 5000 ● Fax: +44 (0)20 7203 0200 ● DX:
19 London/Chancery Lane 
 www.charlesrussellspeechlys.com 

 CONTENTS 
  

							
	 1
	 	DEFINITIONS AND INTERPRETATION	  	 	2	 
			
	 2
	 	CONSTITUTION AND FORM OF WARRANTS	  	 	9	 
			
	 3
	 	CALCULATION OF NUMBER OF WARRANT SHARES	  	 	10	 
			
	 4
	 	CERTIFICATES	  	 	10	 
			
	 5
	 	TIMING FOR EXERCISE OF SUBSCRIPTION RIGHTS	  	 	10	 
			
	 6
	 	EXERCISE OF SUBSCRIPTION RIGHTS	  	 	11	 
			
	 7
	 	AUTOMATIC EXERCISE OF SUBSCRIPTION RIGHTS	  	 	13	 
			
	 8
	 	COMPLETION	  	 	14	 
			
	 9
	 	TRANSFER OF WARRANTS	  	 	15	 
			
	 10
	 	MODIFICATION AND CESSATION OF RIGHTS	  	 	15	 
			
	 11
	 	ADJUSTMENT OF WARRANT	  	 	15	 
			
	 12
	 	LIQUIDATION	  	 	16	 
			
	 13
	 	TAKEOVERS	  	 	16	 
			
	 14
	 	COMPANY REORGANISATIONS – EXCHANGE OF WARRANTS	  	 	18	 
			
	 15
	 	INFORMATION AND RIGHTS OF WARRANTHOLDER(S)	  	 	19	 
			
	 16
	 	RESTRICTIONS ON AND UNDERTAKINGS OF THE COMPANY	  	 	19	 
			
	 17
	 	WARRANTIES	  	 	20	 
			
	 18
	 	NOTICES	  	 	20	 
			
	 19
	 	COSTS AND EXPENSES	  	 	20	 
			
	 20
	 	CONTRACTS (RIGHTS OF THIRD PARTIES) ACT 1999	  	 	21	 
			
	 21
	 	FURTHER ASSURANCE	  	 	21	 
			
	 22
	 	SEVERABILITY	  	 	21	 
			
	 23
	 	GOVERNING LAW	  	 	21	 
		
	 SCHEDULE 1 FORM OF WARRANT CERTIFICATE
	  	 	22	 
		
	 SCHEDULE 2 CONDITIONS
	  	 	28	 

 THIS WARRANT INSTRUMENT is made on 201721 August 2017, as
amended on December 2020 
  

	(0)	 BY: 

  

	(1)	 MEREO BIOPHARMA GROUP PLC, a company incorporated in England and Wales with number 09481161 whose
registered office is at 4th Floor, 1 Cavendish Place, London, England, W1G 0QF (“Company”). 

 BACKGROUND: 

 

	(A)	 The Company, by resolution of its directors, has agreed to issue Warrants to subscribe for Warrant Shares in
the capital of the Company on the terms set out in this instrument, subject to adjustment as set out in this instrument. 

  

	(B)	 Either all of the registered holders of shares in the Company have irrevocably waived all pre-emption rights
conferred on them (whether by the Companies Act, the Articles or otherwise) or such pre-emption rights have been validly disapplied in relation to the number of Warrants and shares in the Company issued pursuant to this instrument.

  

	(C)	 This instrument has been executed by the Company as a deed in favour of the Warrantholder.

 IT IS AGREED: 
  

	1	 DEFINITIONS AND INTERPRETATION 

 

	1.1	 In this instrument the following words and expressions shall (unless the context requires otherwise) have the
following meanings: 

  

			
	2020 Warrants	  	means any warrants issued on the Amendment Date, by way of adjustment to the Initial Warrants;
		
	Adjustment	  	means any sub-division or allconsolidation of Equity Securities by the followingCompany, at any time, after issue of the relevant Warrant, or by reference to any record date, while the
Warrants remain exercisable:
		
		  	 (a)   any allotment or issue of Equity Securities
by the Company by way of capitalisation of profits or reserves;

		
		  	 (b)   any cancellation, purchase or redemption of
Equity Securities, or any reduction or repayment of Equity Securities, by the Company;

		
		  	 (c)   any sub-division or consolidation of Equity
Securities by the Company; and

		
		  	 (d)   any issue of securities or other instruments
convertible into shares in, or Equity Securities of, the Company or any grant of options, warrants or other rights to subscribe for, or call for the allotment or issue of, shares in, or Equity Securities
of, the Company,

  
 2 

			
		
		  	but excluding any issue of Equity Securities of the Company pursuant to (i) the exercise of any options granted to employees, consultants or directors of the Company, or (ii) the loan notes in the
Company currently held by Novartis Pharma AG pursuant to a convertible loan note instrument dated 3 June 2016, as amended;
		
	AIMADS	  	the AIM market operated by the London Stock Exchangemeans American Depositary Shares representing interests
in the Ordinary Shares pursuant to a sponsored American Depositary Receipt facility with the Depositary;
		
	AIM RulesADS Exchange Ratio	  	the AIM Rules for Companies published by the London Stock Exchangemeans the ratio applicable to the exchange
of Ordinary Shares for ADSs from time to time, currently being a ratio of 5 Ordinary Shares for each ADS;
		
	Amendment Date	  	means 15 December 2020;
		
	Articles	  	the articles of association of the Company for the time being;
		
	Auditors	  	the Company’s auditors;
		
	Business	  	means the research, development, production, trading and licensing of rights, intellectual property and/or products within the life sciences industry (or any of the foregoing or any activities connected thereto);
		
	Business Day	  	a day (which for these purposes ends at 5.30 pm) on which banks are open for commercial business in the City of London other than a Saturday or Sunday;
		
	Companies Act	  	the Companies Act 2006;
		
	Competitor	  	means any entity (other than a reputable financial institution) whose business directly competes with the Business carried out by a Group Company;
		
	Conditions	  	the terms and conditions set out in Schedule 2 (subject to any alterations made in accordance with the provisions of this instrument);

  
 3 

			
	Consent	  	either:
		
		  	 (a)   a resolution passed at a meeting of the Warrantholders duly convened and
held and carried by a majority consisting of not less than 75 per cent. of the votes cast upon a show of hands or, if a poll is duly demanded, by a majority consisting of not less than 75 per cent of the votes cast on a poll; or

		
		  	 (b)   the consent in writing of Warrantholders entitled to the right to
subscribe for at least 75 per cent of the Warrant Shares in respect of which Subscription Rights are granted pursuant to this instrument;

		
	CREST	  	the system of paperless settlement of trades and the holding of uncertificated shares administered by Euroclear UK & Ireland Limited or any other relevant paperless settlement system used in
relation to the holding of uncertificated shares in the Company;
		
	Directors	  	the board of directors of the Company (and/or, where relevant, a Group Company) for the time being;
		
	Equity Securities	  	has the meaning given min section 560(1) of the Companies Act;
		
	Exercise Date	  	the date of delivery to the registered office of the Company of the items specified in clause 6.2 (and the date of such delivery shall be the date on which such items are received at the Company’s registered office);
		
	Fair Market Value	  	either:
		
		  	 (a)   if the Ordinary Shares are then traded on a Recognised Investment Exchange
the fair market value of a Warrant Share shall be the volume weighted average price of one (1) Ordinary Share during the ten (10) consecutive trading day period immediately preceding the Exercise Date; or

		
		  	 (b)   if the Ordinary Shares are not traded on a Recognised Investment Exchange, the fair but ADSs are listed on Nasdaq, the implied price of One Ordinary Share in pounds sterling, which shall be determined as
follows:

  
 4 

			
		  	 (i) dividing (x) being the volume
weighted average price of one ADS during the ten (10) consecutive trading day period immediately preceding the Exercise Date by (y) being the number of Ordinary Shares currently represented by a single ADS in accordance with the ADS Exchange Ratio
in effect on such date (Implied USD Price); and

		
		  	 (ii) converting the Implied USD Price to
pounds sterling at the Exchange Rate on the trading day immediately preceding the Exercise Date; or

		
		  	
(c)   if the Ordinary Shares are not traded on a Recognised Investment Exchange and ADSs are not listed on Nasdaq, the fair market value a Warrant Share shall be the Fair
Price;

		
	Fair Price	  	unless otherwise agreed by the board of Directors and the Warrantholder(s) prior to service of the Notice of Subscription, the price per Warrant Share which the Auditors (acting as an expert (the Expert)) shall certify to be
in its opinion a fair price for the Warrant Shares. In arriving at his opinion the Expert will value the Warrant Shares as at the date the Notice of Subscription is to be given on the basis that the Company operates as a going concern, as between a
willing seller and a willing buyer,subject always to the provisions of the Articles. The decision of the Expert as to the fair price for the Warrant Shares shall be final and binding and his costs shall be borne by the Company;
		
	Final Date	  	subject to clause 5, 10 years from the date of this instrument (which, for the avoidance of doubt, shall be 21 August 2027);
		
	London Stock Exchange	  	London Stock Exchange plc;
		
	Group	  	(i) the Company and its subsidiaries (if any), (ii) any holding company of the Company, and (iii) any subsidiaries of such holding companies from time to time and Group Company means any member of the
Group;

  
 5 

			
		
	LoanInitial
AgreementWarrants	  	the loan agreement dated on or around the same date as this instrument between, amongst others, the Company, Kreos Capital V (UK) Limited and Silicon Valley
Bankmeans the warrants of the Company constituted by this Instrument on 27 August 2017 and 29 December 2017 and any further warrants issued prior to the
Amendment Date as an adjustment thereto;
		
	Market Abuse RegulationIssuance and Delivery Instruction	  	Market Abuse Regulation (Regulation 596/2014/EU)means an issuance and delivery instruction in such form as
notified from the Company to the Warrantholders from time to time, the current form of which is attached hereto at Schedule 3;
		
	Marketable Securities	  	means securities in the acquiring entity traded on a Recognised Investment Exchange where the Warrantolder(s) (were it to receive such securities on completion of an Offer having exercised this Warrant) would not be subject to any
restrictions on re-sale of such securities;
		
	Member of the same Fund Group	  	is if the Warrantholder is a fund, partnership, company, syndicate or other entity whose business is managed by a Fund Manager (an “Investment Fund”) or a nominee of that person:
		
		  	 (a)   any participant or partner in or member of any such Investment Fund or the
holders of any unit trust which is a participant or partner in or member of any Investment Fund but only in connection with the dissolution of Investment Fund or any distribution of assets of the Investment Fund pursuant to the operation of the
Investment Fund in the ordinary course of business,

		
		  	 (b)   any Investment Fund managed or exclusively advised by that Fund
Manager,

		
		  	 (c)   a parent undertaking or subsidiary undertaking of that Investment Fund or
Fund Manager, or any subsidiary undertaking of any parent undertaking of that Investment Fund or Fund Manager, or

		
		  	 (d)   any trustee, nominee or custodian of such Investment Fund and vice
versa;

		
	Notice of Subscription	  	the notice addressed to the Company by a Warrantholder exercising its Subscription Rights in the form, or substantially in the form, set out in the schedule to the Warrant
Certificate;

  
 6 

			
		
	Ordinary Shares	  	ordinary shares in the capital of the Company and having the rights and privileges set out in the Articles;
		
	Permitted Transferee	  	are:
		
		  	 (a)   a nominee of the Warrantholders;

		
		  	 (b)   a regulated, reputable financial institution;

		
		  	 (c)   a member of the SVB Financial Group of companies; and/or

		
		  	 (d)   a Member of the same Fund Group;

		
	Recognised Investment Exchange	  	a recognised investment exchange or overseas investment exchange (within the meaning thereof given for the purposes of section 285 of the Financial Services and Markets Act 2000, and shall include, without limitation, AIM or
NASDAQ;
		
	Register	  	the register of persons for the time being entitled to the benefit of the Warrants to be maintained pursuant to the Conditions;
		
	Registrars	  	the registrars of the Company for the time being;
		
	Subscription Price	  	the subscription price per Warrant Share such price being equal to:
		
		  	 (a)   in respect of
the Initial Warrants to be issued on the First Issue Date, such price being equal
to,
£3.02902.95; and

		
		  	 (b)   in respect of
the 2020 Warrants to be issued on the Further Issue Dates, such
price , $0.4144 (being equal to the volume weighted average price of
one (1) Ordinary Share during the ten (10) consecutive trading day period prior to the relevant Issue Dateimmediately preceding the Amendment Date converted into USD at an exchange rate of 1 GBP = 1.3226 USD (being the GBP-USD opening exchange rate published in the Wall Street
Journal on the business day (being a day on which banks are open for commercial business in New York) immediately preceding the Amendment Date);

  
 7 

			
	Subscription Rights	  	the rights of the Warrantholder(s) to subscribe for Warrant Shares under clause 6;
		
	Takeover Code	  	the UK City Code on Takeovers and Mergers (as amended from time to time);
		
	UKLA	  	the United Kingdom Listing Authority;
		
	Warrant Amount	  	£1,100,000;
		
	Warrant Certificate	  	a certificate evidencing a Warrantholder’s entitlement to Warrants in the form set out in Schedule 1;
		
	Warrant Shares	  	Ordinary Shares to be issued pursuant to the terms of the Warrants;
		
	Warrantholder	  	in relation to a Warrant, the person whose name appears in the Register as the holder of the Warrant; and
		
	Warrants	  	the warrants of the Company constituted by this instrumentInitial Warrants and the 2020 Warrants
and all rights conferred by itthis Instrument relating thereto (including the Subscription Rights).

  

	1.2	 In this instrument, unless the context otherwise requires: 

 

	 	1.2.1	 words and expressions defined in the Companies Act or the Articles shall have the same meanings in this
instrument (unless otherwise expressly defined in this instrument); 

  

	 	1.2.2	 headings are used for convenience only and shall be ignored in interpreting this instrument;

  

	 	1.2.3	 reference to a clause or schedule is a reference to a clause of, or schedule to, this instrument;

  

	 	1.2.4	 reference to (or to any specific provision of) this instrument or any other document or instrument shall be
construed as a reference to this instrument, that provision or that document or instrument as in force for the time being and as amended from time to time in accordance with its terms and the prior sanction of a Consent (where consent is required by
the terms of this instrument as a condition to such amendment being made); 

  

	 	1.2.5	 reference to any gender includes all genders, references to the singular includes the plural (and vice versa)
and reference to persons includes bodies corporate, unincorporated associations and partnerships (whether or not any of the same have a separate legal personality); 

  
 8 

	 	1.2.6	 reference to a statutory provision includes reference to: 

 

	 	(a)	 the statute or statutory provision as modified or re-enacted from time to time; and 

 

	 	(b)	 any subordinate legislation made under the statutory provision (as modified or re-enacted as set out in clause
1.2.6(a) above); 

  

	 	1.2.7	 any words following the terms ‘including’, ‘include’, ‘in particular’, ‘for
example’ or any other similar expression shall be construed as illustrative and shall not limit the sense of the words, description, phrase or term preceding those words; and 

 

	 	1.2.8	 references to statutory obligations include obligations arising under articles of the Treaty establishing the
European Community, and regulations, directives and decisions of the European Union as well as United Kingdom Acts of Parliament and subordinate legislation. 

  

	1.3	 Unless otherwise specifically provided, where any notice, resolution or document is required by this instrument
to be signed by any person, the reproduction of the signature of such person by fax or email shall suffice, provided that confirmation by first class letter is despatched by close of business on the next following Business Day, in which case the
effective notice, resolution or document shall be that sent by fax or email (served in accordance with paragraphs 11 and 12 of Schedule 2), not the confirmatory letter. 

 

	1.4	 This instrument incorporates the schedules to it. 

 

	2	 CONSTITUTION AND FORM OF WARRANTS 

 

	2.1	 This instrument constitutes the Warrants, which in aggregate give the Warrantholder(s) the right, upon the
terms and subject to the conditions set out in this instrument, to subscribe in cash (subject to clause 6.3.2) at a price per share equal to the Subscription Price for such number of Warrant Shares calculated in accordance with clause 3.

  

	2.2	 Subject to clause 6.3.2, each Warrantholder shall be entitled to subscribe in cash at the Subscription Price
for that number of Warrant Shares in respect of which it is entitled to be recorded as the holder in the Register on the terms set out in this instrument. 

  

	2.3	 The Warrants shall be in registered form. 

 

	2.4	 The Warrants are issued subject to the Articles and otherwise on the terms of this instrument (including the
Conditions). 

  

	2.5	 The Company agrees with the Warrantholder(s) and, in consideration of being issued a Warrant Certificate, each
Warrantholder agrees with the Company that the Articles (insofar as they relate to the Warrants) and the terms of this instrument shall be binding upon the Company and each Warrantholder and all persons claiming through or under either of them.

  
 9 

	2.6	 No application will be made for the Warrants to be listed or dealt on any Recognised Investment Exchange (as
that term is defined in the Financial Services and Markets Act 2000 (as amended)). 

  

	3	 CALCULATION OF NUMBER OF WARRANT SHARES 

 

	3.1	 The number of Warrant Shares over
which the Initial Warrants will
behave been issued is as
follows:939,150 Warrant Shares. 

  

	 	3.1.1	 At the date of this instrument (the First Issue Date), the Company shall
issue Warrants over 363,156 

  

	3.2	
The
 number of Warrant Shares over which the 2020 Warrants will be issued
is 939,150 Warrant Shares, such. 

 

	3.3	 The 2020 Warrants shall be issued to be issued to Silicon Valley Bank and Kreos Capital V (Expert Fund) LP in equal proportions; and 

  

	 	3.1.2	 In addition to the Warrants issued pursuant to clause 3.1.1 above, on each draw
down pursuant to the Loan Agreement, the Company shall issue within five (5) Business Days of the date of each such drawdown further Warrants over such number of Warrant Shares as is equal to 11% of the amount of each such drawdown divided by the Subscription Price such Warrants to be issued to Silicon Valley Bank and Kreos Capital V (Expert Fund) LP in equal proportions (the Further Issue
Date(s) together with the First Issue Date, the Issue Dates)..

  

	4	 CERTIFICATES 

 

	4.1	 The Company shall issue to each Warrantholder a Warrant Certificate in respect of that number of Warrants to
which it is entitled as soon as reasonably practicable following a Warrantholder becoming entitled to such Warrants in accordance with clause 3.1.1 and/or 3.1.2. 

 

	4.2	 If a Warrant Certificate is mutilated, defaced, lost, stolen or destroyed, the Company will replace it on such
terms as to evidence and indemnity as the Company may reasonably require and subject to the Warrantholder who is seeking the replacement paying the Company’s reasonable costs (if any) in connection with the issue of the replacement.

  

	4.3	 Mutilated or defaced Warrant Certificates must be surrendered before replacements will be issued.

  

	5	 TIMING FOR EXERCISE OF SUBSCRIPTION RIGHTS 

 

	5.1	 The Subscription Rights may be exercised at any time from the date of this instrument until 17:00 GMT on the
Final Date and shall be exercised in accordance with clause 6. 

  
 10 

	5.2	 Subject to clause 7, a failure by any Warrantholder to exercise its Subscription Rights ahead of such time on
the Final Date shall mean that such Warrantholder’s outstanding Warrants shall immediately lapse and be cancelled and such Warrantholder shall have no further rights under this instrument. 

 

	5.3	 Without prejudice to clauses 12, 13 and 14, if the Final Date is likely to occur before the last date for
approval of or acceptance of a liquidation, share buyback, takeover or reorganisation event (that is in each case subject to an existing proposal) such as described in the said clauses, the Final Date shall be extended until such last date for
approval or acceptance of such event as aforesaid. 

  

	6	 EXERCISE OF SUBSCRIPTION RIGHTS 

 

	6.1	 The Subscription Rights may be exercised in whole or in part. If exercised in part, the Subscription Rights
must be exercised in tranches of 50,000 Warrants, or in respect of the last tranche of Warrants attached to the outstanding Subscription Rights held by the Warrantholder concerned, such lesser balancing number of Warrants as may be outstanding.

  

	6.2	 In order to exercise its Subscription Rights validly, a Warrantholder must deliver the following items to the
registered office of the Company: 

  

	 	6.2.1	 the Warrant Certificate for the Warrants in respect of which Subscription Rights are being exercised, together
with the Notice of Subscription duly completed; 

  

	 	6.2.2	 if required pursuant to clause 6.3.1, a remittance by banker’s draft, drawn on a UK clearing bank, (or
such other mode of payment as the Company and the Warrantholder shall agree); and 

  

	 	6.2.3	 the name and address of the Warrantholder to which the Warrant Shares arising on exercise of Subscription
Rights are to be issued; and 

  

	 	6.2.4	 if and to the extent that the
Ordinary Shares issued are to be delivered as ADSs, a completed Issuance and Delivery Instruction in the form set out at Schedule 3 hereto (as such form may be amended from time to time by notice to the Warrantholder) duly completed and executed by
the Warrantholder. 

  

	6.3	 The Subscription Price for each of the Warrant Shares shall, at the absolute discretion of the Warrantholder,
be satisfied by any of the following: 

  

	 	6.3.1	 the payment by banker’s draft for each of the Warrant Shares at the Subscription Price; or

  

	 	6.3.2	 in lieu of a cash
payment in respect of the aggregate Subscription Price for the Warrant Shares, the Warrantholder may elect to
receivefor a reduced number of Warrant Shares (as calculated below)
(“Reduced Warrant
Shares”) to be issued than the number to which it would be
entitled on exercise of the Subscription RightRights in full, payment for such Reduced

  
 11 

	 	
Warrant Shares being satisfied by waiver by the Warrantholder of the right to receive the balance of Warrant Shares to which the Warrantholder is entitled over and above the Reduced Warrant
Shares (“Balance Warrant Shares”). In doing so, the
Company agrees and acknowledges that, subject to the payment of the par value of the Reduced Warrant Shares pursuant to this clause
6.3.2,6.3.2, the Reduced Warrant Shares to be issued to the Warrantholder shall be
issued(or, in the case of a Warrantholder which has specified in the Notice of Subscription in respect of such Reduced Warrant Shares that it requires to
have such Reduced Warrant Shares delivered as ADSs and has delivered a duly completed Issuance and Delivery Instruction to the Company in respect of the same, issued to, deposited with (and otherwise registered in the name of) the custodian of the
Depositary (or its nominee)) as fully paid up at the Subscription Price, and the Warrantholder agrees and acknowledges that it waives its Subscription Rights to the Balance Warrant Shares used as consideration for
the payment of the aggregate Subscription Price. The number of Reduced Warrant Shares the Warrantholder (or Depositary,
as 

applicable)
 will receive shall be determined as follows:

 

X = Y (A
– B) / A 
 where: 

X = the number of Reduced Warrant Shares to be issued to the Warrantholder or Depositary
 (as applicable). 

Y = the number of Warrant Shares with respect to which the Warrant is being exercised by the Warrantholder (without application of the
reduction). 
 A = the Fair Market Value of one Warrant Share 

B = the Subscription Price. (provided that, where the relevant Warrants being exercised have a Subscription Price denominated in USD, the Company shall
convert such Subscription Price to pounds sterling for the purpose of calculating the aggregate nominal value of such Reduced Warrant Shares using the Exchange Rate on the trading day prior to service of the Notice of Subscription or Automatic
Exercise Notice, as the case may be) 
 Provided always that the Warrantholder
shall nevertheless be required to subscribe in cash for the par value of the Reduced Warrant Shares to the extent that if it did not do so the Reduced Warrant Shares would be issued at a discount to the Warrantholder. It being understood that if
Warrant Shares are issued pursuant to this clause 6.3.2, notwithstanding that such Warrant Shares are issued at nominal value, the Warrantholder shall be deemed to have paid the relevant Subscription Price per Warrant Share for the purposes of
calculating any distribution or share of sale proceeds in each case attributable to the Warrant Shares and to other issued shares of the class for the purposes of the Articles and for all other purposes. 

  
 12 

	6.4	 Delivery of the items specified in clause 6.2 to the Company shall, unless the Company expressly consents
otherwise, be an irrevocable election by the Warrantholder to exercise the relevant Subscription Rights. 

  

	7	 AUTOMATIC EXERCISE OF SUBSCRIPTION RIGHTS 

 

	7.1	 If, on the Final Date, the Fair Market Value of one Warrant Share is greater than the Subscription Price on
such date, the Warrantholder shall be deemed to have automatically exercised its Subscription Rights, on a conditional basis, in respect of all unexercised Warrants on such date on a net issuance basis as set out in
clauseClause 6.3.2 (Exercise of Subscription Rights).
In such circumstances, the Company shall (subject at all times to the Company’s obligations under the Takeover Code, the AIM Rules, and all applicable law and any other regulations including the Market Abuse Regulation), send a notice to the Warrantholder(s) within ten (10) Business Days of the Final Date (such notice being the “Automatic Exercise
Notice” for the purposes of this clause 7) requiring them to pay up a cash amount equal to the aggregate nominal value of the Warrant Shares (such payment being the “Nominal Value Payment”) to be
issued pursuant to clause 6.3.2 (“Exercise of Subscription Rights”) and this clause 7.1. 7.1, and to specify whether such Warrantholder requires any such Warrant Shares to be delivered as ADSs. 

 

	7.2	 The Warrantholder shall, within ten (10) Business Days of receipt of the Automatic Exercise Notice (the
“Nominal Value Payment Period”), provide the Company with the Nominal Value Payment, to an account notified by the Company to the Warrantholder.
Warrantholder, and, if such Warrantholder requires any Warrant Shares to be delivered as ADSs, a duly completed Issuance and Delivery Instruction in respect of such
Warrant Shares. Upon receipt of such the Nominal Value Payment,
(and, if applicable, such Issuance and Delivery Instruction) the Warrant Shares to be issued to the Warrantholder on a net issuance basis pursuant to clause
6.3.2(or in the case of a Warrantholder who has delivered an Issuance and Delivery Instruction, the custodian of the Depositary) shall be
allotted and issued to the Warrantholder (or the custodian of the Depositary, as applicable) credited as fully paid up in accordance with clause 6.3.2 (Exercise of Subscription Rights) and clause 8.3.1 (Completion). Any failure
by a Warrantholder to pay the Nominal Value PaymentValuePayment (or deliver a duly completed Issuance and Delivery
Instruction, if applicable) within the Nominal Value Payment Period shall result in the automatic lapse of any Warrants over Warrant Shares for which the Nominal Value Payment was not
made or Issuance and Delivery Instruction not delivered. 

  
 13 

	8	 COMPLETION 

 

	8.1	 Following a valid exercise of Subscription Rights by a Warrantholder or an automatic exercise of Subscription
Rights pursuant to clause 7 or clause 13.2.2, the Company shall in accordance with clause 8.3: 

  

	 	8.1.1	 allot and issue credited as fully paid to the Warrantholder; (or to its nominee
or trustee as notified to the Company in the Notice of Subscription) the Warrant Shares to which the Warrantholder is entitled by exercising the Subscription Rights (“Allotted
Shares”)or in the event that the Warrantholder has required pursuant to clause 6.2 that Ordinary Shares to be issued from the Exercise of
Subscription Rights are to be delivered as ADSs, delivered a duly completed Issuance and Delivery Instruction, and there is an effective registration statement covering the Ordinary Shares to be issued on such exercise, issue to, deposit with (and
otherwise register in the name of) the custodian of the Depositary (or its nominee) (“Allotted Shares”) and following such issuance and deposit the Company will direct the Depositary to issue an amount of ADSs via DTC (with such
ADSs being eligible for listing on Nasdaq) in accordance with the corresponding Issuance and Delivery Instruction; 

  

	 	8.1.2	 immediately following allotment and issue in accordance with clause
8.1.1,8.1.1, enter, or procure that the Company’s Registrars enter the Warrantholder’s name
(or (i) its nominee’s or trustee’s name, as
appropriateor (ii) in the case of any Ordinary Shares to be delivered as ADSs, the custodian of the Depositary’s name) in the register
of members of the Company as the holder of the Allotted Shares; 

  

	 	8.1.3	 immediately following registration in accordance with clause
8.1.2,8.1.2, either: send to the person identified by
the Warrantholder pursuant to clause 8.1.1,8.1.1, free of charge, share certificate(s) in respect of the Allotted
Shares or credit such aggregate number of Allotted Shares to the Warrantholder’s (or its nominee’s or trustee’s) CREST stock account; and 

 

	 	8.1.4	 apply for the admission of the Warrant Shares to trading on (i) AIM, insofar
as the Warrant Shares are listed on AIM or, (ii) on any otherany recognised investment exchange on which the Warrant Shares are listed, at the time of the allotment and issue pursuant to clause 8.1.1, and shall use its reasonable endeavours to secure such admission to trading no later than ten
(10) Business Days after such application. 

  

	8.2	 The obligations of the Company under clause 8.1 shall be fulfilled within ten (10) days after the Notice
of Subscription is lodged at the registered office of the Company. 

  

	8.3	 The Allotted Shares shall: 

 

	 	8.3.1	 be allotted and issued fully paid; 

 

	 	8.3.2	 rank pari passu with the relevant class of fully paid Warrant Shares then in issue; 

 

	 	8.3.3	 rank for any dividend or other distribution which has previously been announced or declared if the date by
which the holder of Warrant Shares must be registered to participate in such dividend or other distribution is after the Exercise Date pursuant to which the Subscription Rights have been exercised; and 

 

	 	8.3.4	 be free from all claims, liens, charges, encumbrances, equities and third party rights. 

  
 14 

	8.4	 If following allotment of shares pursuant to the exercise of some of the Subscription Rights, some Subscription
Rights remain, the Company shall issue a Warrant Certificate to the Warrantholder within 15 Business Days for the balance of the Warrantholder’s Subscription Rights. 

 

	9	 TRANSFER OF WARRANTS 

 

	9.1	 Subject to clause 9.2, the Warrants may be transferred in whole or in part by any Warrantholder to any person,
provided that the Company has given its prior written consent to such transfer. 

  

	9.2	 A Warrantholder has the right, with prior written notice, but without the consent of
the BorrowerCompany, to transfer the Warrants in whole or in part to a Permitted Transferee, subject to compliance
with the provisions of Schedule 2 hereto. 

  

	9.3	 Notwithstanding any other provisions of this instrument, no transfer shall be made to any person which is a
Competitor of the Company or any other Group Company. 

  

	9.4	 The provisions of Schedule 2 to this instrument shall regulate any transfer of a Warrant.

  

	10	 MODIFICATION AND CESSATION OF RIGHTS 

 

	10.1	 This instrument may be modified only with the prior sanction of Consent. 

 

	10.2	 This instrument ceases to have effect on the earlier of: 

 

	 	10.2.1	 the date upon which all Subscription Rights have been exercised in full; and 

 

	 	10.2.2	 the Final Date. 

  

	11	 ADJUSTMENT OF WARRANT 

 

	11.1	 Upon the occurrence of an Adjustment after the date of this Instrument but prior to the Final Date, the number
and/or nominal value of Warrant Shares to be, or capable of being subscribed on any subsequent exercise of the Subscription Rights conferred by each issued Warrant and/or the Subscription Price will be adjusted in such manner as the Auditors shall
certify to be fair and reasonable so that the Warrants shall, after such adjustment, entitle the Warrantholder(s) on exercise to receive the same percentage of the share capital of the Company in issue or capable of being issued following the
implementation of the Adjustment, carrying the same proportion of votes exercisable at a general meeting of shareholders, for the same
priceAggregate Subscription Price, in each case as nearly as practicable, as would have been the case if no Adjustment had occurred, provided
that the Subscription Price shall not in any event be reduced so that, upon exercise of the Subscription Rights, Warrant Shares would fall to be issued at a discount to their nominal value. 

  
 15 

	11.2	 Within ten (10) days after
days after an Adjustment, or, if later, within 10 days after the response of the auditors to any certification required by clause 11.1, notice of
such adjustments will be given to the Warrantholder(s) detailing the number of Warrant Shares for which the Warrantholder(s) are entitled to subscribe in consequence of any such adjustment. Replacement Warrant Certificates shall be issued
accordingly. 

  

	12	 LIQUIDATION 

 

	12.1	 If an order is made or an effective resolution is passed for the winding-up or dissolution of the Company or if
any other dissolution of the Company by operation of law is to be effected whilst any Subscription Rights remain exercisable, then the provisions of clause 12.2 or, as the case may be, clause 12.3 shall apply. 

 

	12.2	 If the winding-up or dissolution is for the purpose of a reconstruction, amalgamation or merger the
Warrantholder shall be entitled to be granted by the reconstructed, amalgamated or merged company a substituted warrant of the value of the Warrant immediately prior to such reconstruction, amalgamation or merger. 

 

	12.3	 If clause 12.2 does not apply, the Company shall immediately notify the Warrantholder(s) in writing that such
an order has been made or resolution has been passed or other dissolution is to be effected. The Warrantholder(s) shall be entitled at any time within three (3) months after the date such notice is given to elect by notice in writing to the
Company to be treated as if they had, immediately before the date of the making of the order or passing of the resolution or other dissolution, exercised the Subscription Rights and they shall be entitled to receive out of the assets which would
otherwise be available in the liquidation to the holders of Warrant Shares, such a sum, if any, as they would have received had they been the holders of and paid for the Warrant Shares to which they would have become entitled by virtue of such
exercise, after deducting from such sum the amount which would have been payable by them in respect of the Warrant Shares if they had exercised the Subscription Rights. Nothing contained in this clause 12.3 shall have the effect of requiring the
Warrantholder(s) to make any actual payment to the Company. 

  

	13	 TAKEOVERS 

  

	13.1	 Subject to clause 13.6, if at any time an offer or invitation is made by the Company to the holders of the
Ordinary Shares for the purchase by the Company of any of its Ordinary Shares, the Company shall promptly and without delay give notice thereof to each Warrantholder who shall be entitled, at any time whilst such offer or invitation is open for
acceptance, to exercise its Subscription Rights to the extent that such rights have not been exercised or lapsed prior to the record date of such offer or invitation so as to take effect, in so far as is reasonably practicable, as if it had
exercised its rights immediately prior to the record date of such offer or invitation. 

  
 16 

  

	13.2	 Subject to clause 13.6, if at any time an offer is made to all holders of Ordinary Shares (or all holders of
Ordinary Shares other than the offeror and/or any company controlled by the offeror and/or persons acting in concert with the offeror) to acquire the whole or any part of the issued share capital of the Company and the Company becomes aware that as
a result of such offer the right to cast a majority of the votes which may ordinarily be cast on a poll at a general meeting of the Company may, if such offer becomes unconditional in all respects, become vested in the offeror and/or such persons or
companies (the “Buyer”) as aforesaid (the “Offer”): 

  

	 	13.2.1	 The Company shall, subject to compliance with the Takeover Code,
give notice to each Warrantholder within ten (10) Business Days of its becoming so aware, and each Warrantholder shall be entitled to exercise its Subscription Rights, conditional upon the Offer being declared unconditional in all respects,
within thirty (30) days of such notice having been given by the Company (to the extent that such rights have not lapsed or been exercised prior to the record date of such Offer), and to accept or otherwise participate in such Offer on the same
terms as made to all holders of Ordinary Shares. 

  

	 	13.2.2	 If the Company fails to give notice as required by clause 13.2.1 (subject at all times to the Company’s
obligations under the Takeover Code, the AIM Rules, and all applicable law and any other regulations including the Market Abuse Regulation) then, provided
that immediately prior to the date that the Offer is made the offer price under the Offer is greater than the Subscription Price on such date and conditional upon the Offer being
declared or becoming unconditional in all respects, the Warrantholder shall be deemed to have automatically exercised its Subscription Rights in respect of all
unexercised Warrants on such date at the Subscription Price on a net issuance basis as set out in clause 6.3.2 (Exercise of Subscription Rights). In such
circumstances, the Company shall send a notice to the Warrantholder(s) promptly and without delay (such notice being the “Exercise Notice” for the purposes of this clause 13.2.2) upon either a Warrantholder notifying the Company of
its failure to give notice as required by clause 13.2.1 or the Company or the Buyer becoming aware of the
Company’’s failure to give such notice requiring the Warrantholder(s) to
pay the Nominal Value Payment. The Warrantholder shall, within ten (10) Business Days of receipt of the Exercise Notice, provide the Company with the Nominal Value Payment, to an account notified by the Company to the
Warrantholder. , and, if such Warrantholder requires any Warrant Shares to be delivered as ADSs, a duly completed issuance
and delivery instruction in respect of such Warrant Shares. Upon receipt of such the Nominal Value Payment and
Issuance and Delivery Instruction (if applicable), subject to clause 13.3 the Warrant Shares to be issued to the Warrantholder (or to the custodian of the
Depositary, if applicable) on a net issuance basis pursuant to clause 6.3.2 (Exercise of Subscription Rights) shall be allotted and issued to the
Warrantholder (or the custodian of the Depositary, if applicable)
credited as fully paid up in accordance with clause 6.3.2 (Exercise of Subscription Rights) and clause
8.3.1. 8.3.1. 

  
 17 

	 	13.2.3	 Nothing in this clause 13.2 shall oblige the Warrantholder(s) to accept any Offer made hereunder, save to the
extent that such Offer, whether by court order or otherwise, shall have become binding on all shareholders and the offer price under such Offer is greater than the Subscription Price, in which case the Warrantholder(s) shall be deemed to have
accepted it on the terms set out herein. 

  

	13.3	 The Company undertakes to the Warrantholders that in the event of an exercise of
Subscription Rights during the course of an Offer (or before the date of an Offer if the Directors of the Company have reason to believe that a bona fide offer might be imminent) it will consult with the Panel on Takeover and Mergers without delay
to get confirmation that the issue of shares represents the exercise of the Subscription Rights pursuant to a pre-existing contractual obligation. In the event that the Panel of Takeover and Mergers does not give such confirmation, the Company will
undertake without delay to call a general meeting of the Company to approve the issue of shares pursuant to the Subscription Rights. [Not
used] 

  

	13.4	 The Company shall use reasonable endeavours to procure that any Buyer extends the
Offer to the Warrantholders in accordance with Rule 15 and Practice Statement 24 of the Takeover Code.[Not used] 

 

	13.5	 For the avoidance of doubt, publication of a compromise or scheme of arrangement under the Companies Act
providing for the acquisition by any person of the whole or any part of the issued share capital of the Company shall be deemed to be the making of an Offer for the purposes of this clause 13. 

 

	13.6	 If, for whatever reason, a Warrantholder fails, refuses or declines to exercise its Subscription Rights within
sixty (60) days of an Offer having become unconditional in all respects, the Warrants held by such Warrantor shall automatically lapse and no Warrant Shares shall be issued to the Warrantholder thereunder. 

 

	14	 COMPANY REORGANISATIONS – EXCHANGE OF WARRANTS 

 

	14.1	 A company reorganisation occurs if the Company merges with or transfers all or substantially all of its assets
and undertaking to a new company (“Newco”) and the shareholders of Newco are substantially the same as the shareholders of the Company immediately before the Company reorganisation, with shares having the same rights as those of the
Company. 

  

	14.2	 If there is a company reorganisation, the Company shall, save to the extent proposed by the Company and
sanctioned by a Consent, use reasonable endeavours to procure that new warrants over the share capital of the Newco are granted with equivalent rights and on terms applying in this instrument mutatis mutandis and on such grant the existing Warrants
shall lapse. 

  
 18 

	15	 INFORMATION AND RIGHTS OF WARRANTHOLDER(S) 

 

	15.1	 The Company shall: 

  

	 	15.1.1	 send to each Warrantholder a copy of its annual reports and audited accounts together with all documents
required by law to be annexed to that report at the same time they are provided to the holders of the Ordinary Shares; 

  

	 	15.1.2	 send to each Warrantholder copies of any statements, notices or circulars sent to the holders of the Ordinary
Shares; and 

  

	 	15.1.3	 give to each Warrantholder not less than 30 days’ prior written notice of its intention to declare or pay
a dividend or other distribution on the Ordinary Shares. 

  

	15.2	 The Warrantholder(s) may attend all general meetings of members of the Company and meetings of the holders of
Ordinary Shares but may not vote at those meetings by virtue of or in respect of their holdings of Warrants. 

  

	15.3	 Each Warrantholder shall keep confidential any information received by it in its capacity as a Warrantholder
which is of a confidential nature except: 

  

	 	15.3.1	 as required by law or any applicable regulations; 

 

	 	15.3.2	 to the extent the information is in the public domain through no default of the Warrantholder; and

  

	 	15.3.3	 each Warrantholder will be entitled to divulge such information to any other Warrantholder and any proposed
transferee of Warrants on the same terms as to confidentiality. 

  

	16	 RESTRICTIONS ON AND UNDERTAKINGS OF THE COMPANY 

 

	16.1	 For so long as the Warrants are outstanding, the Company will: 

 

	 	16.1.1	 to the extent that the Company has a limit on its authorised share capital, keep available for issue and free
from pre-emptive rights, out of its authorised but unissued share capital, such number of Warrant Shares as will enable the Subscription Rights of the Warrantholder(s) to be satisfied in full; 

 

	 	16.1.2	 ensure that the Directors have all necessary authorisations and disapplications of pre-emption (including under
the Companies Act) to allot such number of Warrant Shares as will enable the Subscription Rights of the Warrantholder(s) to be satisfied in full at any time; 

  

	 	16.1.3	 maintain the admission to trading of the Ordinary Shares on AIM, or any other
Recognised Investment Exchange on which the Ordinary Shares are traded from time to time; [Not used] 

  
 19 

  

	 	16.1.4	 not make any issue, grant or distribution or take any other action the effect of which would be that on
exercise of any of the Subscription Rights it would be required to issue Warrant Shares at a discount to their nominal value; and 

  

	 	16.1.5	 not buy any Warrants unless it offers to buy Warrants from all Warrantholders in proportion to their respective
holdings of Warrants. 

  

	17	 WARRANTIES 

  

	17.1	 The Company warrants to the Warrantholder(s) that: 

 

	 	17.1.1	 it has the power to execute and to perform its obligations under this instrument; 

 

	 	17.1.2	 it has taken all action necessary to authorise the execution of, and the performance of its obligations under
this instrument; 

  

	 	17.1.3	 all Warrant Shares which may be issued upon the exercise of the rights represented by this Warrant will be,
upon issuance, be duly authorised, validly issued and fully paid and free of any liens and encumbrances; 

  

	 	17.1.4	 it and the Directors have, and have obtained all necessary shareholder and third party consents (which consents
are subsisting and remain sufficient and have not been revoked at the Issue DatesDate), to grant the Warrant to
the Warrantholder(s) on the Issue DatesDate on the terms of this Warrant; and 

 

	 	17.1.5	 the Ordinary Shares are duly admitted to trading on AIM or on another Recognised
Investment Exchange and no circumstances exist which may cause the suspension or cancellation of such admission. [Not used]

  

	18	 NOTICES 

Any notice to the Warrantholder(s) required for the purposes of any provision of this instrument shall be given in accordance with the
provisions of paragraphs 10 to 13 (inclusive) of Schedule 2. 
  

	19	 COSTS AND EXPENSES 

 

	19.1	 The
BorrowerCompany shall promptly pay to the Warrantholder(s) on the Warrantholder’s demand, the reasonable legal expenses plus applicable VAT
and disbursements incurred by the Warrantholder in connection with: 

  

	 	19.1.1	 any amendment or supplement to this instrument, or any proposal for such an amendment to be made, provided such
amendment or supplement has been requested or necessitated by the Company; and 

  

	 	19.1.2	 any consent or waiver by the Warrantholder(s) concerned under or in connection with this instrument or any
request for such a consent or waiver, provided that such consent or waiver has been requested or necessitated by the Company; and 

  

	 	19.1.3	 any step taken reasonably and properly by the Warrantholder with a view to the protection, exercise or
enforcement of any right or interest created by this instrument. 

  
 20 

	20	 CONTRACTS (RIGHTS OF THIRD PARTIES) ACT 1999 

A person who is not a party to this instrument shall have no rights under the Contracts (Rights of Third Parties) Act 1999 to enforce any term
of this instrument. This clause does not affect any right or remedy of any person which exists or is available otherwise than pursuant to that Act. 
  

	21	 FURTHER ASSURANCE 

The Company shall, at its own cost and expense, execute all such deeds and documents and do all such acts and things as may reasonably be
required in order to give effect to this instrument, including vesting on issue the full legal and beneficial title to the Warrant Shares in the Warrantholder. 
  

	22	 SEVERABILITY 

Each of the provisions of this instrument is distinct and severable from the others and if at any time one or more of such provisions is or
becomes valid, unlawful or unenforceable (whether wholly or to any extent), the validity, lawfulness and enforceability of the remaining provisions (or the same provision to any other extent) of this instrument shall not in any way be affected or
impaired. 
  

	23	 GOVERNING LAW 

The provisions of this instrument and the Conditions and any dispute or claim arising out of or in connection with them (including any dispute
or claim relating to non-contractual obligations) shall be subject to and governed by English law and the Company and the Warrantholder(s) submit to the exclusive jurisdiction of the English Courts in relation to any such dispute or claim. 

The Company intends this instrument to be a deed poll and accordingly it or its duly authorised representatives execute and deliver it as such. 

  
 21 

 SCHEDULE 1 

Form Of Warrant Certificate 

MEREO BIOPHARMA GROUP PLC (“COMPANY”) 

A company registered in England and Wales 

under Company number 09481161 

WARRANT CERTIFICATE 
 This certificate is
issued pursuant to the warrant instrument issued by the Company on                      2017 (“Warrant Instrument”). Words
and expressions used in this certificate which are defined in the Warrant Instrument have the meanings given to them in the Warrant Instrument. 

Certificate number: [•] 
 Date of issue:
                     2017 
  

			
	Name and address of Warrantholder:	  	[Silicon Valley Bank of 3003 Tasman Drive, Santa Clara, California 95054 US (UK branch at Alphabeta 14-18 Finsbury Square, London EC2A 1BR)]
		
		  	[Kreos Capital V (Expert Fund) LP of 47 Esplanade, St. Helier, Jersey JE1 0BD]

 Number of
[Initial/2020] Warrant Shares for which the Warrantholder may
subscribe such number as is calculated by dividing [•] [NB: In respect of the First Issue Date, £550,000 for each of SVB and Kreos; in respect
of the Further Issue Date(s), each of SVB and Kreos will receive an equal share of the aggregate amount of the Warrants issued pursuant to clause 3.1.2.] (being the relevant proportion of the Warrant Amount held by the Warrantholder) by the
Subscription Price, as adjusted in accordance with terms of the Warrant Instrument, if
appropriate.[•]  

Subscription price:
[£2.95/$0.4316] 
 This is to certify that the Warrantholder named above is the registered
holder of the right to subscribe in cash for Warrant Shares at the subscription price set out above subject to the Articles and otherwise on the terms and conditions set out in the Warrant Instrument (a copy of which is available for inspection at
the registered office of the Company). 

EXECUTED as a DEED
by  

MEREO BIOPHARMA GROUP PLC

  

	
	
      
                                         
                       Signature of Director

	
      
                                         
                       Name of Director

	

  
 22 

	
	                         
                                       Signature of
Secretary
	
	
      
                                         
                 Name of Secretary

	

  

			
	 EXECUTED as a deed, but not delivered until)

the date specified on this certificate,
by                    )
                                       
                                         
    )
 MEREO BIOPHARMA GROUP
PLC                 )
 by a director in the presence of a witness:
	  	
		  	  

Director

	 Witness Signature:
	  	  

	 Witness Name (block capitals):
	  	  

	 Witness Address:
	  	  

	 Witness Occupation:
	  	  

 Schedule to the Warrant Certificate 

Notice of Subscription 
  

	To:	 The Directors 

MEREO BIOPHARMA GROUP PLC (“Company”) 

This notice is issued pursuant to the warrant instrument issued by the Company on
                    2017                     
    (“Warrant Instrument”). Words and expressions used in this notice which are defined in the Warrant Instrument have the meanings given to them in the Warrant
Instrument. 
 By this notice we exercise the Subscription Rights
appertaining to [all] [number] of the Warrants evidenced by this certificate. 

  
 23 

We hereby irrevocably elect
to exercise [number] [Initial/2020]Warrants issued to us by the Company pursuant to the Warrant Instrument and purchase thereunder (and surrender herewith the relevant warrant certificate) as follows: 

(1) 

(A)
                    Warrant Shares to be issued to the Warrantholder (or its nominee or trustee) as
                     Ordinary Shares pursuant to the Warrant Instrument; 

(B)
                    Warrant Shares to be issued to the custodian of the Depositary for delivery
to the
                     Warrantholder as ADSs pursuant to the Warrant Instrument. 

(2) We wish to satisfy the aggregate Subscription Price for the Warrant Shares in respect of the Subscription Rights we are exercising as follows [delete options as necessary]: 

1(A) [by payment by banker’s draft, we attach a banker’s draft
to this notice]; 

(B) [by cash payment by wire
transfer of immediately available funds to the following account of the Company: 
 [Use in
case of an aggregate Subscription Price denominated in GBP: 
                     
Account Name: Mereo BioPharma Group plc 
                     Bank:
Silicon Valley Bank 

     
               Account No: 20150636 

     
               Sort Code: 62-10-00 

     
               BIC/SWIFT: SVBKGB2L 

     
               IBAN: GB18 SVBK62 1000 2015 0636] 

[Use in case of an aggregate Subscription Price denominated in USD:

     
               Account Name: Mereo BioPharma Group plc 

     
               Bank: Silicon Valley Bank 

     
               Account No: 20150644 

     
               Sort Code: 62-10-00 

     
               IBAN: GB93SVBK62100020150644]] 

  
 24 

2 (C) [by satisfying the aggregate Subscription Price by electing to
receive a reduced number of Warrant Shares, in accordance with clause 6.3.2]. 
 [We direct the Company to
allot conditional only on the above the:

[use for a
request under option (1)(A) above] to issue [number] of Ordinary Shares to be issued pursuant to this exercise in the following numbers to the following proposed allottees,
each of which is either a Warrantholder, a nominee or trustee of a Warrantholder, or a transferee of one of those persons approved in accordance with clause 9.1 of the Warrant Instrument.] 
  

							
	 Number/percentage of shares
	  	 Name of proposed allottee
	  	 Address of proposed allottee
	  	 CREST
Details

				
		  		  		  	
				
		  		  		  	
				
		  		  		  	
				
		  		  		  	
				
		  		  		  	
				
		  		  		  	
				
		  		  		  	
				
		  		  		  	
				
		  		  		  	
				
		  		  		  	
				
		  		  		  	
				
		  		  		  	
				
		  		  		  	
				
		  		  		  	
				
		  		  		  	
				
		  		  		  	
				
		  		  		  	
				
		  		  		  	
				
		  		  		  	
				
		  		  		  	
				
	 1
	  		  		  	Participant ID: [•]
				
		  		  		  	Member account ID: [•]
				
		  		  		  	INSP Custodian Client
		  		  		  	Ref: [•]
				
		  		  		  	Custodian Name: [•]
				
	 2
1
	  		  		  	Participant ID: [•]
				
		  		  		  	Member account ID: [•]
				
		  		  		  	INSP Custodian Client Ref:
		  		  		  	[•]
				
		  		  		  	Custodian Name: [•]

  

  
 25 

 We request that
certificate(s) for such Ordinary Shares be sent by post at our risk to us at the first address shown above or to the agent lodging this certificate as mentioned below.  

OR 

We hereby request that you register our Warrant Shares in uncertificated form
to the CREST account detailed [below][above]: 
  

			
	CREST Details	  	Participant ID
		
		  	Member Account ID
		
		  	INSP Custodian Client
		  	Ref:
		
		  	Custodian Name

 We agree that such shares are issued and
accepted subject to the memorandum and articles of association of the Company. 
  

	
	Signature of Warrantholder:      -
	
	 Full
name:                        -

	
	
Address:          
                                         
                                         
                                         
                                       

 Lodged by: (agent to whom certificate(s)
should be sent) 

[OR] use for a
request under option (1)(B) above] to issue, allot, and deposit [number] of Ordinary Shares to be issued pursuant to this exercise to the custodian (or its nominee) of the Depositary and that following such issuance and deposit, to
direct the Depositary to issue an amount of ADSs via DTC in accordance with the Issuance and Delivery Instruction corresponding to this Notice of Subscription. 

The Warrantholder represents
and warrants that this Notice of Subscription has been duly signed and constitutes a valid and binding act to exercise the said Warrants. 

Place and date: 

Name of
Warrantholder: 
  

 
  

	
	By:
	
Title:

	

  
 26 

The above exercise is
acknowledged and accepted. Place and date: 
  

			
	MEREO BIOPHARMA GROUP PLC	 	
		
	By:	 	
		
	         Name of agent:	 	-
		
	Address:	 	                                      
                                         
                                         
    

  
 27 

 SCHEDULE 2 

Conditions 
  

	1	 An accurate Register will be kept and maintained at all times by the Company at its registered office and there
shall be entered in the Register: 

  

	1.1	 the names and addresses of the persons for the time being entitled to be registered as the holders of the
Warrants; 

  

	1.2	 the number of Warrants held for the time being by every registered holder; and 

 

	1.3	 the date on which the name of every registered holder is entered in the Register in respect of the Warrants in
its name. 

  

	2	 Any change in the name or address of any Warrantholder shall promptly be notified to the Company which shall
cause the Register to be altered accordingly. The Warrantholders or any of them and any person authorised by any Warrantholder shall be at liberty at all reasonable times during office hours to inspect the Register and to take copies of or extracts
from it or any part of it. 

  

	3	 The Company shall be entitled to treat each Warrantholder as the absolute owner of a Warrant and accordingly
shall not, except as ordered by a court of competent jurisdiction or as required by law, be bound to recognise any equitable or other claim to or interest in a Warrant on the part of any other person, whether or not it shall have express or other
notice of such a claim. 

  

	4	 Each Warrantholder will be recognised by the Company as entitled to the Warrants free from any equity, set-off
or cross-claim on the part of the Company against the original or any intermediate holder of the Warrants. 

  

	5	 Each transfer of a Warrant shall be made by an instrument of transfer in the usual or common form or in any
other form which may be approved for the time being by the Directors. 

  

	6	 The instrument of transfer of a Warrant shall be executed by or on behalf of the transferor but need not be
executed by or on behalf of the transferee. The transferor shall be deemed to remain the holder of the Warrant until the name of the transferee is entered in the Register in respect of the Warrant being transferred. 

 

	7	 The Directors may decline to recognise any instrument of transfer of a Warrant unless the instrument is
deposited at the registered office of the Company accompanied by the Warrant Certificate for the Warrant to which it relates, and such other evidence as the Directors may reasonably require to show the right of the transferor to make the transfer.
The Directors may waive production of any Warrant Certificate upon production to them of satisfactory evidence of the loss or destruction of the Warrant Certificate together with such indemnity as they may require. 

 

	8	 No fee shall be charged for any registration of a transfer of a Warrant or for the registration of any other
documents which in the opinion of the Directors require registration. 

  
 28 

	9	 The registration of a transfer shall be conclusive evidence of the approval by the Directors of such a
transfer. 

  

	10	 Each Warrantholder shall register with the Company an address in the United Kingdom to which notices can be
sent. If any Warrantholder fails to register an address with the Company, notice may be given to that Warrantholder by sending it by any of the methods referred to in paragraph 11 of this Schedule 2 to that Warrantholder’s last known place of
business or residence or, if none, by exhibiting it for three days at the registered office for the time being of the Company. 

  

	11	 Notices and other communications to Warrantholders may be given by personal delivery, prepaid letter by first
class post or, subject to clause 1.3 of this instrument, fax or email. In proving service of any notice or other communication sent by post, it shall be sufficient to prove that the envelope containing the notice or other communication was properly
addressed and stamped and was deposited in a post box or at the post office. 

  

	12	 A notice or other communication given pursuant to the provisions of paragraph 11 of this Schedule 2 shall be
deemed to have been served: 

  

	12.1	 at the time of delivery, if delivered personally to the registered address; 

 

	12.2	 on the second Business Day following its posting, if sent by prepaid letter by first class post to an address
in the United Kingdom; and 

  

	12.3	 at 09:00 hours on the Business Day following the despatch of the fax, if sent by fax. 

 

	13	 All notices and other communications with respect to Warrants standing in the names of joint registered holders
shall be given to whichever of such persons is named first in the Register and such notice so given shall be sufficient notice to all the registered holders of such Warrants. 

 

	14	 Any person who, whether by operation of law, transfer or other means whatsoever, shall become entitled to any
Warrant, shall be bound by every notice in respect of such Warrant which, prior to its name and address being entered on the Register, shall have been duly given to the person from which it derives its title to such Warrant. 

 

	15	 When a given number of days’ notice or notice extending over any other period is required to be given, the
day of service shall be included but the day upon which such notice will expire shall not be included in such number of days or other period. The signature to any notice to be given by the Company may be written or printed. 

 

	16	 Meetings of Warrantholders shall be convened and conducted in the same way as meeting of shareholders of the
Company are convened and conducted. Accordingly, the provisions of Articles shall apply to meetings of the Warrantholders mutatis mutandis. 

  
 29 

SCHEDULE 3

 ADS Issuance and
Delivery Instruction 

[DATE] 

Citibank, N.A., as
Depositary 

388 Greenwich
Street 

New York, New York
10013 

Attn.: Mr. Brian M.
Teitelbaum (brian.m.teitelbaum@citi.com) 
 With a copy simultaneously delivered to: 

Citibank, N.A., London
Branch 

25 Canada Square 

Canary Wharf 

London E14 5LB,
England 

Attn.: UK Custody
Settlements 

Custody Team
(uksettlements@citi.com) 
 Re: Issuance and Delivery Instruction - Mereo BioPharma Group plc (CUSIP No.: 589492107) – Deposit &
Hold 

Dear Sirs: 

Reference is
made to the Deposit Agreement, dated as of April 23, 2018, as amended and supplemented from time to time (the “Deposit Agreement”), by and among Mereo BioPharma Group plc, a public limited company incorporated under the laws of
England and Wales and its successors (the “Company”), Citibank, N.A., a national banking association organized and existing under the laws of the United States of America, as Depositary (the “Depositary”), and all Holders and
Beneficial Owners of American Depositary Shares (the “ADSs”) issued thereunder. All capitalized terms used, but not otherwise defined herein, shall have the meaning assigned thereto in the Deposit Agreement. 

In
accordance with the terms and subject to the limitations set forth in the Deposit Agreement, promptly following the Depositary’s receipt of confirmation from the Custodian that the Custodian has received a deposit of the number of Shares
specified below made by the Company for the benefit of the undersigned holder thereof (the “Holder” and together with the Company, the “Undersigned”), the Undersigned hereby jointly instruct the Depositary, and the Depositary
hereby agrees: 

  
 30 

     
               (i) to promptly accept for deposit the number of Shares and issue the number of ADSs as specified below:

 Number of Shares
deposited:                      Shares 

Number of ADSs (CUSIP No.:
589492107; each ADS representing five (5) Shares to be
issued:                     ADSs  

                    and (ii) to promptly deliver such Program ADSs, as follows:  
 Name of DTC Participant to which the ADSs are to be delivered:                     

 DTC
Participant Account No.:                          

Account No. for recipient of
ADSs at DTC Participant (f/b/o/ information): 

Name on whose behalf the
above number of ADSs are to be issued and delivered:
                  
   

Contact person at DTC
Participant:  

Daytime telephone number of
contact person at DTC:                    
 

The Company hereby confirms
and certifies that (i) the registration statement on Form F-3 (File No. 333-239708) (the “Registration Statement”), filed with the U.S. Securities and Exchange Commission (the “Commission”) on July 6, 2020,
registers the resale of the above Shares represented by ADSs, such ADSs will be freely transferable following the issuance thereof by the Depositary, and there are no legal restrictions on subsequent transfers of the ADSs to be issued hereunder
under the laws of England and Wales or the United States, (ii) the Registration Statement is effective under the Securities Act of 1933, as amended (the “Securities Act”), and (iii) no stop order suspending the effectiveness of
the Registration Statement has been issued and no proceedings for such purpose have been instituted or are pending or, to the best knowledge of the Company, are contemplated or threatened by the Commission. 

  
 31 

The Holder hereby represents
and covenants to, and for the benefit of, the Depositary and Citibank, N.A.—London Branch (the “Custodian”), that (i) the Holder is not an “affiliate” of the Company as that term is defined in Rule 144 promulgated by
the Commission under the Securities Act and has not been an affiliate at any time during the 90 days immediately preceding the date hereof, and (ii) all stamp duty taxes, including, without limitation, the U.K. Stamp Duty Reserve Tax
(“SDRT”), will be paid in full and on a timely basis to the extent such taxes are payable in respect of the deposit of the Shares and the issuance and delivery of the ADSs as contemplated herein. 

Each of the Holder and, to
the extent it is not unlawful for the Company to do so under the applicable laws of England and Wales, the Company agrees to indemnify the Depositary and the Custodian for, and to hold the Depositary and the Custodian harmless against, all losses,
liabilities, taxes, charges, penalties or expenses (including reasonable legal fees and disbursements), incurred by the Depositary and/or by the Custodian or to which the Depositary and/or the Custodian may become subject to and arising directly or
indirectly from the failure by any person to pay (or discharge) any applicable stamp duty taxes, including, without limitation, SDRT, or any other similar duty or tax in connection with the deposit of the Shares and the issuance and delivery of the
ADSs as contemplated herein, save to the extent that such losses, liabilities, taxes, charges, penalties or expenses are due to the negligence or bad faith of the Custodian or the Depositary.

  

									
	[HOLDER]	 		 	MEREO BIOPHARMA GROUP PLC
					
	By:	 	  
	 	            	 	By:	 	  

			
	Name:	 		 	Name:
			
	Title:	 		 	Title:

  
 32 

 SIGNATURE PAGE 

 

			
	 EXECUTED and delivered as a DEED
by
 MEREO BIOPHARMA
GROUP PLC
	 	
		
	
      
                                  Signature of Director
	 	
		
	
      
                                  Name of Director
	 	

  

			
	 EXECUTED as a deed, but not delivered until)

                    the date
specified on this instrument, by     )

                          
                                         
                      )

MEREO BIOPHARMA GROUP
PLC                       )

by                     a
director in the presence of a witness:
	  	
		  	  

Director

	Witness Signature:	  	  

	Witness Name (block capitals):	  	  

	Witness Address:	  	  

		  	  

	Witness Occupation:	  	  

  
  

	
	                         
                   Signature of Secretary
	                         
                   Name of Secretary

  
 33 

 Schedule 2 

2017 Warrant Instrument (clean copy) 

 

 
 EXECUTION VERSION 

DATED             DECEMBER 2020 

MEREO BIOPHARMA GROUP PLC 
  

 
 AMENDED
WARRANT INSTRUMENT DATED 21 
 AUGUST 2017 

relating to the issue of warrants entitling the holders to 

subscribe for Warrant Shares in the capital of 

MEREO BIOPHARMA GROUP PLC 
  

 
 5 Fleet Place
London EC4M 7RD 
 Tel: +44 (0)20 7203 5000 • Fax: +44 (0)20 7203 0200 • DX: 19 London/Chancery Lane 

www.charlesrussellspeechlys.com 

 CONTENTS 
  

							
	 1
	 	DEFINITIONS AND INTERPRETATION	  	 	2	 
			
	 2
	 	CONSTITUTION AND FORM OF WARRANTS	  	 	8	 
			
	 3
	 	CALCULATION OF NUMBER OF WARRANT SHARES	  	 	9	 
			
	 4
	 	CERTIFICATES	  	 	9	 
			
	 5
	 	TIMING FOR EXERCISE OF SUBSCRIPTION RIGHTS	  	 	9	 
			
	 6
	 	EXERCISE OF SUBSCRIPTION RIGHTS	  	 	9	 
			
	 7
	 	AUTOMATIC EXERCISE OF SUBSCRIPTION RIGHTS	  	 	11	 
			
	 8
	 	COMPLETION	  	 	12	 
			
	 9
	 	TRANSFER OF WARRANTS	  	 	13	 
			
	 10
	 	MODIFICATION AND CESSATION OF RIGHTS	  	 	14	 
			
	 11
	 	ADJUSTMENT OF WARRANT	  	 	14	 
			
	 12
	 	LIQUIDATION	  	 	14	 
			
	 13
	 	TAKEOVERS	  	 	15	 
			
	 14
	 	COMPANY REORGANISATIONS – EXCHANGE OF WARRANTS	  	 	16	 
			
	 15
	 	INFORMATION AND RIGHTS OF WARRANTHOLDER(S)	  	 	17	 
			
	 16
	 	RESTRICTIONS ON AND UNDERTAKINGS OF THE COMPANY	  	 	17	 
			
	 17
	 	WARRANTIES	  	 	18	 
			
	 18
	 	NOTICES	  	 	18	 
			
	 19
	 	COSTS AND EXPENSES	  	 	18	 
			
	 20
	 	CONTRACTS (RIGHTS OF THIRD PARTIES) ACT 1999	  	 	19	 
			
	 21
	 	FURTHER ASSURANCE	  	 	19	 
			
	 22
	 	SEVERABILITY	  	 	19	 
			
	 23
	 	GOVERNING LAW	  	 	19	 
		
	 SCHEDULE 1 FORM OF WARRANT CERTIFICATE
	  	 	20	 
		
	 SCHEDULE 2 CONDITIONS
	  	 	24	 

 THIS WARRANT INSTRUMENT is made on 21 August 2017, as amended on
         December 2020 
 BY: 
  

	(1)	 MEREO BIOPHARMA GROUP PLC, a company incorporated in England and Wales with number 09481161 whose
registered office is at 4th Floor, 1 Cavendish Place, London, England, W1G 0QF (“Company”). 

 BACKGROUND: 

 

	(A)	 The Company, by resolution of its directors, has agreed to issue Warrants to subscribe for Warrant Shares in
the capital of the Company on the terms set out in this instrument, subject to adjustment as set out in this instrument. 

  

	(B)	 Either all of the registered holders of shares in the Company have irrevocably waived all pre-emption rights
conferred on them (whether by the Companies Act, the Articles or otherwise) or such pre-emption rights have been validly disapplied in relation to the number of Warrants and shares in the Company issued pursuant to this instrument.

  

	(C)	 This instrument has been executed by the Company as a deed in favour of the Warrantholder.

 IT IS AGREED: 
  

	1	 DEFINITIONS AND INTERPRETATION 

 

	1.1	 In this instrument the following words and expressions shall (unless the context requires otherwise) have the
following meanings: 

  

			
	2020 Warrants	  	means any warrants issued on the Amendment Date, by way of adjustment to the Initial Warrants;
		
	Adjustment	  	means any sub-division or consolidation of Equity Securities by the Company, at any time, after issue of the relevant Warrant, or by reference to any record date, while the Warrants remain exercisable;
		
	ADS	  	means American Depositary Shares representing interests in the Ordinary Shares pursuant to a sponsored American Depositary Receipt facility with the Depositary;
		
	ADS Exchange Ratio	  	means the ratio applicable to the exchange of Ordinary Shares for ADSs from time to time, currently being a ratio of 5 Ordinary Shares for each ADS;
		
	Amendment Date	  	means 15 December 2020;
		
	Articles	  	the articles of association of the Company for the time being;

  
 2 

			
	Auditors	  	the Company’s auditors;
		
	Business	  	means the research, development, production, trading and licensing of rights, intellectual property and/or products within the life sciences industry (or any of the foregoing or any activities connected thereto);
		
	Business Day	  	a day (which for these purposes ends at 5.30 pm) on which banks are open for commercial business in the City of London other than a Saturday or Sunday;
		
	Companies Act	  	the Companies Act 2006;
		
	Competitor	  	means any entity (other than a reputable financial institution) whose business directly competes with the Business carried out by a Group Company;
		
	Conditions	  	the terms and conditions set out in Schedule 2 (subject to any alterations made in accordance with the provisions of this instrument);
		
	Consent	  	either:
		
		  	 (a)   a resolution passed at a meeting of the Warrantholders duly convened and
held and carried by a majority consisting of not less than 75 per cent. of the votes cast upon a show of hands or, if a poll is duly demanded, by a majority consisting of not less than 75 per cent of the votes cast on a poll; or

		
		  	 (b)   the consent in writing of Warrantholders entitled to the right to
subscribe for at least 75 per cent of the Warrant Shares in respect of which Subscription Rights are granted pursuant to this instrument;

		
	Directors	  	the board of directors of the Company (and/or, where relevant, a Group Company) for the time being;
		
	Equity Securities	  	has the meaning given in section 560(1) of the Companies Act;
		
	Exercise Date	  	the date of delivery to the registered office of the Company of the items specified in clause 6.2 (and the date of such delivery shall be the date on which such items are received at the Company’s registered
office);

  
 3 

			
	Fair Market Value	  	either:
		
		  	 (a)   if the Ordinary Shares are then traded on a Recognised Investment Exchange
the fair market value of a Warrant Share shall be the volume weighted average price of one (1) Ordinary Share during the ten (10) consecutive trading day period immediately preceding the Exercise Date; or

		
		  	 (b)   if the Ordinary Shares are not traded on a Recognised Investment Exchange
but ADSs are listed on Nasdaq, the implied price of One Ordinary Share in pounds sterling, which shall be determined as follows:

		
		  	 (i) dividing (x) being the volume weighted average price of one ADS during the ten (10) consecutive trading day period
immediately preceding the Exercise Date by (y) being the number of Ordinary Shares currently represented by a single ADS in accordance with the ADS Exchange Ratio in effect on such date (Implied USD Price); and

		
		  	 (ii) converting the Implied USD Price to pounds sterling at the Exchange Rate on the trading day immediately preceding
the Exercise Date; or

		
		  	 (c)   if the Ordinary Shares are not traded on a Recognised Investment Exchange
and ADSs are not listed on Nasdaq, the fair market value a Warrant Share shall be the Fair Price;

		
	Fair Price	  	unless otherwise agreed by the board of Directors and the Warrantholder(s) prior to service of the Notice of Subscription, the price per Warrant Share which the Auditors (acting as an expert (the Expert)) shall certify to be in its
opinion a fair price for the Warrant Shares. In arriving at his opinion the Expert will value the Warrant Shares as at the date the Notice of Subscription is to be given on the basis that the Company operates as a going concern, as between a willing
seller and a willing buyer, subject always to the provisions of the Articles. The decision of the Expert as to the fair price for the Warrant Shares shall be final and binding and his costs shall be borne by the Company;
		
	Final Date	  	subject to clause 5, 10 years from the date of this instrument (which, for the avoidance of doubt, shall be 21 August 2027);

  
 4 

			
	Group	  	(i) the Company and its subsidiaries (if any), (ii) any holding company of the Company, and (iii) any subsidiaries of such holding companies from time to time and Group Company means any member of the Group;
		
	Initial Warrants	  	means the warrants of the Company constituted by this Instrument on 27 August 2017 and 29 December 2017 and any further warrants issued prior to the Amendment Date as an adjustment thereto;
		
	Issuance and Delivery Instruction	  	means an issuance and delivery instruction in such form as notified from the Company to the Warrantholders from time to time, the current form of which is attached hereto at Schedule 3;
		
	Marketable Securities	  	means securities in the acquiring entity traded on a Recognised Investment Exchange where the Warrantolder(s) (were it to receive such securities on completion of an Offer having exercised this Warrant) would not be subject to any
restrictions on re-sale of such securities;
		
	Member of the same Fund Group	  	is if the Warrantholder is a fund, partnership, company, syndicate or other entity whose business is managed by a Fund Manager (an “Investment Fund”) or a nominee of that person:
		
		  	 (a)   any participant or partner in or member of any such Investment Fund or the
holders of any unit trust which is a participant or partner in or member of any Investment Fund but only in connection with the dissolution of Investment Fund or any distribution of assets of the Investment Fund pursuant to the operation of the
Investment Fund in the ordinary course of business,

		
		  	 (b)   any Investment Fund managed or exclusively advised by that Fund
Manager,

		
		  	 (c)   a parent undertaking or subsidiary undertaking of that Investment Fund or
Fund Manager, or any subsidiary undertaking of any parent undertaking of that Investment Fund or Fund Manager, or

		
		  	 (d)   any trustee, nominee or custodian of such Investment Fund and vice
versa;

  
 5 

			
	Notice of Subscription	  	the notice addressed to the Company by a Warrantholder exercising its Subscription Rights in the form, or substantially in the form, set out in the schedule to the Warrant Certificate;
		
	Ordinary Shares	  	ordinary shares in the capital of the Company and having the rights and privileges set out in the Articles;
		
	Permitted Transferee are:	  	
		
		  	 (a)   a nominee of the Warrantholders;

		
		  	 (b)   a regulated, reputable financial institution;

		
		  	 (c)   a member of the SVB Financial Group of companies; and/or

		
		  	 (d)   a Member of the same Fund Group;

		
	Recognised Investment Exchange	  	a recognised investment exchange or overseas investment exchange (within the meaning thereof given for the purposes of section 285 of the Financial Services and Markets Act 2000, and shall include, without limitation, AIM or
NASDAQ;
		
	Register	  	the register of persons for the time being entitled to the benefit of the Warrants to be maintained pursuant to the Conditions;
		
	Registrars	  	the registrars of the Company for the time being;
		
	Subscription Price	  	the subscription price per Warrant Share such price being equal to:
		
		  	 (a)   in respect of the Initial Warrants, £2.95; and

		
		  	 (b)   in respect of the 2020 Warrants, $0.4144 (being the volume weighted
average price of one (1) Ordinary Share during the ten (10) consecutive trading day period immediately preceding the Amendment Date converted into USD at an exchange rate of 1 GBP = 1.3226 USD (being the GBP-USD opening exchange rate published in
the Wall Street Journal on the business day (being a day on which banks are open for commercial business in New York) immediately preceding the Amendment Date);

  
 6 

			
	Subscription Rights	  	the rights of the Warrantholder(s) to subscribe for Warrant Shares under clause 6;
		
	Warrant Certificate	  	a certificate evidencing a Warrantholder’s entitlement to Warrants in the form set out in Schedule 1;
		
	Warrant Shares	  	Ordinary Shares to be issued pursuant to the terms of the Warrants;
		
	Warrantholder	  	in relation to a Warrant, the person whose name appears in the Register as the holder of the Warrant; and
		
	Warrants	  	the Initial Warrants and the 2020 Warrants and all rights conferred by this Instrument relating thereto (including the Subscription Rights).

  

	1.2	 In this instrument, unless the context otherwise requires: 

 

	 	1.2.1	 words and expressions defined in the Companies Act or the Articles shall have the same meanings in this
instrument (unless otherwise expressly defined in this instrument); 

  

	 	1.2.2	 headings are used for convenience only and shall be ignored in interpreting this instrument;

  

	 	1.2.3	 reference to a clause or schedule is a reference to a clause of, or schedule to, this instrument;

  

	 	1.2.4	 reference to (or to any specific provision of) this instrument or any other document or instrument shall be
construed as a reference to this instrument, that provision or that document or instrument as in force for the time being and as amended from time to time in accordance with its terms and the prior sanction of a Consent (where consent is required by
the terms of this instrument as a condition to such amendment being made); 

  

	 	1.2.5	 reference to any gender includes all genders, references to the singular includes the plural (and vice versa)
and reference to persons includes bodies corporate, unincorporated associations and partnerships (whether or not any of the same have a separate legal personality); 

 

	 	1.2.6	 reference to a statutory provision includes reference to: 

 

	 	(a)	 the statute or statutory provision as modified or re-enacted from time to time; and 

 

	 	(b)	 any subordinate legislation made under the statutory provision (as modified or re-enacted as set out in clause
1.2.6(a) above); 

  
 7 

	 	1.2.7	 any words following the terms ‘including’, ‘include’, ‘in particular’, ‘for
example’ or any other similar expression shall be construed as illustrative and shall not limit the sense of the words, description, phrase or term preceding those words; and 

 

	 	1.2.8	 references to statutory obligations include obligations arising under articles of the Treaty establishing the
European Community, and regulations, directives and decisions of the European Union as well as United Kingdom Acts of Parliament and subordinate legislation. 

  

	1.3	 Unless otherwise specifically provided, where any notice, resolution or document is required by this instrument
to be signed by any person, the reproduction of the signature of such person by fax or email shall suffice, provided that confirmation by first class letter is despatched by close of business on the next following Business Day, in which case the
effective notice, resolution or document shall be that sent by fax or email (served in accordance with paragraphs 11 and 12 of Schedule 2), not the confirmatory letter. 

 

	1.4	 This instrument incorporates the schedules to it. 

 

	2	 CONSTITUTION AND FORM OF WARRANTS 

 

	2.1	 This instrument constitutes the Warrants, which in aggregate give the Warrantholder(s) the right, upon the
terms and subject to the conditions set out in this instrument, to subscribe in cash (subject to clause 6.3.2) at a price per share equal to the Subscription Price for such number of Warrant Shares calculated in accordance with clause 3.

  

	2.2	 Subject to clause 6.3.2, each Warrantholder shall be entitled to subscribe in cash at the Subscription Price
for that number of Warrant Shares in respect of which it is entitled to be recorded as the holder in the Register on the terms set out in this instrument. 

  

	2.3	 The Warrants shall be in registered form. 

 

	2.4	 The Warrants are issued subject to the Articles and otherwise on the terms of this instrument (including the
Conditions). 

  

	2.5	 The Company agrees with the Warrantholder(s) and, in consideration of being issued a Warrant Certificate, each
Warrantholder agrees with the Company that the Articles (insofar as they relate to the Warrants) and the terms of this instrument shall be binding upon the Company and each Warrantholder and all persons claiming through or under either of them.

  

	2.6	 No application will be made for the Warrants to be listed or dealt on any Recognised Investment Exchange (as
that term is defined in the Financial Services and Markets Act 2000 (as amended)). 

  
 8 

	3	 CALCULATION OF NUMBER OF WARRANT SHARES 

 

	3.1	 The number of Warrant Shares over which the Initial Warrants have been issued is 939,150 Warrant Shares.

  

	3.2	 The number of Warrant Shares over which the 2020 Warrants will be issued is 939,150 Warrant Shares.

  

	3.3	 The 2020 Warrants shall be issued to Silicon Valley Bank and Kreos Capital V (Expert Fund) LP in equal
proportions. 

  

	4	 CERTIFICATES 

  

	4.1	 The Company shall issue to each Warrantholder a Warrant Certificate in respect of that number of Warrants to
which it is entitled as soon as reasonably practicable following a Warrantholder becoming entitled to such Warrants in accordance with clause 3.1.1 and/or 3.1.2. 

 

	4.2	 If a Warrant Certificate is mutilated, defaced, lost, stolen or destroyed, the Company will replace it on such
terms as to evidence and indemnity as the Company may reasonably require and subject to the Warrantholder who is seeking the replacement paying the Company’s reasonable costs (if any) in connection with the issue of the replacement.

  

	4.3	 Mutilated or defaced Warrant Certificates must be surrendered before replacements will be issued.

  

	5	 TIMING FOR EXERCISE OF SUBSCRIPTION RIGHTS 

 

	5.1	 The Subscription Rights may be exercised at any time from the date of this instrument until 17:00 GMT on the
Final Date and shall be exercised in accordance with clause 6. 

  

	5.2	 Subject to clause 7, a failure by any Warrantholder to exercise its Subscription Rights ahead of such time on
the Final Date shall mean that such Warrantholder’s outstanding Warrants shall immediately lapse and be cancelled and such Warrantholder shall have no further rights under this instrument. 

 

	5.3	 Without prejudice to clauses 12, 13 and 14, if the Final Date is likely to occur before the last date for
approval of or acceptance of a liquidation, share buyback, takeover or reorganisation event (that is in each case subject to an existing proposal) such as described in the said clauses, the Final Date shall be extended until such last date for
approval or acceptance of such event as aforesaid. 

  

	6	 EXERCISE OF SUBSCRIPTION RIGHTS 

 

	6.1	 The Subscription Rights may be exercised in whole or in part. If exercised in part, the Subscription Rights
must be exercised in tranches of 50,000 Warrants, or in respect of the last tranche of Warrants attached to the outstanding Subscription Rights held by the Warrantholder concerned, such lesser balancing number of Warrants as may be outstanding.

  
 9 

	6.2	 In order to exercise its Subscription Rights validly, a Warrantholder must deliver the following items to the
registered office of the Company: 

  

	 	6.2.1	 the Warrant Certificate for the Warrants in respect of which Subscription Rights are being exercised, together
with the Notice of Subscription duly completed; 

  

	 	6.2.2	 if required pursuant to clause 6.3.1, a remittance by banker’s draft, drawn on a UK clearing bank, (or
such other mode of payment as the Company and the Warrantholder shall agree); 

  

	 	6.2.3	 the name and address of the Warrantholder to which the Warrant Shares arising on exercise of Subscription
Rights are to be issued; and 

  

	 	6.2.4	 if and to the extent that the Ordinary Shares issued are to be delivered as ADSs, a completed Issuance and
Delivery Instruction in the form set out at Schedule 3 hereto (as such form may be amended from time to time by notice to the Warrantholder) duly completed and executed by the Warrantholder. 

 

	6.3	 The Subscription Price for each of the Warrant Shares shall, at the absolute discretion of the Warrantholder,
be satisfied by any of the following: 

  

	 	6.3.1	 the payment by banker’s draft for each of the Warrant Shares at the Subscription Price; or

  

	 	6.3.2	 in lieu of a cash payment in respect of the aggregate Subscription Price for the Warrant Shares, the
Warrantholder may elect for a reduced number of Warrant Shares (as calculated below) (“Reduced Warrant Shares”) to be issued than the number to which it would be entitled on exercise of the Subscription Rights in full, payment for
such Reduced Warrant Shares being satisfied by waiver by the Warrantholder of the right to receive the balance of Warrant Shares to which the Warrantholder is entitled over and above the Reduced Warrant Shares (“Balance Warrant
Shares”). In doing so, the Company agrees and acknowledges that, subject to the payment of the par value of the Reduced Warrant Shares pursuant to this clause 6.3.2, the Reduced Warrant Shares to be issued to the Warrantholder (or, in the
case of a Warrantholder which has specified in the Notice of Subscription in respect of such Reduced Warrant Shares that it requires to have such Reduced Warrant Shares delivered as ADSs and has delivered a duly completed Issuance and Delivery
Instruction to the Company in respect of the same, issued to, deposited with (and otherwise registered in the name of) the custodian of the Depositary (or its nominee)) as fully paid up at the Subscription Price, and the Warrantholder agrees and
acknowledges that it waives its Subscription Rights to the Balance Warrant Shares used as consideration for payment of the aggregate Subscription Price. The number of Reduced Warrant Shares the Warrantholder (or Depositary, as applicable) will
receive shall be determined as follows: 

 X = Y (A – B) / A 

  
 10 

 where: 

X = the number of Reduced Warrant Shares to be issued to the Warrantholder or Depositary (as applicable). 

Y = the number of Warrant Shares with respect to which the Warrant is being exercised by the Warrantholder (without application of the
reduction). 
 A = the Fair Market Value of one Warrant Share 

B = the Subscription Price (provided that, where the relevant Warrants being exercised have a Subscription Price denominated in USD, the
Company shall convert such Subscription Price to pounds sterling for the purpose of calculating the aggregate nominal value of such Reduced Warrant Shares using the Exchange Rate on the trading day prior to service of the Notice of Subscription or
Automatic Exercise Notice, as the case may be) 
 Provided always that the Warrantholder shall nevertheless be required to subscribe in cash
for the par value of the Reduced Warrant Shares to the extent that if it did not do so the Reduced Warrant Shares would be issued at a discount to the Warrantholder. It being understood that if Warrant Shares are issued pursuant to this clause
6.3.2, notwithstanding that such Warrant Shares are issued at nominal value, the Warrantholder shall be deemed to have paid the relevant Subscription Price per Warrant Share for the purposes of calculating any distribution or share of sale proceeds
in each case attributable to the Warrant Shares and to other issued shares of the class for the purposes of the Articles and for all other purposes. 
  

	6.4	 Delivery of the items specified in clause 6.2 to the Company shall, unless the Company expressly consents
otherwise, be an irrevocable election by the Warrantholder to exercise the relevant Subscription Rights. 

  

	7	 AUTOMATIC EXERCISE OF SUBSCRIPTION RIGHTS 

 

	7.1	 If, on the Final Date, the Fair Market Value of one Warrant Share is greater than the Subscription Price on
such date, the Warrantholder shall be deemed to have automatically exercised its Subscription Rights, on a conditional basis, in respect of all unexercised Warrants on such date on a net issuance basis as set out in Clause 6.3.2 (Exercise of
Subscription Rights). In such circumstances, the Company shall (subject at all times to the Company’s obligations under all applicable law and any other regulations, send a notice to the Warrantholder(s)within ten (10) Business Days of the
Final Date (such notice being the Automatic Exercise Notice for the purposes of this clause 7) requiring them to pay up a cash amount equal to the aggregate nominal value of the Warrant Shares (such payment being the “Nominal Value
Payment”) to be issued pursuant to clause 6.3.2 (“Exercise of Subscription Rights”) and this clause 7.1, and to specify whether such Warrantholder requires any such Warrant Shares to be delivered as ADSs.

  
 11 

	7.2	 The Warrantholder shall, within ten (10) Business Days of receipt of the Automatic Exercise Notice (the
“Nominal Value Payment Period”) provide the Company with the Nominal Value Payment to an account notified by the Company to the Warrantholder, and, if such Warrantholder requires any Warrant Shares to be delivered as ADSs, a duly
completed Issuance and Delivery Instruction in respect of such Warrant Shares. Upon receipt of such Nominal Value Payment (and, if applicable, such Issuance and Delivery Instruction) the Warrant Shares to be issued to the Warrantholder (or in the
case of a Warrantholder who has delivered an Issuance and Delivery Instruction, the custodian of the Depositary) shall be allotted and issued to the Warrantholder (or the custodian of the Depositary, as applicable) credited as fully paid up in
accordance with clause 6.3.2 (Exercise of Subscription Rights) and clause 8.3.1 (Completion). Any failure by a Warrantholder to pay the Nominal ValuePayment (or deliver a duly completed Issuance and Delivery Instruction, if applicable) within the
Nominal Value Payment Period shall result in the automatic lapse of any Warrants over Warrant Shares for which the Nominal Value Payment was not made or Issuance and Delivery Instruction not delivered. 

 

	8	 COMPLETION 

  

	8.1	 Following a valid exercise of Subscription Rights by a Warrantholder or an automatic exercise of Subscription
Rights pursuant to clause 7 or clause 13.2.2, the Company shall in accordance with clause 8.3: 

  

	 	8.1.1	 allot and issue credited as fully paid to the Warrantholder; or in the event that the Warrantholder has
required pursuant to clause 6.2 that Ordinary Shares to be issued from the Exercise of Subscription Rights are to be delivered as ADSs, delivered a duly completed Issuance and Delivery Instruction, and there is an effective registration statement
covering the Ordinary Shares to be issued on such exercise, issue to, deposit with (and otherwise register in the name of) the custodian of the Depositary (or its nominee) (“Allotted Shares”) and following such issuance and deposit
the Company will direct the Depositary to issue an amount of ADSs via DTC (with such ADSs being eligible for listing on Nasdaq) in accordance with the corresponding Issuance and Delivery Instruction; 

 

	 	8.1.2	 immediately following allotment and issue in accordance with clause 8.1.1, enter, or procure that the
Company’s Registrars enter the Warrantholder’s name (or (i) its nominee’s or trustee’s name, or (ii) in the case of any Ordinary Shares to be delivered as ADSs, the custodian of the Depositary’s name) in the
register of members of the Company as the holder of the Allotted Shares; 

  
 12 

	 	8.1.3	 immediately following registration in accordance with clause 8.1.2, either: send to the person identified by
the Warrantholder pursuant to clause 8.1.1, free of charge, share certificate(s) in respect of the Allotted Shares; and 

  

	 	8.1.4	 apply for the admission of the Warrant Shares to trading on any recognised investment exchange on which the
Warrant Shares are listed at the time of the allotment and issue pursuant to clause 8.1.1, and shall use its reasonable endeavours to secure such admission to trading no later than ten (10) Business Days after such application.

  

	8.2	 The obligations of the Company under clause 8.1 shall be fulfilled within ten (10) days after the Notice
of Subscription is lodged at the registered office of the Company. 

  

	8.3	 The Allotted Shares shall: 

 

	 	8.3.1	 be allotted and issued fully paid; 

 

	 	8.3.2	 rank pari passu with the relevant class of fully paid Warrant Shares then in issue; 

 

	 	8.3.3	 rank for any dividend or other distribution which has previously been announced or declared if the date by
which the holder of Warrant Shares must be registered to participate in such dividend or other distribution is after the Exercise Date pursuant to which the Subscription Rights have been exercised; and 

 

	 	8.3.4	 be free from all claims, liens, charges, encumbrances, equities and third party rights. 

 

	8.4	 If following allotment of shares pursuant to the exercise of some of the Subscription Rights, some Subscription
Rights remain, the Company shall issue a Warrant Certificate to the Warrantholder within 15 Business Days for the balance of the Warrantholder’s Subscription Rights. 

 

	9	 TRANSFER OF WARRANTS 

 

	9.1	 Subject to clause 9.2, the Warrants may be transferred in whole or in part by any Warrantholder to any person,
provided that the Company has given its prior written consent to such transfer. 

  

	9.2	 A Warrantholder has the right, with prior written notice, but without the consent of the Company, to transfer
the Warrants in whole or in part to a Permitted Transferee, subject to compliance with the provisions of Schedule 2 hereto. 

  

	9.3	 Notwithstanding any other provisions of this instrument, no transfer shall be made to any person which is a
Competitor of the Company or any other Group Company. 

  

	9.4	 The provisions of Schedule 2 to this instrument shall regulate any transfer of a Warrant.

  
 13 

	10	 MODIFICATION AND CESSATION OF RIGHTS 

 

	10.1	 This instrument may be modified only with the prior sanction of Consent. 

 

	10.2	 This instrument ceases to have effect on the earlier of: 

 

	 	10.2.1	 the date upon which all Subscription Rights have been exercised in full; and 

 

	 	10.2.2	 the Final Date. 

  

	11	 ADJUSTMENT OF WARRANT 

 

	11.1	 Upon the occurrence of an Adjustment after the date of this Instrument but prior to the Final Date, the number
and/or nominal value of Warrant Shares to be, or capable of being subscribed on any subsequent exercise of the Subscription Rights conferred by each issued Warrant and/or the Subscription Price will be adjusted in such manner as the Auditors shall
certify to be fair and reasonable so that the Warrants shall, after such adjustment, entitle the Warrantholder(s) on exercise to receive the same percentage of the share capital of the Company in issue or capable of being issued following the
implementation of the Adjustment, carrying the same proportion of votes exercisable at a general meeting of shareholders, for the same Aggregate Subscription Price, in each case as nearly as practicable, as would have been the case if no Adjustment
had occurred, provided that the Subscription Price shall not in any event be reduced so that, upon exercise of the Subscription Rights, Warrant Shares would fall to be issued at a discount to their nominal value. 

 

	11.2	 Within ten (10) days after days after an Adjustment, or, if later, within 10 days after the response of
the auditors to any certification required by clause 11.1, notice of such adjustments will be given to the Warrantholder(s) detailing the number of Warrant Shares for which the Warrantholder(s) are entitled to subscribe in consequence of any such
adjustment. Replacement Warrant Certificates shall be issued accordingly. 

  

	12	 LIQUIDATION 

  

	12.1	 If an order is made or an effective resolution is passed for the winding-up or dissolution of the Company or if
any other dissolution of the Company by operation of law is to be effected whilst any Subscription Rights remain exercisable, then the provisions of clause 12.2 or, as the case may be, clause 12.3 shall apply. 

 

	12.2	 If the winding-up or dissolution is for the purpose of a reconstruction, amalgamation or merger the
Warrantholder shall be entitled to be granted by the reconstructed, amalgamated or merged company a substituted warrant of the value of the Warrant immediately prior to such reconstruction, amalgamation or merger. 

 

	12.3	 If clause 12.2 does not apply, the Company shall immediately notify the Warrantholder(s) in writing that such
an order has been made or resolution has been passed or other dissolution is to be effected. The Warrantholder(s) shall be entitled at any time within three (3) months after the date such notice is given to elect by notice in writing to the
Company to be treated as if they had, immediately before the date of 

  
 14 

	 	
the making of the order or passing of the resolution or other dissolution, exercised the Subscription Rights and they shall be entitled to receive out of the assets which would otherwise be
available in the liquidation to the holders of Warrant Shares, such a sum, if any, as they would have received had they been the holders of and paid for the Warrant Shares to which they would have become entitled by virtue of such exercise, after
deducting from such sum the amount which would have been payable by them in respect of the Warrant Shares if they had exercised the Subscription Rights. Nothing contained in this clause 12.3 shall have the effect of requiring the Warrantholder(s) to
make any actual payment to the Company. 

  

	13	 TAKEOVERS 

  

	13.1	 Subject to clause 13.6, if at any time an offer or invitation is made by the Company to the holders of the
Ordinary Shares for the purchase by the Company of any of its Ordinary Shares, the Company shall promptly and without delay give notice thereof to each Warrantholder who shall be entitled, at any time whilst such offer or invitation is open for
acceptance, to exercise its Subscription Rights to the extent that such rights have not been exercised or lapsed prior to the record date of such offer or invitation so as to take effect, in so far as is reasonably practicable, as if it had
exercised its rights immediately prior to the record date of such offer or invitation. 

  

	13.2	 Subject to clause 13.6, if at any time an offer is made to all holders of Ordinary Shares (or all holders of
Ordinary Shares other than the offeror and/or any company controlled by the offeror and/or persons acting in concert with the offeror) to acquire the whole or any part of the issued share capital of the Company and the Company becomes aware that as
a result of such offer the right to cast a majority of the votes which may ordinarily be cast on a poll at a general meeting of the Company may, if such offer becomes unconditional in all respects, become vested in the offeror and/or such persons or
companies (the “Buyer”) as aforesaid (the “Offer”): 

  

	 	13.2.1	 The Company shall, give notice to each Warrantholder within ten (10) Business Days of its becoming so
aware, and each Warrantholder shall be entitled to exercise its Subscription Rights, conditional upon the Offer being declared unconditional in all respects, within thirty (30) days of such notice having been given by the Company (to the extent
that such rights have not lapsed or been exercised prior to the record date of such Offer), and to accept or otherwise participate in such Offer on the same terms as made to all holders of Ordinary Shares. 

 

	 	13.2.2	 If the Company fails to give notice as required by clause 13.2.1 (subject at all times to the Company’s
obligations under applicable law and any other regulations ) then, provided that immediately prior to the date that the Offer is made the offer price under the Offer is greater than the Subscription Price on such date and conditional upon the Offer
being declared or becoming unconditional in all respects, the Warrantholder shall be deemed to have automatically exercised its Subscription Rights in respect of all unexercised Warrants on such date at the Subscription Price on a net

  
 15 

	 	
issuance basis as set out in clause 6.3.2 (Exercise of Subscription Rights). In such circumstances, the Company shall send a notice to the Warrantholder(s) promptly and without delay (such notice
being the “Exercise Notice” for the purposes of this clause 13.2.2) upon either a Warrantholder notifying the Company of its failure to give notice as required by clause 13.2.1 or the Company or the Buyer becoming aware of the
Company’s failure to give such notice requiring the Warrantholder(s) to provide the Company with the Nominal Value Payment to an account notified by the Company to the Warrantholder, and, if such Warrantholder requires any Warrant Shares to be
delivered as ADSs, a duly completed issuance and delivery instruction in respect of such Warrant Shares. Upon receipt of such Nominal Value Payment and Issuance and Delivery Instruction (if applicable), subject to clause 13.3 the Warrant Shares to
be issued to the Warrantholder (or to the custodian of the Depositary, if applicable) on a net issuance basis pursuant to clause 6.3.2 (Exercise of Subscription Rights) shall be allotted and issued to the Warrantholder (or the custodian of the
Depositary, if applicable) credited as fully paid up in accordance with clause 6.3.2 (Exercise of Subscription Rights) and clause 8.3.1. 

  

	 	13.2.3	 Nothing in this clause 13.2 shall oblige the Warrantholder(s) to accept any Offer made hereunder, save to the
extent that such Offer, whether by court order or otherwise, shall have become binding on all shareholders and the offer price under such Offer is greater than the Subscription Price, in which case the Warrantholder(s) shall be deemed to have
accepted it on the terms set out herein. 

  

	13.3	 [Not used] 

  

	13.4	 [Not used] 

  

	13.5	 For the avoidance of doubt, publication of a compromise or scheme of arrangement under the Companies Act
providing for the acquisition by any person of the whole or any part of the issued share capital of the Company shall be deemed to be the making of an Offer for the purposes of this clause 13. 

 

	13.6	 If, for whatever reason, a Warrantholder fails, refuses or declines to exercise its Subscription Rights within
sixty (60) days of an Offer having become unconditional in all respects, the Warrants held by such Warrantor shall automatically lapse and no Warrant Shares shall be issued to the Warrantholder thereunder. 

 

	14	 COMPANY REORGANISATIONS – EXCHANGE OF WARRANTS 

 

	14.1	 A company reorganisation occurs if the Company merges with or transfers all or substantially all of its assets
and undertaking to a new company (“Newco”) and the shareholders of Newco are substantially the same as the shareholders of the Company immediately before the Company reorganisation, with shares having the same rights as those of the
Company. 

  
 16 

	14.2	 If there is a company reorganisation, the Company shall, save to the extent proposed by the Company and
sanctioned by a Consent, use reasonable endeavours to procure that new warrants over the share capital of the Newco are granted with equivalent rights and on terms applying in this instrument mutatis mutandis and on such grant the existing Warrants
shall lapse. 

  

	15	 INFORMATION AND RIGHTS OF WARRANTHOLDER(S) 

 

	15.1	 The Company shall: 

  

	 	15.1.1	 send to each Warrantholder a copy of its annual reports and audited accounts together with all documents
required by law to be annexed to that report at the same time they are provided to the holders of the Ordinary Shares; 

  

	 	15.1.2	 send to each Warrantholder copies of any statements, notices or circulars sent to the holders of the Ordinary
Shares; and 

  

	 	15.1.3	 give to each Warrantholder not less than 30 days’ prior written notice of its intention to declare or pay
a dividend or other distribution on the Ordinary Shares. 

  

	15.2	 The Warrantholder(s) may attend all general meetings of members of the Company and meetings of the holders of
Ordinary Shares but may not vote at those meetings by virtue of or in respect of their holdings of Warrants. 

  

	15.3	 Each Warrantholder shall keep confidential any information received by it in its capacity as a Warrantholder
which is of a confidential nature except: 

  

	 	15.3.1	 as required by law or any applicable regulations; 

 

	 	15.3.2	 to the extent the information is in the public domain through no default of the Warrantholder; and

  

	 	15.3.3	 each Warrantholder will be entitled to divulge such information to any other Warrantholder and any proposed
transferee of Warrants on the same terms as to confidentiality. 

  

	16	 RESTRICTIONS ON AND UNDERTAKINGS OF THE COMPANY 

 

	16.1	 For so long as the Warrants are outstanding, the Company will: 

 

	 	16.1.1	 to the extent that the Company has a limit on its authorised share capital, keep available for issue and free
from pre-emptive rights, out of its authorised but unissued share capital, such number of Warrant Shares as will enable the Subscription Rights of the Warrantholder(s) to be satisfied in full; 

  
 17 

	 	16.1.2	 ensure that the Directors have all necessary authorisations and disapplications of pre-emption (including under
the Companies Act) to allot such number of Warrant Shares as will enable the Subscription Rights of the Warrantholder(s) to be satisfied in full at any time; 

  

	 	16.1.3	 [Not used] 

  

	 	16.1.4	 not make any issue, grant or distribution or take any other action the effect of which would be that on
exercise of any of the Subscription Rights it would be required to issue Warrant Shares at a discount to their nominal value; and 

  

	 	16.1.5	 not buy any Warrants unless it offers to buy Warrants from all Warrantholders in proportion to their respective
holdings of Warrants. 

  

	17	 WARRANTIES 

  

	17.1	 The Company warrants to the Warrantholder(s) that: 

 

	 	17.1.1	 it has the power to execute and to perform its obligations under this instrument; 

 

	 	17.1.2	 it has taken all action necessary to authorise the execution of, and the performance of its obligations under
this instrument; 

  

	 	17.1.3	 all Warrant Shares which may be issued upon the exercise of the rights represented by this Warrant will be,
upon issuance, be duly authorised, validly issued and fully paid and free of any liens and encumbrances; 

  

	 	17.1.4	 it and the Directors have, and have obtained all necessary shareholder and third party consents (which consents
are subsisting and remain sufficient and have not been revoked at the Issue Date), to grant the Warrant to the Warrantholder(s) on the Issue Date on the terms of this Warrant; and 

 

	 	17.1.5	 [Not used] 

  

	18	 NOTICES 

Any notice to the Warrantholder(s) required for the purposes of any provision of this instrument shall be given in accordance with the
provisions of paragraphs 10 to 13 (inclusive) of Schedule 2. 
  

	19	 COSTS AND EXPENSES 

 

	19.1	 The Company shall promptly pay to the Warrantholder(s) on the Warrantholder’s demand, the reasonable legal
expenses plus applicable VAT and disbursements incurred by the Warrantholder in connection with: 

  

	 	19.1.1	 any amendment or supplement to this instrument, or any proposal for such an amendment to be made, provided such
amendment or supplement has been requested or necessitated by the Company; and 

  
 18 

	 	19.1.2	 any consent or waiver by the Warrantholder(s) concerned under or in connection with this instrument or any
request for such a consent or waiver, provided that such consent or waiver has been requested or necessitated by the Company; and 

  

	 	19.1.3	 any step taken reasonably and properly by the Warrantholder with a view to the protection, exercise or
enforcement of any right or interest created by this instrument. 

  

	20	 CONTRACTS (RIGHTS OF THIRD PARTIES) ACT 1999 

A person who is not a party to this instrument shall have no rights under the Contracts (Rights of Third Parties) Act 1999 to enforce any term
of this instrument. This clause does not affect any right or remedy of any person which exists or is available otherwise than pursuant to that Act. 
  

	21	 FURTHER ASSURANCE 

The Company shall, at its own cost and expense, execute all such deeds and documents and do all such acts and things as may reasonably be
required in order to give effect to this instrument, including vesting on issue the full legal and beneficial title to the Warrant Shares in the Warrantholder. 
  

	22	 SEVERABILITY 

Each of the provisions of this instrument is distinct and severable from the others and if at any time one or more of such provisions is or
becomes valid, unlawful or unenforceable (whether wholly or to any extent), the validity, lawfulness and enforceability of the remaining provisions (or the same provision to any other extent) of this instrument shall not in any way be affected or
impaired. 
  

	23	 GOVERNING LAW 

The provisions of this instrument and the Conditions and any dispute or claim arising out of or in connection with them (including any dispute
or claim relating to non- contractual obligations) shall be subject to and governed by English law and the Company and the Warrantholder(s) submit to the exclusive jurisdiction of the English Courts in relation to any such dispute or claim. 

The Company intends this instrument to be a deed poll and accordingly it or its duly authorised representatives execute and deliver it as such. 

  
 19 

 SCHEDULE 1 

Form Of Warrant Certificate 

MEREO BIOPHARMA GROUP PLC (“COMPANY”) 

A company registered in England and Wales 

under Company number 09481161 

WARRANT CERTIFICATE 
 This certificate is
issued pursuant to the warrant instrument issued by the Company on                      2017 (“Warrant Instrument”). Words
and expressions used in this certificate which are defined in the Warrant Instrument have the meanings given to them in the Warrant Instrument. 

Certificate number: [•] 
  

			
	Date of issue:	  	                         2017
		
	Name and address of Warrantholder:	  	[Silicon Valley Bank of 3003 Tasman Drive, Santa Clara, California 95054 US (UK branch at Alphabeta 14-18 Finsbury Square, London EC2A 1BR)]
		
		  	[Kreos Capital V (Expert Fund) LP of 47 Esplanade, St. Helier, Jersey JE1 0BD]

 Number of [Initial/2020] Warrant Shares for which the Warrantholder may subscribe [•] 

Subscription price: [£2.95/$0.4316] 
 This is to certify
that the Warrantholder named above is the registered holder of the right to subscribe in cash for Warrant Shares at the subscription price set out above subject to the Articles and otherwise on the terms and conditions set out in the Warrant
Instrument (a copy of which is available for inspection at the registered office of the Company). 
  

					
	EXECUTED as a DEED by	  	        	  	
			
	MEREO BIOPHARMA GROUP PLC	  		  	
			
	  
	  		  	Signature of Director
			
	  
	  		  	Name of Director
			
	  
	  		  	Signature of Secretary
			
	  
	  		  	Name of Secretary

  
 20 

 Schedule to the Warrant Certificate 

Notice of Subscription 
  

	To:	 The Directors 

MEREO BIOPHARMA GROUP PLC (“Company”) 

This notice is issued pursuant to the warrant instrument issued by the Company on
                     (“Warrant Instrument”). Words and expressions used in this notice which are defined in the Warrant
Instrument have the meanings given to them in the Warrant Instrument. 
 We hereby irrevocably elect to exercise [number] [Initial/2020]Warrants
issued to us by the Company pursuant to the Warrant Instrument and purchase thereunder (and surrender herewith the relevant warrant certificate) as follows: 
  

	(1)	 

(A)                      Warrant Shares to be
issued to the Warrantholder (or its nominee or trustee) as                     Ordinary Shares pursuant to the Warrant Instrument; 

(B)                      Warrant Shares to be issued
to the custodian of the Depositary for delivery to the                     Warrantholder as ADSs pursuant to the Warrant Instrument. 

(2) We wish to satisfy the aggregate Subscription Price for the Warrant Shares in respect of the Subscription Rights we are exercising as follows [delete
options as necessary]: 
 (A) [by payment by banker’s draft, we attach a banker’s draft to this notice]; 

(B) [by cash payment by wire transfer of immediately available funds to the following account of the Company: 

[Use in case of an aggregate Subscription Price denominated in GBP: 

Account Name: Mereo BioPharma Group plc 

Bank: Silicon Valley Bank 

Account No: 20150636 
 Sort Code:
62-10-00 
 BIC/SWIFT: SVBKGB2L 

IBAN: GB18 SVBK62 1000 2015 0636] 

  
 21 

 [Use in case of an aggregate Subscription Price denominated in USD: 

Account Name: Mereo BioPharma Group plc 

Bank: Silicon Valley Bank 

Account No: 20150644 
 Sort Code:
62-10-00 
 IBAN: GB93SVBK62100020150644]] 
 (C)
[by satisfying the aggregate Subscription Price by electing to receive a reduced number of Warrant Shares, in accordance with clause 6.3.2]. 
 We direct
the Company: 
 [use for a request under option (1)(A) above] to issue [number] of Ordinary Shares to be issued pursuant to this exercise
in the following numbers to the following proposed allottees, each of which is either a Warrantholder, a nominee or trustee of a Warrantholder or a transferee of one of those persons approved in accordance with clause 9.1 of the Warrant Instrument]

  

					
	 Number/percentage of shares
	  	 Name of proposed allottee
	  	 Address of proposed allottee

	 1
	  		  	

 [OR] use for a request under option (1)(B) above] to issue, allot, and deposit [number] of Ordinary
Shares to be issued pursuant to this exercise to the custodian (or its nominee) of the Depositary and that following such issuance and deposit, to direct the Depositary to issue an amount of ADSs via DTC in accordance with the Issuance and Delivery
Instruction corresponding to this Notice of Subscription. 

  
 22 

 The Warrantholder represents and warrants that this Notice of Subscription has been duly signed and
constitutes a valid and binding act to exercise the said Warrants. 
 Place and date: 

Name of Warrantholder: 
  

	
	  
  

By:

	
	Title:

 The above exercise is acknowledged and accepted. Place and date: 

 

	
	MEREO BIOPHARMA GROUP PLC
	  

	
	By:

  
 23 

 SCHEDULE 2 

Conditions 
  

	1	 An accurate Register will be kept and maintained at all times by the Company at its registered office and there
shall be entered in the Register: 

  

	1.1	 the names and addresses of the persons for the time being entitled to be registered as the holders of the
Warrants; 

  

	1.2	 the number of Warrants held for the time being by every registered holder; and 

 

	1.3	 the date on which the name of every registered holder is entered in the Register in respect of the Warrants in
its name. 

  

	2	 Any change in the name or address of any Warrantholder shall promptly be notified to the Company which shall
cause the Register to be altered accordingly. The Warrantholders or any of them and any person authorised by any Warrantholder shall be at liberty at all reasonable times during office hours to inspect the Register and to take copies of or extracts
from it or any part of it. 

  

	3	 The Company shall be entitled to treat each Warrantholder as the absolute owner of a Warrant and accordingly
shall not, except as ordered by a court of competent jurisdiction or as required by law, be bound to recognise any equitable or other claim to or interest in a Warrant on the part of any other person, whether or not it shall have express or other
notice of such a claim. 

  

	4	 Each Warrantholder will be recognised by the Company as entitled to the Warrants free from any equity, set-off
or cross-claim on the part of the Company against the original or any intermediate holder of the Warrants. 

  

	5	 Each transfer of a Warrant shall be made by an instrument of transfer in the usual or common form or in any
other form which may be approved for the time being by the Directors. 

  

	6	 The instrument of transfer of a Warrant shall be executed by or on behalf of the transferor but need not be
executed by or on behalf of the transferee. The transferor shall be deemed to remain the holder of the Warrant until the name of the transferee is entered in the Register in respect of the Warrant being transferred. 

 

	7	 The Directors may decline to recognise any instrument of transfer of a Warrant unless the instrument is
deposited at the registered office of the Company accompanied by the Warrant Certificate for the Warrant to which it relates, and such other evidence as the Directors may reasonably require to show the right of the transferor to make the transfer.
The Directors may waive production of any Warrant Certificate upon production to them of satisfactory evidence of the loss or destruction of the Warrant Certificate together with such indemnity as they may require. 

 

	8	 No fee shall be charged for any registration of a transfer of a Warrant or for the registration of any other
documents which in the opinion of the Directors require registration. 

  
 24 

	9	 The registration of a transfer shall be conclusive evidence of the approval by the Directors of such a
transfer. 

  

	10	 Each Warrantholder shall register with the Company an address in the United Kingdom to which notices can be
sent. If any Warrantholder fails to register an address with the Company, notice may be given to that Warrantholder by sending it by any of the methods referred to in paragraph 11 of this Schedule 2 to that Warrantholder’s last known place of
business or residence or, if none, by exhibiting it for three days at the registered office for the time being of the Company. 

  

	11	 Notices and other communications to Warrantholders may be given by personal delivery, prepaid letter by first
class post or, subject to clause 1.3 of this instrument, fax or email. In proving service of any notice or other communication sent by post, it shall be sufficient to prove that the envelope containing the notice or other communication was properly
addressed and stamped and was deposited in a post box or at the post office. 

  

	12	 A notice or other communication given pursuant to the provisions of paragraph 11 of this Schedule 2 shall be
deemed to have been served: 

  

	12.1	 at the time of delivery, if delivered personally to the registered address; 

 

	12.2	 on the second Business Day following its posting, if sent by prepaid letter by first class post to an address
in the United Kingdom; and 

  

	12.3	 at 09:00 hours on the Business Day following the despatch of the fax, if sent by fax. 

 

	13	 All notices and other communications with respect to Warrants standing in the names of joint registered holders
shall be given to whichever of such persons is named first in the Register and such notice so given shall be sufficient notice to all the registered holders of such Warrants. 

 

	14	 Any person who, whether by operation of law, transfer or other means whatsoever, shall become entitled to any
Warrant, shall be bound by every notice in respect of such Warrant which, prior to its name and address being entered on the Register, shall have been duly given to the person from which it derives its title to such Warrant. 

 

	15	 When a given number of days’ notice or notice extending over any other period is required to be given, the
day of service shall be included but the day upon which such notice will expire shall not be included in such number of days or other period. The signature to any notice to be given by the Company may be written or printed. 

 

	16	 Meetings of Warrantholders shall be convened and conducted in the same way as meeting of shareholders of the
Company are convened and conducted. Accordingly, the provisions of Articles shall apply to meetings of the Warrantholders mutatis mutandis. 

  
 25 

 SCHEDULE 3 

ADS Issuance and Delivery Instruction 

[DATE] 
 Citibank, N.A., as Depositary 

388 Greenwich Street 
 New York, New York 10013 

Attn.: Mr. Brian M. Teitelbaum (brian.m.teitelbaum@citi.com) 

With a copy simultaneously delivered to: 
 Citibank, N.A.,
London Branch 
 25 Canada Square 
 Canary Wharf 

London E14 5LB, England 
 Attn.: UK Custody Settlements 

Custody Team (uksettlements@citi.com) 
 Re: Issuance and
Delivery Instruction - Mereo BioPharma Group plc (CUSIP No.: 589492107) – Deposit & Hold 
 Dear Sirs: 

Reference is made to the Deposit Agreement, dated as of April 23, 2018, as amended and supplemented from time to time (the “Deposit
Agreement”), by and among Mereo BioPharma Group plc, a public limited company incorporated under the laws of England and Wales and its successors (the “Company”), Citibank, N.A., a national banking association organized and existing
under the laws of the United States of America, as Depositary (the “Depositary”), and all Holders and Beneficial Owners of American Depositary Shares (the “ADSs”) issued thereunder. All capitalized terms used, but not otherwise
defined herein, shall have the meaning assigned thereto in the Deposit Agreement. 
 In accordance with the terms and subject to the
limitations set forth in the Deposit Agreement, promptly following the Depositary’s receipt of confirmation from the Custodian that the Custodian has received a deposit of the number of Shares specified below made by the Company for the benefit
of the undersigned holder thereof (the “Holder” and together with the Company, the “Undersigned”), the Undersigned hereby jointly instruct the Depositary, and the Depositary hereby agrees: 

  
 26 

 (i) to promptly accept for deposit the number of Shares and issue the number of ADSs as
specified below: 
  

			
	Number of Shares deposited:	  	                    Shares
		
	Number of ADSs (CUSIP No.: 589492107; each ADS representing five (5) Shares to be issued:	  	
		
		  	                    ADSs
		
	 and (ii) to promptly deliver such Program ADSs, as follows:
	  	
		
	Name of DTC Participant to which the ADSs are to be delivered:	  	 
 

             

		
	DTC Participant Account No.:	  	 

                 

		
	Account No. for recipient of ADSs at DTC Participant (f/b/o/ information):	  	                                      
                      
		
	Name on whose behalf the above number of ADSs are to be issued and delivered:	  	              

		
	Contact person at DTC Participant:	  	              

		
	Daytime telephone number of contact person at DTC:	  	                                      
                      

 The Company hereby confirms and certifies that (i) the registration statement on Form F-3 (File No. 333-239708) (the
“Registration Statement”), filed with the U.S. Securities and Exchange Commission (the “Commission”) on July 6, 2020, registers the resale of the above Shares represented by ADSs, such ADSs will be freely transferable
following the issuance thereof by the Depositary, and there are no legal restrictions on subsequent transfers of the ADSs to be issued hereunder under the laws of England and Wales or the United States, (ii) the Registration Statement is
effective under the Securities Act of 1933, as amended (the “Securities Act”), and (iii) no stop order suspending the effectiveness of the Registration Statement has been issued and no proceedings for such purpose have been instituted
or are pending or, to the best knowledge of the Company, are contemplated or threatened by the Commission. 
 The Holder hereby represents and covenants to,
and for the benefit of, the Depositary and Citibank, N.A.—London Branch (the “Custodian”), that (i) the Holder is not an “affiliate” of the Company as that term is defined in Rule 144 promulgated by the Commission under
the Securities Act and has not been an affiliate at any time during the 90 days immediately preceding the date hereof, and (ii) all stamp duty taxes, including, without limitation, the U.K. Stamp Duty Reserve Tax (“SDRT”), will be
paid in full and on a timely basis to the extent such taxes are payable in respect of the deposit of the Shares and the issuance and delivery of the ADSs as contemplated herein. 

  
 27 

 Each of the Holder and, to the extent it is not unlawful for the Company to do so under the applicable laws
of England and Wales, the Company agrees to indemnify the Depositary and the Custodian for, and to hold the Depositary and the Custodian harmless against, all losses, liabilities, taxes, charges, penalties or expenses (including reasonable legal
fees and disbursements), incurred by the Depositary and/or by the Custodian or to which the Depositary and/or the Custodian may become subject to and arising directly or indirectly from the failure by any person to pay (or discharge) any applicable
stamp duty taxes, including, without limitation, SDRT, or any other similar duty or tax in connection with the deposit of the Shares and the issuance and delivery of the ADSs as contemplated herein, save to the extent that such losses, liabilities,
taxes, charges, penalties or expenses are due to the negligence or bad faith of the Custodian or the Depositary. 
  

									
	[HOLDER]	 		 	MEREO BIOPHARMA GROUP PLC
					
	By:	 	
                     

	 	        	 	By:	 	
                     
        

			
	Name:	 		 	Name:
			
	Title:	 		 	Title:

  
 28 

 SIGNATURE PAGE 

 

					
	EXECUTED and delivered as a DEED by	 	            	 	
	MEREO BIOPHARMA GROUP PLC	 		 	
		 		 	Signature of Director
			
		 		 	Name of Director
	  
	 		 	
			
		 		 	Signature of Secretary
			
		 		 	Name of Secretary
	  
	 		 	

  
 29 

 Schedule 3 

2018 Warrant Instrument (marked changes) 

 

 
 EXECUTION VERSION 

DATED
DECEMBER 2020 2018 

MEREO BIOPHARMA GROUP PLC 
  

 
 AMENDED WARRANT
INSTRUMENT 

DATED 1 OCTOBER
2018 
 relating to the issue of warrants entitling the holders to 

subscribe for Warrant Shares in the capital of 

MEREO BIOPHARMA GROUP PLC 
  

 
 5 Fleet Place London EC4M 7RD 

Tel: +44 (0)20 7203 5000 · Fax: +44 (0)20 7203 0200 · DX: 19 London/Chancery
Lane 
 www.charlesrussellspeechlys.com 

 CONTENTS 
  

							
	 1
	 	DEFINITIONS AND INTERPRETATION	  	 	2	 
			
	 2
	 	CONSTITUTION AND FORM OF WARRANTS	  	 	9	 
			
	 3
	 	CALCULATION OF NUMBER OF WARRANT SHARES	  	 	10	 
			
	 4
	 	CERTIFICATES	  	 	10	 
			
	 5
	 	TIMING FOR EXERCISE OF SUBSCRIPTION RIGHTS	  	 	10	 
			
	 6
	 	EXERCISE OF SUBSCRIPTION RIGHTS	  	 	11	 
			
	 7
	 	AUTOMATIC EXERCISE OF SUBSCRIPTION RIGHTS	  	 	13	 
			
	 8
	 	COMPLETION	  	 	13	 
			
	 9
	 	TRANSFER OF WARRANTS	  	 	15	 
			
	 10
	 	MODIFICATION AND CESSATION OF RIGHTS	  	 	15	 
			
	 11
	 	ADJUSTMENT OF WARRANT	  	 	15	 
			
	 12
	 	LIQUIDATION	  	 	16	 
			
	 13
	 	TAKEOVERS	  	 	16	 
			
	 14
	 	COMPANY REORGANISATIONS – EXCHANGE OF WARRANTS	  	 	18	 
			
	 15
	 	INFORMATION AND RIGHTS OF WARRANTHOLDER(S)	  	 	18	 
			
	 16
	 	RESTRICTIONS ON AND UNDERTAKINGS OF THE COMPANY	  	 	19	 
			
	 17
	 	WARRANTIES	  	 	20	 
			
	 18
	 	NOTICES	  	 	20	 
			
	 19
	 	COSTS AND EXPENSES	  	 	20	 
			
	 20
	 	CONTRACTS (RIGHTS OF THIRD PARTIES) ACT 1999	  	 	21	 
			
	 21
	 	FURTHER ASSURANCE	  	 	21	 
			
	 22
	 	SEVERABILITY	  	 	21	 
			
	 23
	 	GOVERNING LAW	  	 	21	 
		
	 SCHEDULE 1 FORM OF WARRANT CERTIFICATE
	  	 	22	 
		
	 SCHEDULE 2 CONDITIONS
	  	 	27	 

 THIS WARRANT INSTRUMENT is made on 2018 1 October 2018,
as amended on December 2020 
  

	(0)	 BY: 

  

	(1)	 MEREO BIOPHARMA GROUP PLC, a company incorporated in England and Wales with number 09481161 whose
registered office is at 4th Floor, 1 Cavendish Place, London, England, W1G 0QF (“Company”). 

 BACKGROUND: 

 

	(A)	 The Company, by resolution of its directors, has agreed to issue Warrants to subscribe for Warrant Shares in
the capital of the Company on the terms set out in this instrument, subject to adjustment as set out in this instrument. 

  

	(B)	 Either all of the registered holders of shares in the Company have irrevocably waived all pre-emption rights
conferred on them (whether by the Companies Act, the Articles or otherwise) or such pre-emption rights have been validly disapplied in relation to the number of Warrants and shares in the Company issued pursuant to this instrument.

  

	(C)	 This instrument has been executed by the Company as a deed in favour of the Warrantholder.

 IT IS AGREED: 
  

	1	 DEFINITIONS AND INTERPRETATION 

 

	1.1	 In this instrument the following words and expressions shall (unless the context requires otherwise) have the
following meanings: 

  

			
	2020 Warrants	  	means any warrants issued on the Amendment Date, by way of adjustment to the Initial Warrants;
		
	Adjustment	  	means any sub-division or
allconsolidation of Equity
Securities by the followingCompany, at any time, after issue of the relevant Warrant, or by reference
to any record date, while the Warrants remain exercisable:
		
		  	 (a)   any allotment or issue of Equity Securities
by the Company by way of capitalisation of profits or reserves;

		
		  	 (b)   any cancellation, purchase or redemption of
Equity Securities, or any reduction or repayment of Equity Securities, by the Company;

		
		  	 (c)   any sub-division or consolidation of Equity
Securities by the Company; and

  

  
 2 

 
			
		  	 (d)   any issue of securities or other instruments
convertible into shares in, or Equity Securities of, the Company or any grant of options, warrants or other rights to subscribe for, or call for the allotment or issue of, shares in, or Equity Securities of, the
Company,

		
		  	but excluding any issue of Equity Securities of the Company pursuant to (i) the exercise of any options granted to employees, consultants or directors of the Company, or (ii) the loan notes in the
Company currently held by Novartis Pharma AG pursuant to a convertible loan note instrument dated 3 June 2016, as amended;
		
	AIMADS	  	the AIM market operated by the London Stock Exchangemeans American Depositary Shares representing interests
in the Ordinary Shares pursuant to a sponsored American Depositary Receipt facility with the Depositary;
		
	AIM RulesADS Exchange Ratio	  	the AIM Rules for Companies published by the London Stock Exchangemeans the ratio applicable to the exchange
of Ordinary Shares for ADSs from time to time, currently being a ratio of 5 Ordinary Shares for each ADS;
		
	Amendment Date	  	means 15 December 2020;
		
	Articles	  	the articles of association of the Company for the time being;
		
	Auditors	  	the Company’s auditors;
		
	Business	  	means the research, development, production, trading and licensing of rights, intellectual property and/or products within the life sciences industry (or any of the foregoing or any activities connected thereto);
		
	Business Day	  	a day (which for these purposes ends at 5.30 pm) on which banks are open for commercial business in the City of London other than a Saturday or Sunday;
		
	Companies Act	  	the Companies Act 2006;
		
	Competitor	  	means any entity (other than a reputable financial institution) whose business directly competes with the Business carried out by a Group Company;

  
 3 

			
		
	Conditions	  	the terms and conditions set out in Schedule 2 (subject to any alterations made in accordance with the provisions of this instrument);
		
	Consent	  	either:
		
		  	 (a)   a resolution passed at a meeting of the Warrantholders duly convened and
held and carried by a majority consisting of not less than 75 per cent. of the votes cast upon a show of hands or, if a poll is duly demanded, by a majority consisting of not less than 75 per cent of the votes cast on a poll; or

		
		  	 (b)   the consent in writing of Warrantholders entitled to the right to
subscribe for at least 75 per cent of the Warrant Shares in respect of which Subscription Rights are granted pursuant to this instrument;

		
	CREST	  	the system of paperless settlement of trades and the holding of uncertificated shares administered by Euroclear UK & Ireland Limited or any other relevant paperless settlement system used in
relation to the holding of uncertificated shares in the Company;
		
	Directors	  	the board of directors of the Company (and/or, where relevant, a Group Company) for the time being;
		
	Equity Securities	  	has the meaning given in section 560(1) of the Companies Act;
		
	Exercise Date	  	the date of delivery to the registered office of the Company of the items specified in clause 6.2 (and the date of such delivery shall be the date on which such items are received at the Company’s registered office);
		
	Fair Market Value	  	either:
		
		  	 (a)   if the Ordinary Shares are then traded on a Recognised Investment Exchange
the fair market value of a Warrant Share shall be the volume weighted average price of one (1) Ordinary Share during the ten (10) consecutive trading day period immediately preceding the Exercise Date;
or

  
 4 

			
		
		  	 (b)   if the Ordinary Shares are not traded on a Recognised Investment Exchange, the fair but ADSs are listed on Nasdaq, the implied price of One Ordinary Share in pounds sterling, which shall be determined as
follows:

		
		  	 (i) dividing (x) being the volume
weighted average price of one ADS during the ten (10) consecutive trading day period immediately preceding the Exercise Date by (y) being the number of Ordinary Shares currently represented by a single ADS in accordance with the ADS Exchange Ratio
in effect on such date (Implied USD Price); and

		
		  	 (ii) converting the Implied USD Price to
pounds sterling at the Exchange Rate on the trading day immediately preceding the Exercise Date; or

		
		  	
(c)   if the
Ordinary Shares are not traded on a Recognised Investment Exchange and ADSs are not listed on Nasdaq, the fair market value a Warrant Share shall be the Fair Price;

		
	Fair Price	  	unless otherwise agreed by the board of Directors and the Warrantholder(s) prior to service of the Notice of Subscription, the price per Warrant Share which the Auditors (acting as an expert (the Expert)) shall certify to be
in its opinion a fair price for the Warrant Shares. In arriving at his opinion the Expert will value the Warrant Shares as at the date the Notice of Subscription is to be given on the basis that the Company operates as a going concern, as between a
willing seller and a willing buyer, subject always to the provisions of the Articles. The decision of the Expert as to the fair price for the Warrant Shares shall be final and binding and his costs shall be borne by the Company;
		
	Final Date	  	subject to clause 5 (Timing for exercise of Subscription Rights), 10 years from the date of this instrument (which date, for the avoidance of doubt, shall
be 1 October 2028);
		
	London Stock Exchange	  	London Stock Exchange plc;
		
	Group	  	(i) the Company and its subsidiaries (if any), (ii) any holding company of the Company, and (iii) any subsidiaries of such holding companies from time to time and Group Company means any member of the
Group;

  
 5 

			
	Market Abuse RegulationInitial Warrants	  	Market Abuse Regulation (Regulation 596/2014/EU)means the warrants of the Company constituted
by this Instrument on 1 October 2018, and any further warrants issued prior to the Amendment Date as an adjustment thereto;
		
	Issuance and Delivery Instruction	  	means an issuance and delivery instruction in such form as notified from the Company to the Warrantholders from time to time, the current form of
which is attached hereto at Schedule 3;
		
	Marketable Securities	  	means securities in the acquiring entity traded on a Recognised Investment Exchange where the Warrantolder(s) (were it to receive such securities on completion of an Offer having exercised this Warrant) would not be subject to any
restrictions on re-sale of such securities;
		
	Member of the same Fund Group	  	is if the Warrantholder is a fund, partnership, company, syndicate or other entity whose business is managed by a Fund Manager (an “Investment Fund”) or a nominee of that person:
		
		  	 (a)   any participant or partner in or member of any such Investment Fund or the
holders of any unit trust which is a participant or partner in or member of any Investment Fund but only in connection with the dissolution of Investment Fund or any distribution of assets of the Investment Fund pursuant to the operation of the
Investment Fund in the ordinary course of business,

		
		  	 (b)   any Investment Fund managed or exclusively advised by that Fund
Manager,

		
		  	 (c)   a parent undertaking or subsidiary undertaking of that Investment Fund or
Fund Manager, or any subsidiary undertaking of any parent undertaking of that Investment Fund or Fund Manager, or

		
		  	 (d)   any trustee, nominee or custodian of such Investment Fund and vice
versa;

		
	Notice of Subscription	  	the notice addressed to the Company by a Warrantholder exercising its Subscription Rights in the form, or substantially in the form, set out in the schedule to the Warrant Certificate;

  
 6 

			
	Ordinary Shares	  	ordinary shares in the capital of the Company and having the rights and privileges set out in the Articles;
		
	Permitted Transferee	  	are:
		
		  	 (a)   a nominee of the Warrantholders;

		
		  	 (b)   a regulated, reputable financial institution;

		
		  	 (c)   a member of the SVB Financial Group of companies; and/or

		
		  	 (d)   a Member of the same Fund Group;

		
	Recognised Investment Exchange	  	a recognised investment exchange or overseas investment exchange (within the meaning thereof given for the purposes of section 285 of the Financial Services and Markets Act 2000, and shall include, without limitation, AIM or
NASDAQ;
		
	Register	  	the register of persons for the time being entitled to the benefit of the Warrants to be maintained pursuant to the Conditions;
		
	Registrars	  	the registrars of the Company for the time being;
		
	Subscription Price	  	the subscription price per Warrant Share, such price being equal to:
		
		  	
(a)   £ ; in respect of the Initial Warrants £2.95;
and

		
		  	
(b)   in respect of
the 2020 Warrants, $0.4144 (being the volume weighted average price of one (1) Ordinary Share during the ten (10) consecutive trading day period immediately preceding the Amendment Date converted into USD at an exchange rate of 1 GBP = 1.3226 USD
(being the GBP-USD opening exchange rate published in the Wall Street Journal on the business day (being a day on which banks are open for commercial business in New York) immediately preceding the Amendment Date)

		
	Subscription Rights	  	the rights of the Warrantholder(s) to subscribe for Warrant Shares under clause 6 (Exercise of Subscription Rights);
		
	Takeover Code	  	the UK City Code on Takeovers and Mergers (as amended from time to time);

  
 7 

			
	UKLA	  	the United Kingdom Listing Authority;
		
	Warrant Certificate	  	a certificate evidencing a Warrantholder’s entitlement to Warrants in the form set out in Schedule 1;
		
	Warrant Shares	  	Ordinary Shares to be issued pursuant to the terms of the Warrants;
		
	Warrantholder	  	in relation to a Warrant, the person whose name appears in the Register as the holder of the Warrant; and
		
	Warrants	  	the warrants of the Company constituted by this instrumentInitial Warrants and the 2020 Warrants
and all rights conferred by itthis Instrument relating thereto (including the Subscription Rights).

  

	1.2	 In this instrument, unless the context otherwise requires: 

 

	 	1.2.1	 words and expressions defined in the Companies Act or the Articles shall have the same meanings in this
instrument (unless otherwise expressly defined in this instrument); 

  

	 	1.2.2	 headings are used for convenience only and shall be ignored in interpreting this instrument;

  

	 	1.2.3	 reference to a clause or schedule is a reference to a clause of, or schedule to, this instrument;

  

	 	1.2.4	 reference to (or to any specific provision of) this instrument or any other document or instrument shall be
construed as a reference to this instrument, that provision or that document or instrument as in force for the time being and as amended from time to time in accordance with its terms and the prior sanction of a Consent (where consent is required by
the terms of this instrument as a condition to such amendment being made); 

  

	 	1.2.5	 reference to any gender includes all genders, references to the singular includes the plural (and vice versa)
and reference to persons includes bodies corporate, unincorporated associations and partnerships (whether or not any of the same have a separate legal personality); 

 

	 	1.2.6	 reference to a statutory provision includes reference to: 

 

	 	(a)	 the statute or statutory provision as modified or re-enacted from time to time; and 

 

	 	(b)	 any subordinate legislation made under the statutory provision (as modified or re-enacted as set out in clause
1.2.6(a) above); 

  
 8 

	 	1.2.7	 any words following the terms ‘including’, ‘include’, ‘in particular’, ‘for
example’ or any other similar expression shall be construed as illustrative and shall not limit the sense of the words, description, phrase or term preceding those words; and 

 

	 	1.2.8	 references to statutory obligations include obligations arising under articles of the Treaty establishing the
European Community, and regulations, directives and decisions of the European Union as well as United Kingdom Acts of Parliament and subordinate legislation. 

  

	1.3	 Unless otherwise specifically provided, where any notice, resolution or document is required by this instrument
to be signed by any person, the reproduction of the signature of such person by fax or email shall suffice, provided that confirmation by first class letter is despatched by close of business on the next following Business Day, in which case the
effective notice, resolution or document shall be that sent by fax or email (served in accordance with paragraphs 11 and 12 of Schedule 2), not the confirmatory letter. 

 

	1.4	 This instrument incorporates the schedules to it. 

 

	2	 CONSTITUTION AND FORM OF WARRANTS 

 

	2.1	 This instrument constitutes the Warrants, which in aggregate give the Warrantholder(s) the right, upon the
terms and subject to the conditions set out in this instrument, to subscribe in cash (subject to clause 6.3.2) at a price per share equal to the Subscription Price for such number of Warrant Shares calculated in accordance with clause 3
(Calculation of number of Warrant Shares). 

  

	2.2	 Subject to clause 6.3.2 (Exercise of Subscription Rights), each Warrantholder shall be entitled to
subscribe in cash at the Subscription Price for that number of Warrant Shares in respect of which it is entitled to be recorded as the holder in the Register on the terms set out in this instrument. 

 

	2.3	 The Warrants shall be in registered form. 

 

	2.4	 The Warrants are issued subject to the Articles and otherwise on the terms of this instrument (including the
Conditions). 

  

	2.5	 The Company agrees with the Warrantholder(s) and, in consideration of being issued a Warrant Certificate, each
Warrantholder agrees with the Company that the Articles (insofar as they relate to the Warrants) and the terms of this instrument shall be binding upon the Company and each Warrantholder and all persons claiming through or under either of them.

  

	2.6	 No application will be made for the Warrants to be listed or dealt on any Recognised Investment Exchange (as
that term is defined in the Financial Services and Markets Act 2000 (as amended)). 

  
 9 

	3	 CALCULATION OF NUMBER OF WARRANT SHARES 

 

	3.1	 The number of Warrant Shares over
which the Initial Warrants will be issued at the date of this instrument (the Issue Date) shall be have been issued is 304,758 Warrant Shares. 

  

	3.2	 The number of Warrant Shares over
which the 2020 Warrants shall be issued is 304,758 Warrant Shares, such. 

 

	3.3	 The 2020 Warrants toshall be issued to Silicon Valley Bank and Kreos Capital V (Expert Fund) LP in equal proportions.

  

	4	 CERTIFICATES 

  

	4.1	 The Company shall issue to each Warrantholder a Warrant Certificate in respect of that number of Warrants to
which it is entitled as soon as reasonably practicable following a Warrantholder becoming entitled to such Warrants in accordance with clause 3 (Calculation of number of Warrant Shares). 

 

	4.2	 If a Warrant Certificate is mutilated, defaced, lost, stolen or destroyed, the Company will replace it on such
terms as to evidence and indemnity as the Company may reasonably require and subject to the Warrantholder who is seeking the replacement paying the Company’s reasonable costs (if any) in connection with the issue of the replacement.

  

	4.3	 Mutilated or defaced Warrant Certificates must be surrendered before replacements will be issued.

  

	5	 TIMING FOR EXERCISE OF SUBSCRIPTION RIGHTS 

 

	5.1	 The Subscription Rights may be exercised at any time from the date of this instrument until 17:00 GMT on the
Final Date and shall be exercised in accordance with clause 6 (Exercise of Subscription Rights). 

  

	5.2	 Subject to clause 7 (Automatic Exercise of Subscription Rights), a failure by any Warrantholder to
exercise its Subscription Rights ahead of such time on the Final Date shall mean that such Warrantholder’s outstanding Warrants shall immediately lapse and be cancelled and such Warrantholder shall have no further rights under this instrument.

  

	5.3	 Without prejudice to clauses 12 (Liquidation), 13 (Takeovers) and 14 (Company reorganisations
– Exchange of Warrants), if the Final Date is likely to occur before the last date for approval of or acceptance of a liquidation, share buyback, takeover or reorganisation event (that is in each case subject to an existing proposal) such
as described in the said clauses, the Final Date shall be extended until such last date for approval or acceptance of such event as aforesaid. 

  
 10 

	6	 EXERCISE OF SUBSCRIPTION RIGHTS 

 

	6.1	 The Subscription Rights may be exercised in whole or in part. If exercised in part, the Subscription Rights
must be exercised in tranches of 50,000 Warrants, or in respect of the last tranche of Warrants attached to the outstanding Subscription Rights held by the Warrantholder concerned, such lesser balancing number of Warrants as may be outstanding.

  

	6.2	 In order to exercise its Subscription Rights validly, a Warrantholder must deliver the following items to the
registered office of the Company: 

  

	 	6.2.1	 the Warrant Certificate for the Warrants in respect of which Subscription Rights are being exercised, together
with the Notice of Subscription duly completed; 

  

	 	6.2.2	 if required pursuant to clause 6.3.1, a remittance by banker’s draft, drawn on a UK clearing bank, (or
such other mode of payment as the Company and the Warrantholder shall agree); and 

  

	 	6.2.3	 the name and address of the Warrantholder to which the Warrant Shares arising on exercise of Subscription
Rights are to be issued; and 

  

	 	6.2.4	 if and to the extent that the
Ordinary Shares issued are to be delivered as ADSs, a completed Issuance and Delivery Instruction in the form set out at Schedule 3 hereto (as such form may be amended from time to time by notice to the Warrantholder) duly completed and executed by
the Warrantholder. 

  

	6.3	 The Subscription Price for each of the Warrant Shares shall, at the absolute discretion of the Warrantholder,
be satisfied by any of the following: 

  

	 	6.3.1	 the payment by banker’s draft for each of the Warrant Shares at the Subscription Price; or

  

	 	6.3.2	 in lieu of a cash
payment in respect of the aggregate Subscription Price for the Warrant Shares, the Warrantholder may elect to
receivefor a reduced number of Warrant Shares (as calculated below)
(“Reduced Warrant
Shares”) to be issued than the number to which it would be
entitled on exercise of the Subscription RightRights in full, payment for such Reduced Warrant Shares being
satisfied by waiver by the Warrantholder of the right to receive the balance of Warrant Shares to which the Warrantholder is entitled over and above the Reduced Warrant Shares
(“Balance Warrant Shares”). In doing so, the Company
agrees and acknowledges that, subject to the payment of the par value of the Reduced Warrant Shares pursuant to this clause
6.3.2,6.3.2, the Reduced Warrant Shares to be issued to the Warrantholder shall be issued(or, in the case of a Warrantholder which has specified in the Notice of Subscription in respect

  
 11 

	 	
of such Reduced Warrant Shares that it requires to have such Reduced Warrant Shares delivered as ADSs and has
delivered a duly completed Issuance and Delivery Instruction to the Company in respect of the same, issued to, deposited with (and otherwise registered in the name of) the custodian of the Depositary (or its nominee)) as fully paid up at
the Subscription Price, and the Warrantholder agrees and acknowledges that it waives its Subscription Rights to the Balance Warrant Shares used as consideration for the payment of the aggregate
Subscription Price. The number of Reduced Warrant Shares the Warrantholder (or Depositary, as applicable) will receive shall be determined as follows:

  
 

 

X = Y (A
– B) / A 
 where: 

X = the number of Reduced Warrant Shares to be issued to the Warrantholder or Depositary (as
 applicable). 
 Y = the number of Warrant Shares with respect to which the
Warrant is being exercised by the Warrantholder (without application of the reduction). 
 A = the Fair Market Value of one Warrant Share

 B = the Subscription
Price. (provided that, where the relevant Warrants being exercised have a Subscription Price denominated in USD, the
Company shall convert such Subscription Price to pounds sterling for the purpose of calculating the aggregate nominal value of such Reduced Warrant Shares using the Exchange Rate on the trading day prior to service of the Notice of Subscription or
Automatic Exercise Notice, as the case may be) 
 Provided always that the
Warrantholder shall nevertheless be required to subscribe in cash for the par value of the Reduced Warrant Shares to the extent that if it did not do so the Reduced Warrant Shares would be issued at a discount to the Warrantholder. It being
understood that if Warrant Shares are issued pursuant to this clause 6.3.2, notwithstanding that such Warrant Shares are issued at nominal value, the Warrantholder shall be deemed to have paid the relevant Subscription Price per Warrant Share for
the purposes of calculating any distribution or share of sale proceeds in each case attributable to the Warrant Shares and to other issued shares of the class for the purposes of the Articles and for all other purposes. 

 

	6.4	 Delivery of the items specified in clause 6.2 to the Company shall, unless the Company expressly consents
otherwise, be an irrevocable election by the Warrantholder to exercise the relevant Subscription Rights. 

  
 12 

	7	 AUTOMATIC EXERCISE OF SUBSCRIPTION RIGHTS 

 

	7.1	 If, on the Final Date, the Fair Market Value of one Warrant Share is greater than the Subscription Price on
such date, the Warrantholder shall be deemed to have automatically exercised its Subscription Rights, on a conditional basis, in respect of all unexercised Warrants on such date on a net issuance basis as set out in
clauseClause 6.3.2 (Exercise of Subscription Rights). In such circumstances, the Company shall (subject at all times to the Company’s
obligations under the Takeover Code, the AIM Rules, and all applicable law and any other regulations including the Market Abuse Regulation), send a notice to
the Warrantholder(s) within ten (10) Business Days of the Final Date (such notice being the “Automatic Exercise Notice” for the purposes of this clause 7) requiring them to pay up a cash amount equal to the aggregate nominal value of
the Warrant Shares (such payment being the “Nominal Value Payment”) to be issued pursuant to clause 6.3.2 (“Exercise of Subscription Rights”) and this clause 7.1. 7.1, and to specify whether such Warrantholder requires any such Warrant Shares to be delivered as ADSs. 

 

	7.2	 The Warrantholder shall, within ten (10) Business Days of receipt of the Automatic Exercise Notice (the
“Nominal Value Payment Period”), provide the Company with the Nominal Value Payment, to an account notified by the Company to the Warrantholder. Warrantholder, and, if such Warrantholder requires any Warrant Shares to be delivered
as ADSs, a duly completed Issuance and Delivery Instruction in respect of such Warrant Shares. Upon receipt of such
the Nominal Value Payment, (and, if applicable, such Issuance and Delivery Instruction) the Warrant Shares to be issued to the Warrantholder on a net issuance basis pursuant to clause 6.3.2 (Exercise of Subscription Rights(or in the case of a Warrantholder who
has delivered an Issuance and Delivery Instruction, the custodian of the Depositary) shall be allotted and issued to the Warrantholder (or the custodian of the
Depositary, as applicable) credited as fully paid up in accordance with clause 6.3.2 (Exercise of Subscription Rights) and clause 8.3.1 (Completion). Any failure by a Warrantholder to pay the Nominal Value
PaymentValuePayment (or deliver a duly completed Issuance and Delivery Instruction, if applicable) within the Nominal Value Payment Period shall
result in the automatic lapse of any Warrants over Warrant Shares for which the Nominal Value Payment was not made or Issuance and Delivery Instruction not
delivered. 

  

	8	 COMPLETION 

  

	8.1	 Following a valid exercise of Subscription Rights by a Warrantholder or an automatic exercise of Subscription
Rights pursuant to clause 7 (Automatic exercise of Subscription Rights) or clause 13.2.2 (Takeovers), the Company shall in accordance with clause 8.3: 

 

	 	8.1.1	 allot and issue credited as fully paid to the Warrantholder; (or to its nominee
or trustee as notified to the Company in the Notice of Subscription) the Warrant Shares to which the Warrantholder is entitled by exercising the Subscription Rights (“Allotted
Shares”)or in the event that

  
 13 

	 	
the Warrantholder has required pursuant to clause 6.2 that Ordinary Shares to be issued from the Exercise of
Subscription Rights are to be delivered as ADSs, delivered a duly completed Issuance and Delivery Instruction, and there is an effective registration statement covering the Ordinary Shares to be issued on such exercise, issue to, deposit with (and
otherwise register in the name of) the custodian of the Depositary (or its nominee) (“Allotted Shares”) and following such issuance and deposit the Company will direct the Depositary to issue an amount of ADSs via DTC (with such
ADSs being eligible for listing on Nasdaq) in accordance with the corresponding Issuance and Delivery Instruction; 

  

	 	8.1.2	 immediately following allotment and issue in accordance with clause
8.1.1,8.1.1, enter, or procure that the Company’s Registrars enter the Warrantholder’s name
(or (i) its nominee’s or trustee’s name, as
appropriateor
(ii) in the case of any Ordinary Shares to be delivered as ADSs, the
custodian of the Depositary’s name) in the register of members of the Company as the holder of the Allotted Shares; 

  

	 	8.1.3	 immediately following registration in accordance with clause
8.1.2,8.1.2, either: send to the person identified by the Warrantholder pursuant to clause 8.1.1,8.1.1, free of charge, share certificate(s) in respect of the Allotted Shares or credit such aggregate number of Allotted Shares to the
Warrantholder’s (or its nominee’s or trustee’s) CREST stock account; and 

  

	 	8.1.4	 apply for the admission of the Warrant Shares to trading on (i) AIM, insofar
as the Warrant Shares are listed on AIM or, (ii) on any otherany recognised investment exchange on which the Warrant Shares are listed, at the time of the allotment and issue pursuant to clause 8.1.1, and shall use its reasonable endeavours to secure such admission to trading no later than ten
(10) Business Days after such application. 

  

	8.2	 The obligations of the Company under clause 8.1 shall be fulfilled within ten (10) days after the Notice
of Subscription is lodged at the registered office of the Company. 

  

	8.3	 The Allotted Shares shall: 

 

	 	8.3.1	 be allotted and issued fully paid; 

 

	 	8.3.2	 rank pari passu with the relevant class of fully paid Warrant Shares then in issue; 

 

	 	8.3.3	 rank for any dividend or other distribution which has previously been announced or declared if the date by
which the holder of Warrant Shares must be registered to participate in such dividend or other distribution is after the Exercise Date pursuant to which the Subscription Rights have been exercised; and 

  
 14 

	 	8.3.4	 be free from all claims, liens, charges, encumbrances, equities and third party rights. 

 

	8.4	 If following allotment of shares pursuant to the exercise of some of the Subscription Rights, some Subscription
Rights remain, the Company shall issue a Warrant Certificate to the Warrantholder within 15 Business Days for the balance of the Warrantholder’s Subscription Rights. 

 

	9	 TRANSFER OF WARRANTS 

 

	9.1	 Subject to clause 9.2, the Warrants may be transferred in whole or in part by any Warrantholder to any person,
provided that the Company has given its prior written consent to such transfer. 

  

	9.2	 A Warrantholder has the right, with prior written notice, but without the consent of the Company, to transfer
the Warrants in whole or in part to a Permitted Transferee, subject to compliance with the provisions of Schedule 2 hereto. 

  

	9.3	 Notwithstanding any other provisions of this instrument, no transfer shall be made to any person which is a
Competitor of the Company or any other Group Company. 

  

	9.4	 The provisions of Schedule 2 to this instrument shall regulate any transfer of a Warrant.

  

	10	 MODIFICATION AND CESSATION OF RIGHTS 

 

	10.1	 This instrument may be modified only with the prior sanction of Consent. 

 

	10.2	 This instrument ceases to have effect on the earlier of: 

 

	 	10.2.1	 the date upon which all Subscription Rights have been exercised in full; and 

 

	 	10.2.2	 the Final Date. 

  

	11	 ADJUSTMENT OF WARRANT 

 

	11.1	 Upon the occurrence of an Adjustment after the date of this Instrument but prior to the Final Date, the number
and/or nominal value of Warrant Shares to be, or capable of being subscribed on any subsequent exercise of the Subscription Rights conferred by each issued Warrant and/or the Subscription Price will be adjusted in such manner as the Auditors shall
certify to be fair and reasonable so that the Warrants shall, after such adjustment, entitle the Warrantholder(s) on exercise to receive the same percentage of the share capital of the Company in issue or capable of being issued following the
implementation of the Adjustment, carrying the same proportion of votes exercisable at a general meeting of shareholders, for the same
priceAggregate Subscription Price, in each case as nearly as practicable, as would have been the case if no Adjustment had occurred, provided
that the Subscription Price shall not in any event be reduced so that, upon exercise of the Subscription Rights, Warrant Shares would fall to be issued at a discount to their nominal value. 

  
 15 

	11.2	 Within ten (10) days after
days after an Adjustment, or, if later, within 10 days after the response of the auditors to any certification required by clause 11.1, notice of
such adjustments will be given to the Warrantholder(s) detailing the number of Warrant Shares for which the Warrantholder(s) are entitled to subscribe in consequence of any such adjustment. Replacement Warrant Certificates shall be issued
accordingly. 

  

	12	 LIQUIDATION 

  

	12.1	 If an order is made or an effective resolution is passed for the winding-up or dissolution of the Company or if
any other dissolution of the Company by operation of law is to be effected whilst any Subscription Rights remain exercisable, then the provisions of clause 12.2 or, as the case may be, clause 12.3 shall apply. 

 

	12.2	 If the winding-up or dissolution is for the purpose of a reconstruction, amalgamation or merger the
Warrantholder shall be entitled to be granted by the reconstructed, amalgamated or merged company a substituted warrant of the value of the Warrant immediately prior to such reconstruction, amalgamation or merger. 

 

	12.3	 If clause 12.2 does not apply, the Company shall immediately notify the Warrantholder(s) in writing that such
an order has been made or resolution has been passed or other dissolution is to be effected. The Warrantholder(s) shall be entitled at any time within three (3) months after the date such notice is given to elect by notice in writing to the
Company to be treated as if they had, immediately before the date of the making of the order or passing of the resolution or other dissolution, exercised the Subscription Rights and they shall be entitled to receive out of the assets which would
otherwise be available in the liquidation to the holders of Warrant Shares, such a sum, if any, as they would have received had they been the holders of and paid for the Warrant Shares to which they would have become entitled by virtue of such
exercise, after deducting from such sum the amount which would have been payable by them in respect of the Warrant Shares if they had exercised the Subscription Rights. Nothing contained in this clause 12.3 shall have the effect of requiring the
Warrantholder(s) to make any actual payment to the Company. 

  

	13	 TAKEOVERS 

  

	13.1	 Subject to clause 13.6, if at any time an offer or invitation is made by the Company to the holders of the
Ordinary Shares for the purchase by the Company of any of its Ordinary Shares, the Company shall promptly and without delay give notice thereof to each Warrantholder who shall be entitled, at any time whilst such offer or invitation is open for
acceptance, to exercise its Subscription Rights to the extent that such rights have not been exercised or lapsed prior to the record date of such offer or invitation so as to take effect, in so far as is reasonably practicable, as if it had
exercised its rights immediately prior to the record date of such offer or invitation. 

  
 16 

	13.2	 Subject to clause 13.6, if at any time an offer is made to all holders of Ordinary Shares (or all holders of
Ordinary Shares other than the offeror and/or any company controlled by the offeror and/or persons acting in concert with the offeror) to acquire the whole or any part of the issued share capital of the Company and the Company becomes aware that as
a result of such offer the right to cast a majority of the votes which may ordinarily be cast on a poll at a general meeting of the Company may, if such offer becomes unconditional in all respects, become vested in the offeror and/or such persons or
companies (the “Buyer”) as aforesaid (the “Offer”): 

  

	 	13.2.1	 The Company shall, subject to compliance with the Takeover Code,
give notice to each Warrantholder within ten (10) Business Days of its becoming so aware, and each Warrantholder shall be entitled to exercise its Subscription Rights, conditional upon the Offer being declared unconditional in all respects,
within thirty (30) days of such notice having been given by the Company (to the extent that such rights have not lapsed or been exercised prior to the record date of such Offer), and to accept or otherwise participate in such Offer on the same
terms as made to all holders of Ordinary Shares. 

  

	 	13.2.2	 If the Company fails to give notice as required by clause 13.2.1 (subject at all times to the Company’s
obligations under the Takeover Code, the AIM Rules, and all applicable law and any other regulations including the Market Abuse Regulation) then, provided
that immediately prior to the date that the Offer is made the offer price under the Offer is greater than the Subscription Price on such date and conditional upon the Offer being
declared or becoming unconditional in all respects, the Warrantholder shall be deemed to have automatically exercised its Subscription Rights in respect of all
unexercised Warrants on such date at the Subscription Price on a net issuance basis as set out in clause 6.3.2 (Exercise of Subscription Rights). In such circumstances, the Company shall send a notice to the Warrantholder(s) promptly and without
delay (such notice being the “Exercise Notice” for the purposes of this clause 13.2.2) upon either a Warrantholder notifying the Company of its failure to give notice as required by clause 13.2.1 or the Company or the Buyer becoming
aware of the Company’’s failure to give such notice requiring the Warrantholder(s) to pay the Nominal Value Payment. The Warrantholder shall, within ten (10) Business Days of receipt of the Exercise
Notice, provide the Company with the Nominal Value Payment, to an account notified by the Company to the
Warrantholder. , and, if such Warrantholder requires any Warrant Shares to be delivered as ADSs, a duly completed issuance
and delivery instruction in respect of such Warrant Shares. Upon receipt of such the Nominal Value Payment and
Issuance and Delivery Instruction (if applicable), subject to clause 13.3 the Warrant Shares to be issued to the Warrantholder (or to the custodian of the
Depositary, if applicable) on a net issuance basis pursuant to clause 6.3.2 (Exercise of Subscription Rights) shall be allotted and issued to the Warrantholder
(or the custodian of the Depositary, if applicable) credited as fully paid up in accordance with clause 6.3.2 (Exercise of Subscription Rights) and clause
8.3.1. 8.3.1. 

  
 17 

	 	13.2.3	 Nothing in this clause 13.2 shall oblige the Warrantholder(s) to accept any Offer made hereunder, save to the
extent that such Offer, whether by court order or otherwise, shall have become binding on all shareholders and the offer price under such Offer is greater than the Subscription Price, in which case the Warrantholder(s) shall be deemed to have
accepted it on the terms set out herein. 

  

	13.3	 The Company undertakes to the Warrantholders that in the event of an exercise of
Subscription Rights during the course of an Offer (or before the date of an Offer if the Directors of the Company have reason to believe that a bona fide offer might be imminent) it will consult with the Panel on Takeover and Mergers without delay
to get confirmation that the issue of shares represents the exercise of the Subscription Rights pursuant to a pre-existing contractual obligation. In the event that the Panel of Takeover and Mergers does not give such confirmation, the Company will
undertake without delay to call a general meeting of the Company to approve the issue of shares pursuant to the Subscription Rights. [Not
used] 

  

	13.4	 The Company shall use reasonable endeavours to procure that any Buyer extends the
Offer to the Warrantholders in accordance with Rule 15 and Practice Statement 24 of the Takeover Code.[Not used] 

 

	13.5	 For the avoidance of doubt, publication of a compromise or scheme of arrangement under the Companies Act
providing for the acquisition by any person of the whole or any part of the issued share capital of the Company shall be deemed to be the making of an Offer for the purposes of this clause 13. 

 

	13.6	 If, for whatever reason, a Warrantholder fails, refuses or declines to exercise its Subscription Rights within
sixty (60) days of an Offer having become unconditional in all respects, the Warrants held by such Warrantor shall automatically lapse and no Warrant Shares shall be issued to the Warrantholder thereunder. 

 

	14	 COMPANY REORGANISATIONS – EXCHANGE OF WARRANTS 

 

	14.1	 A company reorganisation occurs if the Company merges with or transfers all or substantially all of its assets
and undertaking to a new company (“Newco”) and the shareholders of Newco are substantially the same as the shareholders of the Company immediately before the Company reorganisation, with shares having the same rights as those of the
Company. 

  

	14.2	 If there is a company reorganisation, the Company shall, save to the extent proposed by the Company and
sanctioned by a Consent, use reasonable endeavours to procure that new warrants over the share capital of the Newco are granted with equivalent rights and on terms applying in this instrument mutatis mutandis and on such grant the existing Warrants
shall lapse. 

  

	15	 INFORMATION AND RIGHTS OF WARRANTHOLDER(S) 

 

	15.1	 The Company shall: 

  
 18 

	 	15.1.1	 send to each Warrantholder a copy of its annual reports and audited accounts together with all documents
required by law to be annexed to that report at the same time they are provided to the holders of the Ordinary Shares; 

  

	 	15.1.2	 send to each Warrantholder copies of any statements, notices or circulars sent to the holders of the Ordinary
Shares; and 

  

	 	15.1.3	 give to each Warrantholder not less than 30 days’ prior written notice of its intention to declare or pay
a dividend or other distribution on the Ordinary Shares. 

  

	15.2	 The Warrantholder(s) may attend all general meetings of members of the Company and meetings of the holders of
Ordinary Shares but may not vote at those meetings by virtue of or in respect of their holdings of Warrants. 

  

	15.3	 Each Warrantholder shall keep confidential any information received by it in its capacity as a Warrantholder
which is of a confidential nature except: 

  

	 	15.3.1	 as required by law or any applicable regulations; 

 

	 	15.3.2	 to the extent the information is in the public domain through no default of the Warrantholder; and

  

	 	15.3.3	 each Warrantholder will be entitled to divulge such information to any other Warrantholder and any proposed
transferee of Warrants on the same terms as to confidentiality. 

  

	16	 RESTRICTIONS ON AND UNDERTAKINGS OF THE COMPANY 

 

	16.1	 For so long as the Warrants are outstanding, the Company will: 

 

	 	16.1.1	 to the extent that the Company has a limit on its authorised share capital, keep available for issue and free
from pre-emptive rights, out of its authorised but unissued share capital, such number of Warrant Shares as will enable the Subscription Rights of the Warrantholder(s) to be satisfied in full; 

 

	 	16.1.2	 ensure that the Directors have all necessary authorisations and disapplications of pre-emption (including under
the Companies Act) to allot such number of Warrant Shares as will enable the Subscription Rights of the Warrantholder(s) to be satisfied in full at any time; 

  

	 	16.1.3	 maintain the admission to trading of the Ordinary Shares on AIM, or any other
Recognised Investment Exchange on which the Ordinary Shares are traded from time to time; [Not used] 

 

	 	16.1.4	 not make any issue, grant or distribution or take any other action the effect of which would be that on
exercise of any of the Subscription Rights it would be required to issue Warrant Shares at a discount to their nominal value; and 

  
 19 

	 	16.1.5	 not buy any Warrants unless it offers to buy Warrants from all Warrantholders in proportion to their respective
holdings of Warrants. 

  

	17	 WARRANTIES 

  

	17.1	 The Company warrants to the Warrantholder(s) that: 

 

	 	17.1.1	 it has the power to execute and to perform its obligations under this instrument; 

 

	 	17.1.2	 it has taken all action necessary to authorise the execution of, and the performance of its obligations under
this instrument; 

  

	 	17.1.3	 all Warrant Shares which may be issued upon the exercise of the rights represented by this Warrant will be,
upon issuance, be duly authorised, validly issued and fully paid and free of any liens and encumbrances; 

  

	 	17.1.4	 it and the Directors have, and have obtained all necessary shareholder and third party consents (which consents
are subsisting and remain sufficient and have not been revoked at the Issue Date), to grant the Warrant to the Warrantholder(s) on the Issue Date on the terms of this Warrant; and 

 

	 	17.1.5	 the Ordinary Shares are duly admitted to trading on AIM or on another Recognised
Investment Exchange and no circumstances exist which may cause the suspension or cancellation of such admission. [Not used].

  

	18	 NOTICES 

Any notice to the Warrantholder(s) required for the purposes of any provision of this instrument shall be given in accordance with the
provisions of paragraphs 10 to 13 (inclusive) of Schedule 2. 
  

	19	 COSTS AND EXPENSES 

 

	19.1	 The Company shall promptly pay to the Warrantholder(s) on the Warrantholder’s demand, the reasonable legal
expenses plus applicable VAT and disbursements incurred by the Warrantholder in connection with: 

  

	 	19.1.1	 any amendment or supplement to this instrument, or any proposal for such an amendment to be made, provided such
amendment or supplement has been requested or necessitated by the Company; and 

  

	 	19.1.2	 any consent or waiver by the Warrantholder(s) concerned under or in connection with this instrument or any
request for such a consent or waiver, provided that such consent or waiver has been requested or necessitated by the Company; and 

  
 20 

	 	19.1.3	 any step taken reasonably and properly by the Warrantholder with a view to the protection, exercise or
enforcement of any right or interest created by this instrument. 

  

	20	 CONTRACTS (RIGHTS OF THIRD PARTIES) ACT 1999 

A person who is not a party to this instrument shall have no rights under the Contracts (Rights of Third Parties) Act 1999 to enforce any term
of this instrument. This clause does not affect any right or remedy of any person which exists or is available otherwise than pursuant to that Act. 
  

	21	 FURTHER ASSURANCE 

The Company shall, at its own cost and expense, execute all such deeds and documents and do all such acts and things as may reasonably be
required in order to give effect to this instrument, including vesting on issue the full legal and beneficial title to the Warrant Shares in the Warrantholder. 
  

	22	 SEVERABILITY 

Each of the provisions of this instrument is distinct and severable from the others and if at any time one or more of such provisions is or
becomes valid, unlawful or unenforceable (whether wholly or to any extent), the validity, lawfulness and enforceability of the remaining provisions (or the same provision to any other extent) of this instrument shall not in any way be affected or
impaired. 
  

	23	 GOVERNING LAW 

The provisions of this instrument and the Conditions and any dispute or claim arising out of or in connection with them (including any dispute
or claim relating to non-contractual obligations) shall be subject to and governed by English law and the Company and the Warrantholder(s) submit to the exclusive jurisdiction of the English Courts in relation to any such dispute or claim. 

The Company intends this instrument to be a deed poll and accordingly it or its duly authorised representatives execute and deliver it as such. 

  
 21 

 SCHEDULE 1 

Form Of Warrant Certificate 

MEREO BIOPHARMA GROUP PLC (“COMPANY”) 

A company registered in England and Wales 

under Company number 09481161 

WARRANT CERTIFICATE 
 This certificate is
issued pursuant to the warrant instrument issued by the Company on                     2018 (“Warrant Instrument”). Words and
expressions used in this certificate which are defined in the Warrant Instrument have the meanings given to them in the Warrant Instrument. 
 Certificate
number: [•] 
  

			
	Date of issue:	  	                    2018
		
	Name and address of Warrantholder:	  	[Silicon Valley Bank of 3003 Tasman Drive, Santa Clara, California 95054 US (UK branch at Alphabeta 14-18 Finsbury Square, London EC2A 1BR)]
		
		  	[Kreos Capital V (Expert Fund) LP of 47 Esplanade, St. Helier, Jersey JE1 0BD]

 Number of
[Initial/2020] Warrant Shares for which the Warrantholder may
subscribe such number as is [number], as adjusted in accordance with terms of the Warrant Instrument, if appropriate[•]. 

Subscription Price:
[£2.95/$0.4316] 
 This is to certify that the Warrantholder named above is the registered
holder of the right to subscribe in cash for Warrant Shares at the subscription price set out above subject to the Articles and otherwise on the terms and conditions set out in the Warrant Instrument (a copy of which is available for inspection at
the registered office of the Company). 
  

					
	EXECUTED as a deed, but not delivered until	 	)        	  	
	the date specified on this certificate, by	 	)	  	
		 	)	  	
	MEREO BIOPHARMA GROUP PLC	 	)	  	
		
	by                                    
                    a director in the	  	
	presence of a witness:	 		  	
			
		 		  	
                 

		 		  	Director
			
	Witness Signature:	 		  	
             

  
 22 

					
		 		  	              

			
	Witness Name (block capitals):	 		  	              

			
	Witness Address:	 		  	              

			
		 		  	              

			
	Witness Occupation:	 		  	              

 Schedule to the Warrant Certificate 

Notice of Subscription 
 To: The Directors

 MEREO BIOPHARMA GROUP PLC (“Company”) 

This notice is issued pursuant to the warrant instrument issued by the Company on
2018                        (“Warrant Instrument”). Words and expressions used in this notice which are
defined in the Warrant Instrument have the meanings given to them in the Warrant Instrument. 
 By this notice we exercise the Subscription Rights appertaining to [all] [number] of the Warrants evidenced by this certificate. 

We hereby irrevocably elect
to exercise [number] [Initial/2020] Warrants issued to us by the Company pursuant to the Warrant Instrument and purchase thereunder (and surrender herewith the relevant warrant certificate) as follows: 
  

	(1)	 

 (A) Warrant Shares to be issued to the Warrantholder (or its nominee or trustee) as Ordinary Shares pursuant to the Warrant
Instrument; 

(B) Warrant Shares to be
issued to the custodian of the Depositary for delivery to the Warrantholder as ADSs pursuant to the Warrant Instrument. 

(2) We wish to satisfy the aggregate Subscription Price for the Warrant Shares in respect of the Subscription Rights we are exercising as follows
[delete options as necessary]: 
 1(A) [by payment by banker’s draft, we attach a banker’s draft
to this notice]; 

(B) [by cash payment by wire
transfer of immediately available funds to the following account of the Company: 

  
 23 

[Use in case of an aggregate Subscription Price denominated in GBP:

Account
Name: Mereo BioPharma Group plc 
 Bank: Silicon Valley Bank 

Account No:
20150636 
 Sort Code: 62-10-00 

BIC/SWIFT:
SVBKGB2L 
 IBAN: GB18 SVBK62 1000 2015 0636] 

[Use in case of an aggregate Subscription Price denominated in USD:

Account
Name: Mereo BioPharma Group plc 
 Bank: Silicon Valley Bank 

Account No:
20150644 
 Sort Code: 62-10-00 

IBAN:
GB93SVBK62100020150644]] 
 2(C) [by satisfying the aggregate Subscription Price by electing to receive a reduced number of Warrant Shares, in accordance with clause 6.3.2 (Exercise of Subscription Rights)]. 

[We direct the Company to allot conditional only on the above
the: 

[use for a request under
option (1)(A) above] to issue [number] of Ordinary Shares to be issued pursuant to this exercise in the following numbers to the following proposed allottees, each of which is either a
Warrantholder, a nominee or trustee of a Warrantholder, or a transferee of one of those persons approved in accordance with clause 9.1 of the Warrant Instrument.] 

  
 24 

							
	 Number/percentage of shares
	 	 Name of proposed allottee
	 	 Address of
	 	 CREST
Details

		 		 		 	proposed allott ee
	1	 		 		 	 Participant ID: [•]

Member account ID: [•]

INSP Custodian Client Ref: [•]

Custodian Name: [•]

	2 1	 		 		 	 Participant ID: [•]

Member account ID: [•]

INSP Custodian Client Ref: [•]

Custodian Name: [•]

 We request that certificate(s) for such
Ordinary Shares be sent by post at our risk to us at the first address shown above or to the agent lodging this certificate as mentioned below.  

OR 

We hereby request that you register our Warrant Shares in uncertificated
form to the CREST account detailed [below][above]: 
  

			
	CREST Details	  	Participant ID
		
		  	Member Account ID
		
		  	INSP Custodian Client Ref:
		
		  	Custodian Name

 We agree that such shares are issued and
accepted subject to the memorandum and articles of association of the Company. 

  
 25 

	
	Signature of Warrantholder:
	
	Full name:
	
	Address:

 Lodged by: (agent to whom certificate(s)
should be sent) 

[OR] use for a
request under option (1)(B) above] to issue, allot, and deposit [number] of Ordinary Shares to be issued pursuant to this exercise to the custodian (or its nominee) of the Depositary and that following such issuance and deposit, to
direct the Depositary to issue an amount of ADSs via DTC in accordance with the Issuance and Delivery Instruction corresponding to this Notice of Subscription. 

The Warrantholder represents
and warrants that this Notice of Subscription has been duly signed and constitutes a valid and binding act to exercise the said Warrants. 

Place and date: 
  

	
	
Name of
Warrantholder:

	         

	
By:

	
Title:

The above exercise is
acknowledged and accepted. Place and date: 
  

	
	
MEREO BIOPHARMA
GROUP PLC

	
	
By:

	
Title:

  

	
	Name of agent:
                                        

	
	 Address:
                                        

	

  
 26 

 SCHEDULE 2 

Conditions 
  

	1	 An accurate Register will be kept and maintained at all times by the Company at its registered office and there
shall be entered in the Register: 

  

	1.1	 the names and addresses of the persons for the time being entitled to be registered as the holders of the
Warrants; 

  

	1.2	 the number of Warrants held for the time being by every registered holder; and 

 

	1.3	 the date on which the name of every registered holder is entered in the Register in respect of the Warrants in
its name. 

  

	2	 Any change in the name or address of any Warrantholder shall promptly be notified to the Company which shall
cause the Register to be altered accordingly. The Warrantholders or any of them and any person authorised by any Warrantholder shall be at liberty at all reasonable times during office hours to inspect the Register and to take copies of or extracts
from it or any part of it. 

  

	3	 The Company shall be entitled to treat each Warrantholder as the absolute owner of a Warrant and accordingly
shall not, except as ordered by a court of competent jurisdiction or as required by law, be bound to recognise any equitable or other claim to or interest in a Warrant on the part of any other person, whether or not it shall have express or other
notice of such a claim. 

  

	4	 Each Warrantholder will be recognised by the Company as entitled to the Warrants free from any equity, set-off
or cross-claim on the part of the Company against the original or any intermediate holder of the Warrants. 

  

	5	 Each transfer of a Warrant shall be made by an instrument of transfer in the usual or common form or in any
other form which may be approved for the time being by the Directors. 

  

	6	 The instrument of transfer of a Warrant shall be executed by or on behalf of the transferor but need not be
executed by or on behalf of the transferee. The transferor shall be deemed to remain the holder of the Warrant until the name of the transferee is entered in the Register in respect of the Warrant being transferred. 

 

	7	 The Directors may decline to recognise any instrument of transfer of a Warrant unless the instrument is
deposited at the registered office of the Company accompanied by the Warrant Certificate for the Warrant to which it relates, and such other evidence as the Directors may reasonably require to show the right of the transferor to make the transfer.
The Directors may waive production of any Warrant Certificate upon production to them of satisfactory evidence of the loss or destruction of the Warrant Certificate together with such indemnity as they may require. 

 

	8	 No fee shall be charged for any registration of a transfer of a Warrant or for the registration of any other
documents which in the opinion of the Directors require registration. 

  
 27 

	9	 The registration of a transfer shall be conclusive evidence of the approval by the Directors of such a
transfer. 

  

	10	 Each Warrantholder shall register with the Company an address in the United Kingdom to which notices can be
sent. If any Warrantholder fails to register an address with the Company, notice may be given to that Warrantholder by sending it by any of the methods referred to in paragraph 11 of this Schedule 2 to that Warrantholder’s last known place of
business or residence or, if none, by exhibiting it for three days at the registered office for the time being of the Company. 

  

	11	 Notices and other communications to Warrantholders may be given by personal delivery, prepaid letter by first
class post or, subject to clause 1.3 of this instrument, fax or email. In proving service of any notice or other communication sent by post, it shall be sufficient to prove that the envelope containing the notice or other communication was properly
addressed and stamped and was deposited in a post box or at the post office. 

  

	12	 A notice or other communication given pursuant to the provisions of paragraph 11 of this Schedule 2 shall be
deemed to have been served: 

  

	12.1	 at the time of delivery, if delivered personally to the registered address; 

 

	12.2	 on the second Business Day following its posting, if sent by prepaid letter by first class post to an address
in the United Kingdom; and 

  

	12.3	 at 09:00 hours on the Business Day following the despatch of the fax, if sent by fax. 

 

	13	 All notices and other communications with respect to Warrants standing in the names of joint registered holders
shall be given to whichever of such persons is named first in the Register and such notice so given shall be sufficient notice to all the registered holders of such Warrants. 

 

	14	 Any person who, whether by operation of law, transfer or other means whatsoever, shall become entitled to any
Warrant, shall be bound by every notice in respect of such Warrant which, prior to its name and address being entered on the Register, shall have been duly given to the person from which it derives its title to such Warrant. 

 

	15	 When a given number of days’ notice or notice extending over any other period is required to be given, the
day of service shall be included but the day upon which such notice will expire shall not be included in such number of days or other period. The signature to any notice to be given by the Company may be written or printed. 

 

	16	 Meetings of Warrantholders shall be convened and conducted in the same way as meeting of shareholders of the
Company are convened and conducted. Accordingly, the provisions of Articles shall apply to meetings of the Warrantholders mutatis mutandis. 

  
 28 

SCHEDULE 3

 ADS Issuance and
Delivery Instruction 

[DATE] 

Citibank, N.A., as
Depositary 

388 Greenwich
Street 

New York, New York
10013 

Attn.:
Mr. Brian M. Teitelbaum (brian.m.teitelbaum@citi.com) 
 With a copy simultaneously delivered to: 

Citibank, N.A., London
Branch 

25 Canada Square 

Canary Wharf 

London E14 5LB,
England 

Attn.: UK Custody
Settlements 

Custody Team
(uksettlements@citi.com) 
 Re: Issuance and Delivery Instruction—Mereo BioPharma Group plc (CUSIP No.: 589492107) – Deposit &
Hold 

Dear Sirs: 

Reference is made to the
Deposit Agreement, dated as of April 23, 2018, as amended and supplemented from time to time (the “Deposit Agreement”), by and among Mereo BioPharma Group plc, a public limited company incorporated under the laws of England and Wales
and its successors (the “Company”), Citibank, N.A., a national banking association organized and existing under the laws of the United States of America, as Depositary (the “Depositary”), and all Holders and Beneficial Owners of
American Depositary Shares (the “ADSs”) issued thereunder. All capitalized terms used, but not otherwise defined herein, shall have the meaning assigned thereto in the Deposit Agreement.

 In accordance
with the terms and subject to the limitations set forth in the Deposit Agreement, promptly following the Depositary’s receipt of confirmation from the Custodian that the Custodian has received a deposit of the number of Shares specified below
made by the Company for the benefit of the undersigned holder thereof (the “Holder” 

and together with the
Company, the “Undersigned”), the Undersigned hereby jointly instruct the Depositary, and the Depositary hereby agrees: 

(i) to
promptly accept for deposit the number of Shares and issue the number of ADSs as specified below: 

Number of Shares deposited:
Shares 

Number of ADSs (CUSIP No.:
589492107; each 

ADS representing five
(5) Shares to be issued: 
 ADSs 

and (ii) to promptly
deliver such Program ADSs, as follows: 
 Name of DTC Participant to which the ADSs are 

to be delivered: 

DTC Participant Account
No.: 
  
 Account No. for recipient of ADSs at DTC 

Participant (f/b/o/
information): 

Name on whose behalf the
above number of ADSs 

are to be issued and
delivered:  

Contact person at DTC
Participant: 

Daytime telephone number of
contact person at 

DTC: 

The Company hereby confirms
and certifies that (i) the registration statement on Form F-3 (File No. 333-239708) (the “Registration Statement”), filed with the U.S. Securities and Exchange Commission (the “Commission”) on July 6, 2020,
registers the resale of the above Shares represented by ADSs, such ADSs will be freely transferable following the issuance thereof by the Depositary, and there are no legal restrictions on subsequent transfers of the ADSs to be issued hereunder
under the laws of England and Wales or the United States, (ii) the Registration Statement is effective under the Securities Act of 1933, as amended (the “Securities Act”), and (iii) no stop order suspending the effectiveness of
the Registration Statement has been issued and no proceedings for such purpose have been instituted or are pending or, to the best knowledge of the Company, are contemplated or threatened by the Commission. 

The Holder hereby represents
and covenants to, and for the benefit of, the Depositary and Citibank, N.A.—London Branch (the “Custodian”), that (i) the Holder is not an “affiliate” of the Company as that term is defined in Rule 144 promulgated by
the Commission under the Securities Act and has not been an affiliate at any time during the 90 days immediately preceding the date hereof, and (ii) all stamp duty taxes, including, without limitation, the U.K. Stamp Duty Reserve Tax
(“SDRT”), will be paid in full and on a timely basis to the extent such taxes are payable in respect of the deposit of the Shares and the issuance and delivery of the ADSs as contemplated herein. 

Each of the Holder and, to
the extent it is not unlawful for the Company to do so under the applicable laws of England and Wales, the Company agrees to indemnify the Depositary and the Custodian for, and to hold the Depositary and the Custodian harmless against, all losses,
liabilities, taxes, charges, penalties or expenses (including reasonable legal fees and disbursements), incurred by the Depositary and/or by the Custodian or to which the Depositary and/or the Custodian may become subject to and arising directly or
indirectly from the failure by any person to pay (or discharge) any applicable stamp duty taxes, including, without limitation, SDRT, or any other similar duty or tax in connection with the deposit of the Shares and the issuance and delivery of the
ADSs as contemplated herein, save to the extent that such losses, liabilities, taxes, charges, penalties or expenses are due to the negligence or bad faith of the Custodian or the Depositary.

  

			
	[HOLDER]	  	MEREO BIOPHARMA GROUP PLC
		
	By:                         
               	  	By:                         
               
	Name:	  	Name:
	Title:	  	Title:

 SIGNATURE PAGE 

 

					
	EXECUTED and delivered as a DEED by	 		 	
	MEREO BIOPHARMA GROUP PLC	 		 	
			
		 	Signature of Director	 	
			
		 	Name of Director	 	
			
		 	Signature of Secretary	 	
			
		 	Name of Secretary	 	

  

					
	EXECUTED as a deed, but not delivered until	 	)	  	
	the date specified on this instrument, by 	 	)	  	
		 	)	  	
	MEREO BIOPHARMA GROUP PLC	 	)	  	
	by a director in the	 		  	
	presence of a witness:	 		  	  

		 		  	Director
			
	Witness Signature:	 		  	  

	Witness Name (block capitals):	 		  	  

	Witness Address:	 		  	              

		 		  	  

	Witness Occupation:	 		  	  

 Schedule 4 

2018 Warrant Instrument (clean copy) 

 

 
 EXECUTION VERSION 

DATED              DECEMBER 2020 

MEREO BIOPHARMA GROUP PLC 
  

 
 AMENDED
WARRANT INSTRUMENT DATED 1 
 OCTOBER 2018 

relating to the issue of warrants entitling the holders to 

subscribe for Warrant Shares in the capital of 

MEREO BIOPHARMA GROUP PLC 
  

 
 5 Fleet Place
London EC4M 7RD 
 Tel: +44 (0)20 7203 5000 • Fax: +44 (0)20 7203 0200 • DX: 19 London/Chancery Lane 

www.charlesrussellspeechlys.com 

 CONTENTS 
  

							
	 1
	  	DEFINITIONS AND INTERPRETATION	  	 	2	 
			
	 2
	  	CONSTITUTION AND FORM OF WARRANTS	  	 	8	 
			
	 3
	  	CALCULATION OF NUMBER OF WARRANT SHARES	  	 	9	 
			
	 4
	  	CERTIFICATES	  	 	9	 
			
	 5
	  	TIMING FOR EXERCISE OF SUBSCRIPTION RIGHTS	  	 	9	 
			
	 6
	  	EXERCISE OF SUBSCRIPTION RIGHTS	  	 	10	 
			
	 7
	  	AUTOMATIC EXERCISE OF SUBSCRIPTION RIGHTS	  	 	12	 
			
	 8
	  	COMPLETION	  	 	12	 
			
	 9
	  	TRANSFER OF WARRANTS	  	 	14	 
			
	 10
	  	MODIFICATION AND CESSATION OF RIGHTS	  	 	14	 
			
	 11
	  	ADJUSTMENT OF WARRANT	  	 	14	 
			
	 12
	  	LIQUIDATION	  	 	15	 
			
	 13
	  	TAKEOVERS	  	 	15	 
			
	 14
	  	COMPANY REORGANISATIONS – EXCHANGE OF WARRANTS	  	 	17	 
			
	 15
	  	INFORMATION AND RIGHTS OF WARRANTHOLDER(S)	  	 	17	 
			
	 16
	  	RESTRICTIONS ON AND UNDERTAKINGS OF THE COMPANY	  	 	18	 
			
	 17
	  	WARRANTIES	  	 	18	 
			
	 18
	  	NOTICES	  	 	19	 
			
	 19
	  	COSTS AND EXPENSES	  	 	19	 
			
	 20
	  	CONTRACTS (RIGHTS OF THIRD PARTIES) ACT 1999	  	 	19	 
			
	 21
	  	FURTHER ASSURANCE	  	 	19	 
			
	 22
	  	SEVERABILITY	  	 	20	 
			
	 23
	  	GOVERNING LAW	  	 	20	 
		
	 SCHEDULE 1 FORM OF WARRANT CERTIFICATE
	  	 	21	 
		
	 SCHEDULE 2 CONDITIONS
	  	 	25	 

 THIS WARRANT INSTRUMENT is made on 1 October 2018, as amended on     
December 2020 
 BY: 
  

	(1)	 MEREO BIOPHARMA GROUP PLC, a company incorporated in England and Wales with number 09481161 whose
registered office is at 4th Floor, 1 Cavendish Place, London, England, W1G 0QF (“Company”). 

 BACKGROUND: 

 

	(A)	 The Company, by resolution of its directors, has agreed to issue Warrants to subscribe for Warrant Shares in
the capital of the Company on the terms set out in this instrument, subject to adjustment as set out in this instrument. 

  

	(B)	 Either all of the registered holders of shares in the Company have irrevocably waived all pre-emption rights
conferred on them (whether by the Companies Act, the Articles or otherwise) or such pre-emption rights have been validly disapplied in relation to the number of Warrants and shares in the Company issued pursuant to this instrument.

  

	(C)	 This instrument has been executed by the Company as a deed in favour of the Warrantholder.

 IT IS AGREED: 
  

	1	 DEFINITIONS AND INTERPRETATION 

 

	1.1	 In this instrument the following words and expressions shall (unless the context requires otherwise) have the
following meanings: 

  

			
	2020 Warrants	  	means any warrants issued on the Amendment Date, by way of adjustment to the Initial Warrants;
		
	Adjustment	  	means any sub-division or consolidation of Equity Securities by the Company, at any time, after issue of the relevant Warrant, or by reference to any record date, while the Warrants remain exercisable;
		
	ADS	  	means American Depositary Shares representing interests in the Ordinary Shares pursuant to a sponsored American Depositary Receipt facility with the Depositary;
		
	ADS Exchange Ratio	  	means the ratio applicable to the exchange of Ordinary Shares for ADSs from time to time, currently being a ratio of 5 Ordinary Shares for each ADS;
		
	Amendment Date	  	means 15 December 2020;

  
 2 

			
	Articles	  	the articles of association of the Company for the time being;
		
	Auditors	  	the Company’s auditors;
		
	Business	  	means the research, development, production, trading and licensing of rights, intellectual property and/or products within the life sciences industry (or any of the foregoing or any activities connected thereto);
		
	Business Day	  	a day (which for these purposes ends at 5.30 pm) on which banks are open for commercial business in the City of London other than a Saturday or Sunday;
		
	Companies Act	  	the Companies Act 2006;
		
	Competitor	  	means any entity (other than a reputable financial institution) whose business directly competes with the Business carried out by a Group Company;
		
	Conditions	  	the terms and conditions set out in Schedule 2 (subject to any alterations made in accordance with the provisions of this instrument);
		
	Consent	  	either:
		
		  	 (a)   a resolution passed at a meeting of the Warrantholders duly convened and
held and carried by a majority consisting of not less than 75 per cent. of the votes cast upon a show of hands or, if a poll is duly demanded, by a majority consisting of not less than 75 per cent of the votes cast on a poll; or

		
		  	 (b)   the consent in writing of Warrantholders entitled to the right to
subscribe for at least 75 per cent of the Warrant Shares in respect of which Subscription Rights are granted pursuant to this instrument;

		
	Directors	  	the board of directors of the Company (and/or, where relevant, a Group Company) for the time being;
		
	Equity Securities	  	has the meaning given in section 560(1) of the Companies Act;

  
 3 

			
	Exercise Date	  	the date of delivery to the registered office of the Company of the items specified in clause 6.2 (and the date of such delivery shall be the date on which such items are received at the Company’s registered office);
		
	Fair Market Value	  	either:
		
		  	 (a)   if the Ordinary Shares are then traded on a Recognised Investment Exchange
the fair market value of a Warrant Share shall be the volume weighted average price of one (1) Ordinary Share during the ten (10) consecutive trading day period immediately preceding the Exercise Date; or

		
		  	 (b)   if the Ordinary Shares are not traded on a Recognised Investment Exchange
but ADSs are listed on Nasdaq, the implied price of One Ordinary Share in pounds sterling, which shall be determined as follows:

		
		  	 (i) dividing (x) being the volume weighted average price of one ADS during the ten (10) consecutive trading day period
immediately preceding the Exercise Date by (y) being the number of Ordinary Shares currently represented by a single ADS in accordance with the ADS Exchange Ratio in effect on such date (Implied USD Price); and

		
		  	 (ii) converting the Implied USD Price to pounds sterling at the Exchange Rate on the trading day immediately preceding
the Exercise Date; or

		
		  	 (c)   if the Ordinary Shares are not traded on a Recognised Investment Exchange
and ADSs are not listed on Nasdaq, the fair market value a Warrant Share shall be the Fair Price;

  
 4 

			
	Fair Price	  	unless otherwise agreed by the board of Directors and the Warrantholder(s) prior to service of the Notice of Subscription, the price per Warrant Share which the Auditors (acting as an expert (the Expert)) shall certify to be in its
opinion a fair price for the Warrant Shares. In arriving at his opinion the Expert will value the Warrant Shares as at the date the Notice of Subscription is to be given on the basis that the Company operates as a going concern, as between a willing
seller and a willing buyer, subject always to the provisions of the Articles. The decision of the Expert as to the fair price for the Warrant Shares shall be final and binding and his costs shall be borne by the Company;
		
	Final Date	  	subject to clause 5 (Timing for exercise of Subscription Rights), 10 years from the date of this instrument (which date, for the avoidance of doubt, shall be 1 October 2028);
		
	Group	  	(i) the Company and its subsidiaries (if any), (ii) any holding company of the Company, and (iii) any subsidiaries of such holding companies from time to time and Group Company means any member of the Group;
		
	Initial Warrants	  	means the warrants of the Company constituted by this Instrument on 1 October 2018, and any further warrants issued prior to the Amendment Date as an adjustment thereto;
		
	Issuance and Delivery Instruction	  	means an issuance and delivery instruction in such form as notified from the Company to the Warrantholders from time to time, the current form of which is attached hereto at Schedule 3;
		
	Marketable Securities	  	means securities in the acquiring entity traded on a Recognised Investment Exchange where the Warrantolder(s) (were it to receive such securities on completion of an Offer having exercised this Warrant) would not be subject to any
restrictions on re-sale of such securities;
		
	Member of the same Fund Group	  	is if the Warrantholder is a fund, partnership, company, syndicate or other entity whose business is managed by a Fund Manager (an “Investment Fund”) or a nominee of that
person:

  
 5 

			
		  	 (a)   any participant or partner in or member of any such Investment Fund or the
holders of any unit trust which is a participant or partner in or member of any Investment Fund but only in connection with the dissolution of Investment Fund or any distribution of assets of the Investment Fund pursuant to the operation of the
Investment Fund in the ordinary course of business,

		
		  	 (b)   any Investment Fund managed or exclusively advised by that Fund
Manager,

		
		  	 (c)   a parent undertaking or subsidiary undertaking of that Investment Fund or
Fund Manager, or any subsidiary undertaking of any parent undertaking of that Investment Fund or Fund Manager, or

		
		  	 (d)   any trustee, nominee or custodian of such Investment Fund and vice
versa;

		
	 Notice of Subscription
	  	the notice addressed to the Company by a Warrantholder exercising its Subscription Rights in the form, or substantially in the form, set out in the schedule to the Warrant Certificate;
		
	 Ordinary Shares
	  	ordinary shares in the capital of the Company and having the rights and privileges set out in the Articles;
		
	 Permitted Transferee are:
	  	
		
		  	 (a)   a nominee of the Warrantholders;

		
		  	 (b)   a regulated, reputable financial institution;

		
		  	 (c)   a member of the SVB Financial Group of companies; and/or

		
		  	 (d)   a Member of the same Fund Group;

		
	 Recognised Investment Exchange
	  	a recognised investment exchange or overseas investment exchange (within the meaning thereof given for the purposes of section 285 of the Financial Services and Markets Act 2000, and shall include, without limitation, AIM or
NASDAQ;
		
	 Register
	  	the register of persons for the time being entitled to the benefit of the Warrants to be maintained pursuant to the Conditions;
		
	 Registrars
	  	the registrars of the Company for the time being;

  
 6 

			
	 Subscription Price
	  	the subscription price per Warrant Share, such price being equal to:
		
		  	 (a)   in respect of the Initial Warrants £2.95; and

		
		  	 (b)   in respect of the 2020 Warrants, $0.4144 (being the volume weighted
average price of one (1) Ordinary Share during the ten (10) consecutive trading day period immediately preceding the Amendment Date converted into USD at an exchange rate of 1 GBP = 1.3226 USD (being the GBP-USD opening exchange rate published in
the Wall Street Journal on the business day (being a day on which banks are open for commercial business in New York) immediately preceding the Amendment Date)

		
	 Subscription Rights
	  	the rights of the Warrantholder(s) to subscribe for Warrant Shares under clause 6 (Exercise of Subscription Rights);
		
	 Warrant Certificate
	  	a certificate evidencing a Warrantholder’s entitlement to Warrants in the form set out in Schedule 1;
		
	 Warrant Shares
	  	Ordinary Shares to be issued pursuant to the terms of the Warrants;
		
	 Warrantholder
	  	in relation to a Warrant, the person whose name appears in the Register as the holder of the Warrant; and
		
	 Warrants
	  	the Initial Warrants and the 2020 Warrants and all rights conferred by this Instrument relating thereto (including the Subscription Rights).

  

	1.2	 In this instrument, unless the context otherwise requires: 

 

	 	1.2.1	 words and expressions defined in the Companies Act or the Articles shall have the same meanings in this
instrument (unless otherwise expressly defined in this instrument); 

  

	 	1.2.2	 headings are used for convenience only and shall be ignored in interpreting this instrument;

  

	 	1.2.3	 reference to a clause or schedule is a reference to a clause of, or schedule to, this instrument;

  

  
 7 

	 	1.2.4	 reference to (or to any specific provision of) this instrument or any other document or instrument shall be
construed as a reference to this instrument, that provision or that document or instrument as in force for the time being and as amended from time to time in accordance with its terms and the prior sanction of a Consent (where consent is required by
the terms of this instrument as a condition to such amendment being made); 

  

	 	1.2.5	 reference to any gender includes all genders, references to the singular includes the plural (and vice versa)
and reference to persons includes bodies corporate, unincorporated associations and partnerships (whether or not any of the same have a separate legal personality); 

 

	 	1.2.6	 reference to a statutory provision includes reference to: 

 

	 	(a)	 the statute or statutory provision as modified or re-enacted from time to time; and 

 

	 	(b)	 any subordinate legislation made under the statutory provision (as modified or re-enacted as set out in clause
1.2.6(a) above); 

  

	 	1.2.7	 any words following the terms ‘including’, ‘include’, ‘in particular’, ‘for
example’ or any other similar expression shall be construed as illustrative and shall not limit the sense of the words, description, phrase or term preceding those words; and 

 

	 	1.2.8	 references to statutory obligations include obligations arising under articles of the Treaty establishing the
European Community, and regulations, directives and decisions of the European Union as well as United Kingdom Acts of Parliament and subordinate legislation. 

  

	1.3	 Unless otherwise specifically provided, where any notice, resolution or document is required by this instrument
to be signed by any person, the reproduction of the signature of such person by fax or email shall suffice, provided that confirmation by first class letter is despatched by close of business on the next following Business Day, in which case the
effective notice, resolution or document shall be that sent by fax or email (served in accordance with paragraphs 11 and 12 of Schedule 2), not the confirmatory letter. 

 

	1.4	 This instrument incorporates the schedules to it. 

 

	2	 CONSTITUTION AND FORM OF WARRANTS 

 

	2.1	 This instrument constitutes the Warrants, which in aggregate give the Warrantholder(s) the right, upon the
terms and subject to the conditions set out in this instrument, to subscribe in cash (subject to clause 6.3.2) at a price per share equal to the Subscription Price for such number of Warrant Shares calculated in accordance with clause 3
(Calculation of number of Warrant Shares). 

  

	2.2	 Subject to clause 6.3.2 (Exercise of Subscription Rights), each Warrantholder shall be entitled to
subscribe in cash at the Subscription Price for that number of Warrant Shares in respect of which it is entitled to be recorded as the holder in the Register on the terms set out in this instrument. 

  
 8 

	2.3	 The Warrants shall be in registered form. 

 

	2.4	 The Warrants are issued subject to the Articles and otherwise on the terms of this instrument (including the
Conditions). 

  

	2.5	 The Company agrees with the Warrantholder(s) and, in consideration of being issued a Warrant Certificate, each
Warrantholder agrees with the Company that the Articles (insofar as they relate to the Warrants) and the terms of this instrument shall be binding upon the Company and each Warrantholder and all persons claiming through or under either of them.

  

	2.6	 No application will be made for the Warrants to be listed or dealt on any Recognised Investment Exchange (as
that term is defined in the Financial Services and Markets Act 2000 (as amended)). 

  

	3	 CALCULATION OF NUMBER OF WARRANT SHARES 

 

	3.1	 The number of Warrant Shares over which the Initial Warrants have been issued is 304,758 Warrant Shares.

  

	3.2	 The number of Warrant Shares over which the 2020 Warrants shall be issued is 304,758 Warrant Shares.

  

	3.3	 The 2020 Warrants shall be issued to Silicon Valley Bank and Kreos Capital V (Expert Fund) LP in equal
proportions. 

  

	4	 CERTIFICATES 

  

	4.1	 The Company shall issue to each Warrantholder a Warrant Certificate in respect of that number of Warrants to
which it is entitled as soon as reasonably practicable following a Warrantholder becoming entitled to such Warrants in accordance with clause 3 (Calculation of number of Warrant Shares). 

 

	4.2	 If a Warrant Certificate is mutilated, defaced, lost, stolen or destroyed, the Company will replace it on such
terms as to evidence and indemnity as the Company may reasonably require and subject to the Warrantholder who is seeking the replacement paying the Company’s reasonable costs (if any) in connection with the issue of the replacement.

  

	4.3	 Mutilated or defaced Warrant Certificates must be surrendered before replacements will be issued.

  

	5	 TIMING FOR EXERCISE OF SUBSCRIPTION RIGHTS 

 

	5.1	 The Subscription Rights may be exercised at any time from the date of this instrument until 17:00 GMT on the
Final Date and shall be exercised in accordance with clause 6 (Exercise of Subscription Rights). 

  

  
 9 

	5.2	 Subject to clause 7 (Automatic Exercise of Subscription Rights), a failure by any Warrantholder to
exercise its Subscription Rights ahead of such time on the Final Date shall mean that such Warrantholder’s outstanding Warrants shall immediately lapse and be cancelled and such Warrantholder shall have no further rights under this instrument.

  

	5.3	 Without prejudice to clauses 12 (Liquidation), 13 (Takeovers) and 14 (Company reorganisations
– Exchange of Warrants), if the Final Date is likely to occur before the last date for approval of or acceptance of a liquidation, share buyback, takeover or reorganisation event (that is in each case subject to an existing proposal) such
as described in the said clauses, the Final Date shall be extended until such last date for approval or acceptance of such event as aforesaid. 

  

	6	 EXERCISE OF SUBSCRIPTION RIGHTS 

 

	6.1	 The Subscription Rights may be exercised in whole or in part. If exercised in part, the Subscription Rights
must be exercised in tranches of 50,000 Warrants, or in respect of the last tranche of Warrants attached to the outstanding Subscription Rights held by the Warrantholder concerned, such lesser balancing number of Warrants as may be outstanding.

  

	6.2	 In order to exercise its Subscription Rights validly, a Warrantholder must deliver the following items to the
registered office of the Company: 

  

	 	6.2.1	 the Warrant Certificate for the Warrants in respect of which Subscription Rights are being exercised, together
with the Notice of Subscription duly completed; 

  

	 	6.2.2	 if required pursuant to clause 6.3.1, a remittance by banker’s draft, drawn on a UK clearing bank, (or
such other mode of payment as the Company and the Warrantholder shall agree); 

  

	 	6.2.3	 the name and address of the Warrantholder to which the Warrant Shares arising on exercise of Subscription
Rights are to be issued; and 

  

	 	6.2.4	 if and to the extent that the Ordinary Shares issued are to be delivered as ADSs, a completed Issuance and
Delivery Instruction in the form set out at Schedule 3 hereto (as such form may be amended from time to time by notice to the Warrantholder) duly completed and executed by the Warrantholder. 

 

	6.3	 The Subscription Price for each of the Warrant Shares shall, at the absolute discretion of the Warrantholder,
be satisfied by any of the following: 

  

	 	6.3.1	 the payment by banker’s draft for each of the Warrant Shares at the Subscription Price; or

  

  
 10 

	 	6.3.2	 in lieu of a cash payment in respect of the aggregate Subscription Price for the Warrant Shares, the
Warrantholder may elect for a reduced number of Warrant Shares (as calculated below) (“Reduced Warrant Shares”) to be issued than the number to which it would be entitled on exercise of the Subscription Rights in full, payment for
such Reduced Warrant Shares being satisfied by waiver by the Warrantholder of the right to receive the balance of Warrant Shares to which the Warrantholder is entitled over and above the Reduced Warrant Shares (“Balance Warrant Shares”).
In doing so, the Company agrees and acknowledges that, subject to the payment of the par value of the Reduced Warrant Shares pursuant to this clause 6.3.2, the Reduced Warrant Shares to be issued to the Warrantholder (or, in the case of a
Warrantholder which has specified in the Notice of Subscription in respect of such Reduced Warrant Shares that it requires to have such Reduced Warrant Shares delivered as ADSs and has delivered a duly completed Issuance and Delivery Instruction to
the Company in respect of the same, issued to, deposited with (and otherwise registered in the name of) the custodian of the Depositary (or its nominee)) as fully paid up at the Subscription Price, and the Warrantholder agrees and acknowledges that
it waives its Subscription Rights to the Balance Warrant Shares used as consideration for payment of the aggregate Subscription Price. The number of Reduced Warrant Shares the Warrantholder (or Depositary, as applicable) will receive shall be
determined as follows: 

 X = Y (A – B) / A 

where: 
 X = the number of
Reduced Warrant Shares to be issued to the Warrantholder or Depositary (as applicable). 
 Y = the number of Warrant Shares with respect to
which the Warrant is being exercised by the Warrantholder (without application of the reduction). 
 A = the Fair Market Value of one
Warrant Share 
 B = the Subscription Price (provided that, where the relevant Warrants being exercised have a Subscription Price
denominated in USD, the Company shall convert such Subscription Price to pounds sterling for the purpose of calculating the aggregate nominal value of such Reduced Warrant Shares using the Exchange Rate on the trading day prior to service of the
Notice of Subscription or Automatic Exercise Notice, as the case may be) 
 Provided always that the Warrantholder shall nevertheless be
required to subscribe in cash for the par value of the Reduced Warrant Shares to the extent that if it did not do so the Reduced Warrant Shares would be issued at a discount to the Warrantholder. It being understood that if Warrant 

  
 11 

 Shares are issued pursuant to this clause 6.3.2, notwithstanding that such Warrant Shares
are issued at nominal value, the Warrantholder shall be deemed to have paid the relevant Subscription Price per Warrant Share for the purposes of calculating any distribution or share of sale proceeds in each case attributable to the Warrant Shares
and to other issued shares of the class for the purposes of the Articles and for all other purposes. 
  

	6.4	 Delivery of the items specified in clause 6.2 to the Company shall, unless the Company expressly consents
otherwise, be an irrevocable election by the Warrantholder to exercise the relevant Subscription Rights. 

  

	7	 AUTOMATIC EXERCISE OF SUBSCRIPTION RIGHTS 

 

	7.1	 If, on the Final Date, the Fair Market Value of one Warrant Share is greater than the Subscription Price on
such date, the Warrantholder shall be deemed to have automatically exercised its Subscription Rights, on a conditional basis, in respect of all unexercised Warrants on such date on a net issuance basis as set out in Clause 

 

	6.3.2	 (Exercise of Subscription Rights). In such circumstances, the Company shall (subject at all times to the
Company’s obligations under all applicable law and any other regulations, send a notice to the Warrantholder(s)within ten (10) Business Days of the Final Date (such notice being the Automatic Exercise Notice for the purposes of this clause
7) requiring them to pay up a cash amount equal to the aggregate nominal value of the Warrant Shares (such payment being the “Nominal Value Payment”) to be issued pursuant to clause 6.3.2 (“Exercise of Subscription Rights”) and
this clause 7.1, and to specify whether such Warrantholder requires any such Warrant Shares to be delivered as ADSs. 

  

	7.2	 The Warrantholder shall, within ten (10) Business Days of receipt of the Automatic Exercise Notice (the
“Nominal Value Payment Period”) provide the Company with the Nominal Value Payment to an account notified by the Company to the Warrantholder, and, if such Warrantholder requires any Warrant Shares to be delivered as ADSs, a duly
completed Issuance and Delivery Instruction in respect of such Warrant Shares. Upon receipt of such Nominal Value Payment (and, if applicable, such Issuance and Delivery Instruction) the Warrant Shares to be issued to the Warrantholder (or in the
case of a Warrantholder who has delivered an Issuance and Delivery Instruction, the custodian of the Depositary) shall be allotted and issued to the Warrantholder (or the custodian of the Depositary, as applicable) credited as fully paid up in
accordance with clause 6.3.2 (Exercise of Subscription Rights) and clause 8.3.1 (Completion). Any failure by a Warrantholder to pay the Nominal ValuePayment (or deliver a duly completed Issuance and Delivery Instruction, if applicable) within the
Nominal Value Payment Period shall result in the automatic lapse of any Warrants over Warrant Shares for which the Nominal Value Payment was not made or Issuance and Delivery Instruction not delivered. 

 

	8	 COMPLETION 

  

	8.1	 Following a valid exercise of Subscription Rights by a Warrantholder or an automatic exercise of Subscription
Rights pursuant to clause 7 (Automatic exercise of Subscription Rights) or clause 13.2.2 (Takeovers), the Company shall in accordance with clause 8.3: 

 

  
 12 

	 	8.1.1	 allot and issue credited as fully paid to the Warrantholder; or in the event that the Warrantholder has
required pursuant to clause 6.2 that Ordinary Shares to be issued from the Exercise of Subscription Rights are to be delivered as ADSs, delivered a duly completed Issuance and Delivery Instruction, and there is an effective registration statement
covering the Ordinary Shares to be issued on such exercise, issue to, deposit with (and otherwise register in the name of) the custodian of the Depositary (or its nominee) (“Allotted Shares”) and following such issuance and deposit
the Company will direct the Depositary to issue an amount of ADSs via DTC (with such ADSs being eligible for listing on Nasdaq) in accordance with the corresponding Issuance and Delivery Instruction; 

 

	 	8.1.2	 immediately following allotment and issue in accordance with clause 8.1.1, enter, or procure that the
Company’s Registrars enter the Warrantholder’s name (or (i) its nominee’s or trustee’s name, or (ii) in the case of any Ordinary Shares to be delivered as ADSs, the custodian of the Depositary’s name) in the
register of members of the Company as the holder of the Allotted Shares; 

  

	 	8.1.3	 immediately following registration in accordance with clause 8.1.2, either: send to the person identified by
the Warrantholder pursuant to clause 8.1.1, free of charge, share certificate(s) in respect of the Allotted Shares; and 

  

	 	8.1.4	 apply for the admission of the Warrant Shares to trading on any recognised investment exchange on which the
Warrant Shares are listed at the time of the allotment and issue pursuant to clause 8.1.1, and shall use its reasonable endeavours to secure such admission to trading no later than ten (10) Business Days after such application.

  

	8.2	 The obligations of the Company under clause 8.1 shall be fulfilled within ten (10) days after the Notice
of Subscription is lodged at the registered office of the Company. 

  

	8.3	 The Allotted Shares shall: 

 

	 	8.3.1	 be allotted and issued fully paid; 

 

	 	8.3.2	 rank pari passu with the relevant class of fully paid Warrant Shares then in issue; 

 

	 	8.3.3	 rank for any dividend or other distribution which has previously been announced or declared if the date by
which the holder of Warrant Shares must be registered to participate in such dividend or other distribution is after the Exercise Date pursuant to which the Subscription Rights have been exercised; and 

  
 13 

	 	8.3.4	 be free from all claims, liens, charges, encumbrances, equities and third party rights. 

 

	8.4	 If following allotment of shares pursuant to the exercise of some of the Subscription Rights, some Subscription
Rights remain, the Company shall issue a Warrant Certificate to the Warrantholder within 15 Business Days for the balance of the Warrantholder’s Subscription Rights. 

 

	9	 TRANSFER OF WARRANTS 

 

	9.1	 Subject to clause 9.2, the Warrants may be transferred in whole or in part by any Warrantholder to any person,
provided that the Company has given its prior written consent to such transfer. 

  

	9.2	 A Warrantholder has the right, with prior written notice, but without the consent of the Company, to transfer
the Warrants in whole or in part to a Permitted Transferee, subject to compliance with the provisions of Schedule 2 hereto. 

  

	9.3	 Notwithstanding any other provisions of this instrument, no transfer shall be made to any person which is a
Competitor of the Company or any other Group Company. 

  

	9.4	 The provisions of Schedule 2 to this instrument shall regulate any transfer of a Warrant.

  

	10	 MODIFICATION AND CESSATION OF RIGHTS 

 

	10.1	 This instrument may be modified only with the prior sanction of Consent. 

 

	10.2	 This instrument ceases to have effect on the earlier of: 

 

	 	10.2.1	 the date upon which all Subscription Rights have been exercised in full; and 

 

	 	10.2.2	 the Final Date. 

  

	11	 ADJUSTMENT OF WARRANT 

 

	11.1	 Upon the occurrence of an Adjustment after the date of this Instrument but prior to the Final Date, the number
and/or nominal value of Warrant Shares to be, or capable of being subscribed on any subsequent exercise of the Subscription Rights conferred by each issued Warrant and/or the Subscription Price will be adjusted in such manner as the Auditors shall
certify to be fair and reasonable so that the Warrants shall, after such adjustment, entitle the Warrantholder(s) on exercise to receive the same percentage of the share capital of the Company in issue or capable of being issued following the
implementation of the Adjustment, carrying the same proportion of votes exercisable at a general meeting of shareholders, for the same Aggregate Subscription Price, in each case as nearly as practicable, as would have been the case if no Adjustment
had occurred, provided that the Subscription Price shall not in any event be reduced so that, upon exercise of the Subscription Rights, Warrant Shares would fall to be issued at a discount to their nominal value. 

  
 14 

	11.2	 Within ten (10) days after days after an Adjustment, or, if later, within 10 days after the response of
the auditors to any certification required by clause 11.1, notice of such adjustments will be given to the Warrantholder(s) detailing the number of Warrant Shares for which the Warrantholder(s) are entitled to subscribe in consequence of any such
adjustment. Replacement Warrant Certificates shall be issued accordingly. 

  

	12	 LIQUIDATION 

  

	12.1	 If an order is made or an effective resolution is passed for the winding-up or dissolution of the Company or if
any other dissolution of the Company by operation of law is to be effected whilst any Subscription Rights remain exercisable, then the provisions of clause 12.2 or, as the case may be, clause 12.3 shall apply. 

 

	12.2	 If the winding-up or dissolution is for the purpose of a reconstruction, amalgamation or merger the
Warrantholder shall be entitled to be granted by the reconstructed, amalgamated or merged company a substituted warrant of the value of the Warrant immediately prior to such reconstruction, amalgamation or merger. 

 

	12.3	 If clause 12.2 does not apply, the Company shall immediately notify the Warrantholder(s) in writing that such
an order has been made or resolution has been passed or other dissolution is to be effected. The Warrantholder(s) shall be entitled at any time within three (3) months after the date such notice is given to elect by notice in writing to the
Company to be treated as if they had, immediately before the date of the making of the order or passing of the resolution or other dissolution, exercised the Subscription Rights and they shall be entitled to receive out of the assets which would
otherwise be available in the liquidation to the holders of Warrant Shares, such a sum, if any, as they would have received had they been the holders of and paid for the Warrant Shares to which they would have become entitled by virtue of such
exercise, after deducting from such sum the amount which would have been payable by them in respect of the Warrant Shares if they had exercised the Subscription Rights. Nothing contained in this clause 12.3 shall have the effect of requiring the
Warrantholder(s) to make any actual payment to the Company. 

  

	13	 TAKEOVERS 

  

	13.1	 Subject to clause 13.6, if at any time an offer or invitation is made by the Company to the holders of the
Ordinary Shares for the purchase by the Company of any of its Ordinary Shares, the Company shall promptly and without delay give notice thereof to each Warrantholder who shall be entitled, at any time whilst such offer or invitation is open for
acceptance, to exercise its Subscription Rights to the extent that such rights have not been exercised or lapsed prior to the record date of such offer or invitation so as to take effect, in so far as is reasonably practicable, as if it had
exercised its rights immediately prior to the record date of such offer or invitation. 

  

  
 15 

	13.2	 Subject to clause 13.6, if at any time an offer is made to all holders of Ordinary Shares (or all holders of
Ordinary Shares other than the offeror and/or any company controlled by the offeror and/or persons acting in concert with the offeror) to acquire 

	 	the whole or any part of the issued share capital of the Company and the Company becomes aware that as a result of such offer the right to cast a majority of the votes which may ordinarily be cast on a poll at a general
meeting of the Company may, if such offer becomes unconditional in all respects, become vested in the offeror and/or such persons or companies (the “Buyer”) as aforesaid (the “Offer”): 

 

	 	13.2.1	 The Company shall, give notice to each Warrantholder within ten (10) Business Days of its becoming so
aware, and each Warrantholder shall be entitled to exercise its Subscription Rights, conditional upon the Offer being declared unconditional in all respects, within thirty (30) days of such notice having been given by the Company (to the extent
that such rights have not lapsed or been exercised prior to the record date of such Offer), and to accept or otherwise participate in such Offer on the same terms as made to all holders of Ordinary Shares. 

 

	 	13.2.2	 If the Company fails to give notice as required by clause 13.2.1 (subject at all times to the Company’s
obligations under applicable law and any other regulations ) then, provided that immediately prior to the date that the Offer is made the offer price under the Offer is greater than the Subscription Price on such date and conditional upon the Offer
being declared or becoming unconditional in all respects, the Warrantholder shall be deemed to have automatically exercised its Subscription Rights in respect of all unexercised Warrants on such date at the Subscription Price on a net issuance basis
as set out in clause 6.3.2 (Exercise of Subscription Rights). In such circumstances, the Company shall send a notice to the Warrantholder(s) promptly and without delay (such notice being the “Exercise Notice” for the purposes of
this clause 13.2.2) upon either a Warrantholder notifying the Company of its failure to give notice as required by clause 13.2.1 or the Company or the Buyer becoming aware of the Company’s failure to give such notice requiring the
Warrantholder(s) to provide the Company with the Nominal Value Payment to an account notified by the Company to the Warrantholder, and, if such Warrantholder requires any Warrant Shares to be delivered as ADSs, a duly completed issuance and delivery
instruction in respect of such Warrant Shares. Upon receipt of such Nominal Value Payment and Issuance and Delivery Instruction (if applicable), subject to clause 13.3 the Warrant Shares to be issued to the Warrantholder (or to the custodian of the
Depositary, if applicable) on a net issuance basis pursuant to clause 6.3.2 (Exercise of Subscription Rights) shall be allotted and issued to the Warrantholder (or the custodian of the Depositary, if applicable) credited as fully paid up in
accordance with clause 6.3.2 (Exercise of Subscription Rights) and clause 8.3.1. 

  

	 	13.2.3	 Nothing in this clause 13.2 shall oblige the Warrantholder(s) to accept any Offer made hereunder, save to the
extent that such Offer, whether by court order or otherwise, shall have become binding on all shareholders and the offer price under such Offer is greater than the Subscription Price, in which case the Warrantholder(s) shall be deemed to have
accepted it on the terms set out herein. 

  
 16 

	13.3	 [Not used] 

  

	13.4	 [Not used] 

  

	13.5	 For the avoidance of doubt, publication of a compromise or scheme of arrangement under the Companies Act
providing for the acquisition by any person of the whole or any part of the issued share capital of the Company shall be deemed to be the making of an Offer for the purposes of this clause 13. 

 

	13.6	 If, for whatever reason, a Warrantholder fails, refuses or declines to exercise its Subscription Rights within
sixty (60) days of an Offer having become unconditional in all respects, the Warrants held by such Warrantor shall automatically lapse and no Warrant Shares shall be issued to the Warrantholder thereunder. 

 

	14	 COMPANY REORGANISATIONS – EXCHANGE OF WARRANTS 

 

	14.1	 A company reorganisation occurs if the Company merges with or transfers all or substantially all of its assets
and undertaking to a new company (“Newco”) and the shareholders of Newco are substantially the same as the shareholders of the Company immediately before the Company reorganisation, with shares having the same rights as those of the
Company. 

  

	14.2	 If there is a company reorganisation, the Company shall, save to the extent proposed by the Company and
sanctioned by a Consent, use reasonable endeavours to procure that new warrants over the share capital of the Newco are granted with equivalent rights and on terms applying in this instrument mutatis mutandis and on such grant the existing Warrants
shall lapse. 

  

	15	 INFORMATION AND RIGHTS OF WARRANTHOLDER(S) 

 

	15.1	 The Company shall: 

  

	 	15.1.1	 send to each Warrantholder a copy of its annual reports and audited accounts together with all documents
required by law to be annexed to that report at the same time they are provided to the holders of the Ordinary Shares; 

  

	 	15.1.2	 send to each Warrantholder copies of any statements, notices or circulars sent to the holders of the Ordinary
Shares; and 

  

	 	15.1.3	 give to each Warrantholder not less than 30 days’ prior written notice of its intention to declare or pay
a dividend or other distribution on the Ordinary Shares. 

  

	15.2	 The Warrantholder(s) may attend all general meetings of members of the Company and meetings of the holders of
Ordinary Shares but may not vote at those meetings by virtue of or in respect of their holdings of Warrants. 

  
 17 

	15.3	 Each Warrantholder shall keep confidential any information received by it in its capacity as a Warrantholder
which is of a confidential nature except: 

  

	 	15.3.1	 as required by law or any applicable regulations; 

 

	 	15.3.2	 to the extent the information is in the public domain through no default of the Warrantholder; and

  

	 	15.3.3	 each Warrantholder will be entitled to divulge such information to any other Warrantholder and any proposed
transferee of Warrants on the same terms as to confidentiality. 

	16	 RESTRICTIONS ON AND UNDERTAKINGS OF THE COMPANY 

 

	16.1	 For so long as the Warrants are outstanding, the Company will: 

 

	 	16.1.1	 to the extent that the Company has a limit on its authorised share capital, keep available for issue and free
from pre-emptive rights, out of its authorised but unissued share capital, such number of Warrant Shares as will enable the Subscription Rights of the Warrantholder(s) to be satisfied in full; 

 

	 	16.1.2	 ensure that the Directors have all necessary authorisations and disapplications of pre-emption (including under
the Companies Act) to allot such number of Warrant Shares as will enable the Subscription Rights of the Warrantholder(s) to be satisfied in full at any time; 

  

	 	16.1.3	 [Not used] 

  

	 	16.1.4	 not make any issue, grant or distribution or take any other action the effect of which would be that on
exercise of any of the Subscription Rights it would be required to issue Warrant Shares at a discount to their nominal value; and 

  

	 	16.1.5	 not buy any Warrants unless it offers to buy Warrants from all Warrantholders in proportion to their respective
holdings of Warrants. 

  

	17	 WARRANTIES 

  

	17.1	 The Company warrants to the Warrantholder(s) that: 

 

	 	17.1.1	 it has the power to execute and to perform its obligations under this instrument; 

 

	 	17.1.2	 it has taken all action necessary to authorise the execution of, and the performance of its obligations under
this instrument; 

  

	 	17.1.3	 all Warrant Shares which may be issued upon the exercise of the rights represented by this Warrant will be,
upon issuance, be duly authorised, validly issued and fully paid and free of any liens and encumbrances; 

  
 18 

	 	17.1.4	 it and the Directors have, and have obtained all necessary shareholder and third party consents (which consents
are subsisting and remain sufficient and have not been revoked at the Issue Date), to grant the Warrant to the Warrantholder(s) on the Issue Date on the terms of this Warrant; and 

 

	 	17.1.5	 [Not used]. 

  

	18	 NOTICES 

Any notice to the Warrantholder(s) required for the purposes of any provision of this instrument shall be given in accordance with the
provisions of paragraphs 10 to 13 (inclusive) of Schedule 2. 
  

	19	 COSTS AND EXPENSES 

 

	19.1	 The Company shall promptly pay to the Warrantholder(s) on the Warrantholder’s demand, the reasonable legal
expenses plus applicable VAT and disbursements incurred by the Warrantholder in connection with: 

  

	 	19.1.1	 any amendment or supplement to this instrument, or any proposal for such an amendment to be made, provided such
amendment or supplement has been requested or necessitated by the Company; and 

  

	 	19.1.2	 any consent or waiver by the Warrantholder(s) concerned under or in connection with this instrument or any
request for such a consent or waiver, provided that such consent or waiver has been requested or necessitated by the Company; and 

  

	 	19.1.3	 any step taken reasonably and properly by the Warrantholder with a view to the protection, exercise or
enforcement of any right or interest created by this instrument. 

  

	20	 CONTRACTS (RIGHTS OF THIRD PARTIES) ACT 1999 

A person who is not a party to this instrument shall have no rights under the Contracts (Rights of Third Parties) Act 1999 to enforce any term
of this instrument. This clause does not affect any right or remedy of any person which exists or is available otherwise than pursuant to that Act. 
  

	21	 FURTHER ASSURANCE 

The Company shall, at its own cost and expense, execute all such deeds and documents and do all such acts and things as may reasonably be
required in order to give effect to this instrument, including vesting on issue the full legal and beneficial title to the Warrant Shares in the Warrantholder. 

  
 19 

	22	 SEVERABILITY 

Each of the provisions of this instrument is distinct and severable from the others and if at any time one or more of such provisions is or
becomes valid, unlawful or unenforceable (whether wholly or to any extent), the validity, lawfulness and enforceability of the remaining provisions (or the same provision to any other extent) of this instrument shall not in any way be affected or
impaired. 
  

	23	 GOVERNING LAW 

The provisions of this instrument and the Conditions and any dispute or claim arising out of or in connection with them (including any dispute
or claim relating to non- contractual obligations) shall be subject to and governed by English law and the Company and the Warrantholder(s) submit to the exclusive jurisdiction of the English Courts in relation to any such dispute or claim. 

The Company intends this instrument to be a deed poll and accordingly it or its duly authorised representatives execute and deliver it as such. 

  
 20 

 SCHEDULE 1 

Form Of Warrant Certificate 

MEREO BIOPHARMA GROUP PLC (“COMPANY”) 

A company registered in England and Wales under Company number 09481161 

WARRANT CERTIFICATE 
 This certificate is
issued pursuant to the warrant instrument issued by the Company on                      2018 (“Warrant Instrument”). Words
and expressions used in this certificate which are defined in the Warrant Instrument have the meanings given to them in the Warrant Instrument. 

Certificate number: [•] 
  

			
	Date of issue:	  	                     2018
		
	Name and address of Warrantholder:	  	[Silicon Valley Bank of 3003 Tasman Drive, Santa Clara, California 95054 US (UK branch at Alphabeta 14-18 Finsbury Square, London EC2A 1BR)]
		
		  	[Kreos Capital V (Expert Fund) LP of 47 Esplanade, St. Helier, Jersey JE1 0BD]

 Number of [Initial/2020] Warrant Shares for which the Warrantholder may subscribe [•]. 

Subscription Price: [£2.95/$0.4316] 
 This is to certify
that the Warrantholder named above is the registered holder of the right to subscribe in cash for Warrant Shares at the subscription price set out above subject to the Articles and otherwise on the terms and conditions set out in the Warrant
Instrument (a copy of which is available for inspection at the registered office of the Company). 
  

					
	EXECUTED as a deed, but not delivered until)	  	
	the date specified on this certificate, by	  	)	  	
	MEREO BIOPHARMA GROUP PLC	  	)	  	
	by                         a director in the)	  	
	presence of a witness:	  		  	  

		  		  	Director
			
	Witness Signature:	  		  	  

			
	Witness Name (block capitals):	  		  	  

			
	Witness Address:	  		  	  

			
		  		  	  

			
	Witness Occupation:	  		  	  

  
 21 

 Schedule to the Warrant Certificate 

Notice of Subscription 
 To: The Directors

 MEREO BIOPHARMA GROUP PLC (“Company”) 

This notice is issued pursuant to the warrant instrument issued by the Company on
                         (“Warrant Instrument”). Words and expressions used in this notice which are
defined in the Warrant Instrument have the meanings given to them in the Warrant Instrument. 
 We hereby irrevocably elect to exercise [number]
[Initial/2020] Warrants issued to us by the Company pursuant to the Warrant Instrument and purchase thereunder (and surrender herewith the relevant warrant certificate) as follows: 

 

	(1)	 

(A)          Warrant Shares to be issued to the Warrantholder (or its nominee or trustee)
as                 Ordinary Shares pursuant to the Warrant Instrument; 

(B)          Warrant Shares to be issued to the custodian of the Depositary for delivery to the
                Warrantholder as ADSs pursuant to the Warrant Instrument. 

(2) We wish to satisfy the aggregate Subscription Price for the Warrant Shares in respect of the Subscription Rights we are exercising as follows [delete
options as necessary]: 
 (A) [by payment by banker’s draft, we attach a banker’s draft to this notice]; 

(B) [by cash payment by wire transfer of immediately available funds to the following account of the Company: 

[Use in case of an aggregate Subscription Price denominated in GBP: 

Account Name: Mereo BioPharma Group plc 

Bank: Silicon Valley Bank 

Account No: 20150636 
 Sort Code:
62-10-00 
 BIC/SWIFT: SVBKGB2L 

IBAN: GB18 SVBK62 1000 2015 0636] 

  
 22 

 [Use in case of an aggregate Subscription Price denominated in USD: 

Account Name: Mereo BioPharma Group plc 

Bank: Silicon Valley Bank 

Account No: 20150644 
 Sort Code:
62-10-00 
 IBAN: GB93SVBK62100020150644]] 
 (C)
[by satisfying the aggregate Subscription Price by electing to receive a reduced number of Warrant Shares, in accordance with clause 6.3.2]. 
 We direct
the Company: 
 [use for a request under option (1)(A) above] to issue [number] of Ordinary Shares to be issued pursuant to this exercise in the
following numbers to the following proposed allottees, each of which is either a Warrantholder, a nominee or trustee of a Warrantholder or a transferee of one of those persons approved in accordance with clause 9.1 of the Warrant Instrument] 

 

					
	 Number/percentage of shares
	  	 Name of proposed allottee
	  	 Address of proposed allottee

	1	  		  	

 [OR] use for a request under option (1)(B) above] to issue, allot, and deposit [number] of Ordinary Shares to be issued
pursuant to this exercise to the custodian (or its nominee) of the Depositary and that following such issuance and deposit, to direct the Depositary to issue an amount of ADSs via DTC in accordance with the Issuance and Delivery Instruction
corresponding to this Notice of Subscription. 
 The Warrantholder represents and warrants that this Notice of Subscription has been duly signed and
constitutes a valid and binding act to exercise the said Warrants. 
 Place and date: 

  
 23 

	
	Name of Warrantholder:
	
	  

	By:
	Title:

 The above exercise is acknowledged and accepted. Place and date: 

 

	
	MEREO BIOPHARMA GROUP PLC
	
	  

	By:
	Title:

  
 24 

 SCHEDULE 2 

Conditions 
  

	1	 An accurate Register will be kept and maintained at all times by the Company at its registered office and there
shall be entered in the Register: 

  

	1.1	 the names and addresses of the persons for the time being entitled to be registered as the holders of the
Warrants; 

  

	1.2	 the number of Warrants held for the time being by every registered holder; and 

 

	1.3	 the date on which the name of every registered holder is entered in the Register in respect of the Warrants in
its name. 

  

	2	 Any change in the name or address of any Warrantholder shall promptly be notified to the Company which shall
cause the Register to be altered accordingly. The Warrantholders or any of them and any person authorised by any Warrantholder shall be at liberty at all reasonable times during office hours to inspect the Register and to take copies of or extracts
from it or any part of it. 

  

	3	 The Company shall be entitled to treat each Warrantholder as the absolute owner of a Warrant and accordingly
shall not, except as ordered by a court of competent jurisdiction or as required by law, be bound to recognise any equitable or other claim to or interest in a Warrant on the part of any other person, whether or not it shall have express or other
notice of such a claim. 

  

	4	 Each Warrantholder will be recognised by the Company as entitled to the Warrants free from any equity, set-off
or cross-claim on the part of the Company against the original or any intermediate holder of the Warrants. 

  

	5	 Each transfer of a Warrant shall be made by an instrument of transfer in the usual or common form or in any
other form which may be approved for the time being by the Directors. 

  

	6	 The instrument of transfer of a Warrant shall be executed by or on behalf of the transferor but need not be
executed by or on behalf of the transferee. The transferor shall be deemed to remain the holder of the Warrant until the name of the transferee is entered in the Register in respect of the Warrant being transferred. 

 

	7	 The Directors may decline to recognise any instrument of transfer of a Warrant unless the instrument is
deposited at the registered office of the Company accompanied by the Warrant Certificate for the Warrant to which it relates, and such other evidence as the Directors may reasonably require to show the right of the transferor to make the transfer.
The Directors may waive production of any Warrant Certificate upon production to them of satisfactory evidence of the loss or destruction of the Warrant Certificate together with such indemnity as they may require. 

  
 25 

	8	 No fee shall be charged for any registration of a transfer of a Warrant or for the registration of any other
documents which in the opinion of the Directors require registration. 

  

	9	 The registration of a transfer shall be conclusive evidence of the approval by the Directors of such a
transfer. 

  

	10	 Each Warrantholder shall register with the Company an address in the United Kingdom to which notices can be
sent. If any Warrantholder fails to register an address with the Company, notice may be given to that Warrantholder by sending it by any of the methods referred to in paragraph 11 of this Schedule 2 to that Warrantholder’s last known place of
business or residence or, if none, by exhibiting it for three days at the registered office for the time being of the Company. 

  

	11	 Notices and other communications to Warrantholders may be given by personal delivery, prepaid letter by first
class post or, subject to clause 1.3 of this instrument, fax or email. In proving service of any notice or other communication sent by post, it shall be sufficient to prove that the envelope containing the notice or other communication was properly
addressed and stamped and was deposited in a post box or at the post office. 

  

	12	 A notice or other communication given pursuant to the provisions of paragraph 11 of this Schedule 2 shall be
deemed to have been served: 

  

	12.1	 at the time of delivery, if delivered personally to the registered address; 

 

	12.2	 on the second Business Day following its posting, if sent by prepaid letter by first class post to an address
in the United Kingdom; and 

  

	12.3	 at 09:00 hours on the Business Day following the despatch of the fax, if sent by fax. 

 

	13	 All notices and other communications with respect to Warrants standing in the names of joint registered holders
shall be given to whichever of such persons is named first in the Register and such notice so given shall be sufficient notice to all the registered holders of such Warrants. 

 

	14	 Any person who, whether by operation of law, transfer or other means whatsoever, shall become entitled to any
Warrant, shall be bound by every notice in respect of such Warrant which, prior to its name and address being entered on the Register, shall have been duly given to the person from which it derives its title to such Warrant. 

 

	15	 When a given number of days’ notice or notice extending over any other period is required to be given, the
day of service shall be included but the day upon which such notice will expire shall not be included in such number of days or other period. The signature to any notice to be given by the Company may be written or printed. 

 

	16	 Meetings of Warrantholders shall be convened and conducted in the same way as meeting of shareholders of the
Company are convened and conducted. Accordingly, the provisions of Articles shall apply to meetings of the Warrantholders mutatis mutandis. 

  
 26 

 SCHEDULE 3 

ADS Issuance and Delivery Instruction 

[DATE] 
 Citibank, N.A., as Depositary 

388 Greenwich Street 
 New York, New York 10013 

Attn.: Mr. Brian M. Teitelbaum (brian.m.teitelbaum@citi.com) 

With a copy simultaneously delivered to: 
 Citibank, N.A., London
Branch 
 25 Canada Square 
 Canary Wharf 

London E14 5LB, England 
 Attn.: UK Custody Settlements 

Custody Team (uksettlements@citi.com) 
 Re: Issuance and Delivery
Instruction - Mereo BioPharma Group plc (CUSIP No.: 589492107) – Deposit & Hold 
 Dear Sirs: 

Reference is made to the Deposit Agreement, dated as of April 23, 2018, as amended and supplemented from time to time (the “Deposit
Agreement”), by and among Mereo BioPharma Group plc, a public limited company incorporated under the laws of England and Wales and its successors (the “Company”), Citibank, N.A., a national banking association organized and existing
under the laws of the United States of America, as Depositary (the “Depositary”), and all Holders and Beneficial Owners of American Depositary Shares (the “ADSs”) issued thereunder. All capitalized terms used, but not otherwise
defined herein, shall have the meaning assigned thereto in the Deposit Agreement. 
 In accordance with the terms and subject to the
limitations set forth in the Deposit Agreement, promptly following the Depositary’s receipt of confirmation from the Custodian that the Custodian has received a deposit of the number of Shares specified below made by the Company for the benefit
of the undersigned holder thereof (the “Holder” and together with the Company, the “Undersigned”), the Undersigned hereby jointly instruct the Depositary, and the Depositary hereby agrees: 

(i) to promptly accept for deposit the number of Shares and issue the number of ADSs as specified below: 

  
 27 

			
	Number of Shares deposited:	  	                                      
                               Shares
		
	Number of ADSs (CUSIP No.: 589492107; each ADS representing five (5) Shares to be issued:	  	
		
		  	                                      
                               ADSs
	
	 and (ii) to promptly deliver such Program ADSs, as follows:

		
	Name of DTC Participant to which the ADSs are to be delivered:	  	  

		
	DTC Participant Account No.:	  	  

		
	Account No. for recipient of ADSs at DTC Participant (f/b/o/ information):	  	  

		
	Name on whose behalf the above number of ADSs are to be issued and delivered:	  	  

		
	Contact person at DTC Participant:	  	  

		
	Daytime telephone number of contact person at DTC:	  	  

 The Company hereby confirms and certifies that (i) the registration statement on Form F-3 (File No. 333-239708) (the
“Registration Statement”), filed with the U.S. Securities and Exchange Commission (the “Commission”) on July 6, 2020, registers the resale of the above Shares represented by ADSs, such ADSs will be freely transferable
following the issuance thereof by the Depositary, and there are no legal restrictions on subsequent transfers of the ADSs to be issued hereunder under the laws of England and Wales or the United States, (ii) the Registration Statement is
effective under the Securities Act of 1933, as amended (the “Securities Act”), and (iii) no stop order suspending the effectiveness of the Registration Statement has been issued and no proceedings for such purpose have been instituted
or are pending or, to the best knowledge of the Company, are contemplated or threatened by the Commission. 
 The Holder hereby represents and covenants to,
and for the benefit of, the Depositary and Citibank, N.A.—London Branch (the “Custodian”), that (i) the Holder is not an “affiliate” of the Company as that term is defined in Rule 144 promulgated by the Commission under
the Securities Act and has not been an affiliate at any time during the 90 days immediately preceding the date hereof, and (ii) all stamp duty taxes, including, without limitation, the U.K. Stamp Duty Reserve Tax (“SDRT”), will be
paid in full and on a timely basis to the extent such taxes are payable in respect of the deposit of the Shares and the issuance and delivery of the ADSs as contemplated herein. 

  
 28 

 Each of the Holder and, to the extent it is not unlawful for the Company to do so under the applicable laws
of England and Wales, the Company agrees to indemnify the Depositary and the Custodian for, and to hold the Depositary and the Custodian harmless against, all losses, liabilities, taxes, charges, penalties or expenses (including reasonable legal
fees and disbursements), incurred by the Depositary and/or by the Custodian or to which the Depositary and/or the Custodian may become subject to and arising directly or indirectly from the failure by any person to pay (or discharge) any applicable
stamp duty taxes, including, without limitation, SDRT, or any other similar duty or tax in connection with the deposit of the Shares and the issuance and delivery of the ADSs as contemplated herein, save to the extent that such losses, liabilities,
taxes, charges, penalties or expenses are due to the negligence or bad faith of the Custodian or the Depositary. 
  

									
	[HOLDER]	  		  	MEREO BIOPHARMA GROUP PLC
					
	By:	  	
                 
	  		  	By:	  	
                     

	Name:	  		  		  	Name:	  	
	Title:	  		  		  	Title:	  	

  
 29 

 SIGNATURE PAGE 

 

					
	EXECUTED and delivered as a DEED by	 	
	MEREO BIOPHARMA GROUP PLC	 	
			
		 	 Signature of Director
	 	
			
	  
	 	 Name of Director
	 	
			
		 	 Signature of Secretary
	 	
			
	  
	 	 Name of Director
	 	

  
 30 

 IN WITNESS WHEREOF this agreement has been executed as a deed and delivered by the parties on the
date first above written. 
  

					
	EXECUTED and delivered as a DEED by	 	
	MEREO BIOPHARMA GROUP PLC	 	
			
		 	 Signature of Director
	 	
			
	  
	 	 Name of Director
	 	
			
		 	 Signature of Secretary
	 	
			
	  
	 	 Name of Secretary
	 	

  

			
	Executed and delivered	  	
	as a DEED by KREOS CAPITAL V	  	
	 (UK) LIMITED
 acting by two
directors
	  	                                      
               Director
		
	a director	  	
		
	a director	  	                                      
               Director

  

			
	Executed and delivered	  	
		
	as a DEED by SILICON VALLEY BANK	  	                                      
                              
		
	a California corporation acting by	  	
		  	Authorised Signatory
	                 an authorised signatory, being a person who, in accordance with the laws of that territory, is acting under the authority of the
corporation	  	
		  	                                      
                              
		  	Authorised Signatory

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00331-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00331-of-00352.parquet"}]]